<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">99752</article-id><article-id pub-id-type="doi">10.7554/eLife.99752</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.99752.4</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group><subj-group subj-group-type="heading"><subject>Physics of Living Systems</subject></subj-group></article-categories><title-group><article-title>Heterogeneous efflux pump expression underpins phenotypic resistance to antimicrobial peptides</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Ka Kiu</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2061-3694</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Łapińska</surname><given-names>Urszula</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Tolle</surname><given-names>Giulia</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Micaletto</surname><given-names>Maureen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Bing</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Phetsang</surname><given-names>Wanida</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Verderosa</surname><given-names>Anthony D</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Invergo</surname><given-names>Brandon M</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author"><name><surname>Westley</surname><given-names>Joseph</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Bebes</surname><given-names>Attila</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Yuecel</surname><given-names>Raif</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>O'Neill</surname><given-names>Paul A</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Farbos</surname><given-names>Audrey</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Jeffries</surname><given-names>Aaron R</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>van Houte</surname><given-names>Stineke</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Caboni</surname><given-names>Pierluigi</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Blaskovich</surname><given-names>Mark AT</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Housden</surname><given-names>Benjamin E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9134-4279</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Tsaneva-Atanasova</surname><given-names>Krasimira</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6294-7051</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Pagliara</surname><given-names>Stefano</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9796-1956</contrib-id><email>s.pagliara@exeter.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03yghzc09</institution-id><institution>Living Systems Institute, University of Exeter</institution></institution-wrap><addr-line><named-content content-type="city">Exeter</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03yghzc09</institution-id><institution>Biosciences, University of Exeter</institution></institution-wrap><addr-line><named-content content-type="city">Exeter</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/003109y17</institution-id><institution>Department of Life and Environmental Sciences, University of Cagliari, Cittadella Universitaria</institution></institution-wrap><addr-line><named-content content-type="city">Cagliari</named-content></addr-line><country>Italy</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00rqy9422</institution-id><institution>Centre for Superbug Solutions, Institute for Molecular Bioscience, The University of Queensland, St. Lucia</institution></institution-wrap><addr-line><named-content content-type="city">Brisbane</named-content></addr-line><country>Australia</country></aff><aff id="aff5"><label>5</label><institution>Process Integration and Predictive Analytics, PIPA LLC</institution><addr-line><named-content content-type="city">Davis</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03yghzc09</institution-id><institution>Centre for Ecology and Conservation and Environment and Sustainability Institute, University of Exeter</institution></institution-wrap><addr-line><named-content content-type="city">Exeter</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03yghzc09</institution-id><institution>Exeter Centre for Cytomics, Henry Wellcome Building for Biocatalysis, Biosciences, University of Exeter</institution></institution-wrap><addr-line><named-content content-type="city">Exeter</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03yghzc09</institution-id><institution>Exeter Sequencing Service, Biosciences, University of Exeter</institution></institution-wrap><addr-line><named-content content-type="city">Exeter</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00rqy9422</institution-id><institution>ARC Training Centre for Environmental and Agricultural Solutions to Antimicrobial Resistance (CEAStAR), Institute for Molecular Bioscience, The University of Queensland, St. Lucia</institution></institution-wrap><addr-line><named-content content-type="city">Brisbane</named-content></addr-line><country>Australia</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03yghzc09</institution-id><institution>Department of Clinical and Biomedical Sciences, University of Exeter</institution></institution-wrap><addr-line><named-content content-type="city">Exeter</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03yghzc09</institution-id><institution>Department of Mathematics and Statistics, University of Exeter</institution></institution-wrap><addr-line><named-content content-type="city">Exeter</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Soldati-Favre</surname><given-names>Dominique</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01swzsf04</institution-id><institution>University of Geneva</institution></institution-wrap><country>Switzerland</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Soldati-Favre</surname><given-names>Dominique</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01swzsf04</institution-id><institution>University of Geneva</institution></institution-wrap><country>Switzerland</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>03</day><month>07</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP99752</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-06-10"><day>10</day><month>06</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-06-11"><day>11</day><month>06</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.04.22.590445"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-09-03"><day>03</day><month>09</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.99752.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-05-23"><day>23</day><month>05</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.99752.2"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-06-19"><day>19</day><month>06</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.99752.3"/></event></pub-history><permissions><copyright-statement>© 2024, Lee et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Lee et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-99752-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-99752-figures-v1.pdf"/><abstract><p>Antimicrobial resistance threatens the viability of modern medical interventions. There is a dire need to develop novel approaches to counter resistance mechanisms employed by starved or slow-growing pathogens that are refractory to conventional antimicrobial therapies. Antimicrobial peptides have been advocated as potential therapeutic solutions due to the low levels of genetic resistance observed in bacteria against these compounds. However, here we show that subpopulations of stationary phase <italic>Escherichia coli</italic> and <italic>Pseudomonas aeruginosa</italic> survive tachyplesin treatment without acquiring genetic mutations. These phenotypic variants display enhanced efflux activity to limit intracellular peptide accumulation. Differential regulation of genes involved in outer membrane vesicle secretion, membrane modification, and protease activity was also observed between phenotypically resistant and susceptible cells. We discovered that the formation of these phenotypic variants could be prevented by administering tachyplesin in combination with sertraline, a clinically used antidepressant, suggesting a novel approach for combatting antimicrobial-refractory stationary phase bacteria.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>antibiotics</kwd><kwd>antimicrobial resistance</kwd><kwd>membrane transport</kwd><kwd>heterogeneity</kwd><kwd>efflux pumps</kwd><kwd>microfluidics</kwd><kwd>antimicrobial peptides</kwd><kwd>gene expression</kwd><kwd>transcriptomics</kwd><kwd>efflux pump inhibitors</kwd><kwd>antibiotic accumulation</kwd><kwd>stationary phase</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>E. coli</italic></kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000268</institution-id><institution>Biotechnology and Biological Sciences Research Council</institution></institution-wrap></funding-source><award-id>BB/V008021/1</award-id><principal-award-recipient><name><surname>Pagliara</surname><given-names>Stefano</given-names></name><name><surname>Tsaneva-Atanasova</surname><given-names>Krasimira</given-names></name><name><surname>Łapińska</surname><given-names>Urszula</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000266</institution-id><institution>Engineering and Physical Sciences Research Council</institution></institution-wrap></funding-source><award-id>EP/Y023528/1</award-id><principal-award-recipient><name><surname>Pagliara</surname><given-names>Stefano</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MR/Y033892/1</award-id><principal-award-recipient><name><surname>Pagliara</surname><given-names>Stefano</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000266</institution-id><institution>Engineering and Physical Sciences Research Council</institution></institution-wrap></funding-source><award-id>EP/T017856/1</award-id><principal-award-recipient><name><surname>Tsaneva-Atanasova</surname><given-names>Krasimira</given-names></name><name><surname>Invergo</surname><given-names>Brandon M</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000265</institution-id><institution>Medical Research Council</institution></institution-wrap></funding-source><award-id>MR/V009583/1</award-id><principal-award-recipient><name><surname>Housden</surname><given-names>Benjamin E</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id award-id-type="doi">10.35802/097835</award-id><principal-award-recipient><name><surname>Jeffries</surname><given-names>Aaron R</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id award-id-type="doi">10.35802/101650</award-id><principal-award-recipient><name><surname>Jeffries</surname><given-names>Aaron R</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000268</institution-id><institution>Biotechnology and Biological Sciences Research Council</institution></institution-wrap></funding-source><award-id>BB/K003240/1</award-id><principal-award-recipient><name><surname>Jeffries</surname><given-names>Aaron R</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000737</institution-id><institution>QUEX Institute</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Pagliara</surname><given-names>Stefano</given-names></name><name><surname>Tsaneva-Atanasova</surname><given-names>Krasimira</given-names></name><name><surname>Blaskovich</surname><given-names>Mark AT</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000737</institution-id><institution>Living Systems Institute</institution></institution-wrap></funding-source><award-id>PhD studentship</award-id><principal-award-recipient><name><surname>Lee</surname><given-names>Ka Kiu</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. For the purpose of Open Access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Sub-populations of non growing bacteria survive treatment with antimicrobial peptides by mounting an efflux response.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Antimicrobial resistance (AMR) was estimated to claim 1.27 million lives in 2019 (<xref ref-type="bibr" rid="bib103">Murray et al., 2022</xref>) and is predicted to claim 10 million lives annually by 2050 (<xref ref-type="bibr" rid="bib104">Naghavi et al., 2024</xref>). Besides the deaths caused directly by infections, AMR also threatens the viability of many modern medical interventions, such as surgery and organ transplant. This challenging situation has motivated the development of strategies to combat resistance mechanisms utilised by bacterial pathogens, particularly when they enter states of dormancy or slow growth and become more refractory to conventional antimicrobial treatments (<xref ref-type="bibr" rid="bib134">Tamer and Toprak, 2017</xref>; <xref ref-type="bibr" rid="bib1">Ahmad et al., 2025</xref>). In recent decades, natural defences such as bacteriocin proteins, peptides, endolysins, and antibodies have garnered substantial attention as potential clinical antimicrobial agents (<xref ref-type="bibr" rid="bib89">MacNair et al., 2024</xref>). Antimicrobial peptides (AMPs) have been advocated as potential therapeutic solutions to the AMR crisis. Notably, polymyxin-B and -E are in clinical use, and additional AMPs are undergoing clinical trials (<xref ref-type="bibr" rid="bib116">Rima et al., 2021</xref>). AMPs can simultaneously target different cellular subsystems: they target the double membrane of Gram-negative bacteria by interacting with negatively charged membrane lipids while simultaneously disrupting cytoplasmic processes such as protein synthesis, DNA replication, cell wall biosynthesis, metabolism, and cell division (<xref ref-type="bibr" rid="bib20">Blair et al., 2022</xref>).</p><p>Bacteria have developed genetic resistance to AMPs, including proteolysis by proteases, modifications in membrane charge and fluidity to reduce affinity, and extrusion by AMP transporters. However, compared to small molecule antimicrobials, AMP resistance genes typically confer smaller increases in resistance in experimental evolution analyses, with polymyxin-B and CAP18 being notable exceptions (<xref ref-type="bibr" rid="bib131">Spohn et al., 2019</xref>). Moreover, mobile resistance genes against AMPs are relatively rare and horizontal acquisition of AMP resistance is hindered by phylogenetic barriers owing to functional incompatibility with the new host bacteria (<xref ref-type="bibr" rid="bib65">Kintses et al., 2019b</xref>). Plasmid-transmitted polymyxin resistance constitutes a notable exception (<xref ref-type="bibr" rid="bib106">Nang et al., 2019</xref>), possibly because polymyxins are the only AMPs that have been in clinical use to date (<xref ref-type="bibr" rid="bib65">Kintses et al., 2019b</xref>). However, whether bacterial populations harbour subpopulations that are transiently phenotypically resistant to AMPs without the acquisition of genetic mutations remains an open question. While there is limited understanding regarding AMPs and transient phenotypic resistance (<xref ref-type="bibr" rid="bib63">Kepiro et al., 2020</xref>), this phenomenon has been widely investigated in the case of small molecule antimicrobials and bacteriophages (<xref ref-type="bibr" rid="bib14">Bamford et al., 2017</xref>; <xref ref-type="bibr" rid="bib6">Attrill et al., 2021</xref>; <xref ref-type="bibr" rid="bib7">Attrill et al., 2023</xref>; <xref ref-type="bibr" rid="bib26">Bollen et al., 2023</xref>; <xref ref-type="bibr" rid="bib139">Urbaniec et al., 2022</xref>; <xref ref-type="bibr" rid="bib31">Campey et al., 2024</xref>). Phenotypic resistance to antimicrobials is known to result in negative clinical outcomes and contributes to the emergence of genetic resistance (<xref ref-type="bibr" rid="bib140">Van den Bergh et al., 2017</xref>; <xref ref-type="bibr" rid="bib27">Brandis et al., 2023</xref>; <xref ref-type="bibr" rid="bib16">Barrett et al., 2019</xref>; <xref ref-type="bibr" rid="bib150">Windels et al., 2019a</xref>). Therefore, further investigation into understanding the initial trajectories of the emergence of AMP resistance is required for the development of affordable, safe, and effective AMP treatments while simultaneously circumventing the pitfalls that have fuelled the current AMR crisis (<xref ref-type="bibr" rid="bib62">Jangir et al., 2021</xref>; <xref ref-type="bibr" rid="bib73">Lazzaro et al., 2020</xref>).</p><p>The 17 amino acid cationic β-hairpin AMP tachyplesin (2.27 kDa) (<xref ref-type="bibr" rid="bib105">Nakamura et al., 1988</xref>) is a promising candidate AMP because it displays broad-spectrum, potent antibacterial and antifungal efficacy, minimal haemolytic effect, and minimal evolution of bacterial resistance (<xref ref-type="bibr" rid="bib131">Spohn et al., 2019</xref>). It has been speculated that tachyplesin simultaneously targets multiple cellular components (<xref ref-type="bibr" rid="bib83">Liu et al., 2018</xref>; <xref ref-type="bibr" rid="bib61">Imura et al., 2007</xref>). However, further investigation is needed to fully understand this aspect, along with exploring bacteria’s potential to transiently survive tachyplesin exposure without acquiring genetic mutations. Understanding the emergence of phenotypic resistance to tachyplesin could provide valuable insights into optimising the therapeutic potential of tachyplesin and other AMPs against microbial threats.</p><p>Achieving inhibitory concentrations proximal to its cellular target is crucial for tachyplesin (and antimicrobials in general) efficacy (<xref ref-type="bibr" rid="bib119">Rybenkov et al., 2021</xref>). At low concentrations, AMPs induce the formation of transient pores in bacterial membranes that allow transmembrane conduction of ions but not leakage of intracellular molecules (<xref ref-type="bibr" rid="bib116">Rima et al., 2021</xref>; <xref ref-type="bibr" rid="bib20">Blair et al., 2022</xref>). Beyond a critical ratio between the AMP and membrane lipid concentrations, these pores become stable, leading to leakage of cellular content, loss of transmembrane potential, and eventual cell death (<xref ref-type="bibr" rid="bib116">Rima et al., 2021</xref>; <xref ref-type="bibr" rid="bib20">Blair et al., 2022</xref>). Moreover, it is conceivable that tachyplesin, and other AMPs, must penetrate the bacterial inner membrane and accumulate at intracellular concentrations sufficient to interfere with cellular targets (<xref ref-type="bibr" rid="bib127">Silver, 2016</xref>). Simultaneously, tachyplesin must avoid efflux via protein pumps, such as the <italic>Escherichia coli</italic> and <italic>Yersinia pestis</italic> tripartite pumps AcrAB-TolC and EmrAB-TolC, that confer genetic resistance against AMPs like protamine and polymyxin-B (<xref ref-type="bibr" rid="bib147">Weatherspoon-Griffin et al., 2014</xref>; <xref ref-type="bibr" rid="bib81">Lister et al., 2012</xref>).</p><p>Crucially, recent discoveries have unveiled an association between reduced antimicrobial accumulation and transient phenotypic resistance to antimicrobials (<xref ref-type="bibr" rid="bib113">Pu et al., 2016</xref>; <xref ref-type="bibr" rid="bib133">Stone et al., 2020</xref>; <xref ref-type="bibr" rid="bib149">Whittle et al., 2021</xref>; <xref ref-type="bibr" rid="bib42">El Meouche and Dunlop, 2018</xref>; <xref ref-type="bibr" rid="bib70">Łapińska et al., 2022</xref>). Therefore, we hypothesise that phenotypic variations in the mechanisms regulating membrane lipid and protein compositions allow bacterial subpopulations to shift the balance between influx and efflux, reduce the intracellular accumulation of tachyplesin, and survive treatment without the emergence of genetic mutations.</p><p>To test this hypothesis, we investigated the accumulation and efficacy of tachyplesin-1 against individual <italic>E. coli</italic>, <italic>Pseudomonas aeruginosa</italic>, <italic>Klebsiella pneumoniae,</italic> and <italic>Staphylococcus aureus</italic> cells in their stationary phase of growth. To determine the mechanisms underpinning phenotypic resistance to tachyplesin, we performed comparative gene expression profiling and membrane lipid abundance analysis between subpopulations susceptible and transiently resistant to tachyplesin treatment. We used this knowledge to design a novel drug combination that increases tachyplesin efficacy in killing non-growing bacteria that are notoriously more refractory to treatment with AMPs or other antimicrobials. Our data demonstrate that streamlining antibacterial drug discovery could be facilitated by addressing the fundamental issue of low intracellular drug accumulation. We propose new combination treatments as a promising foundation for developing peptide-based drug combinations against dormant or slow-growing bacteria.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Tachyplesin accumulates heterogeneously within clonal <italic>E. coli</italic> and <italic>P. aeruginosa</italic> populations</title><p>To investigate the accumulation of tachyplesin in individual bacteria, we utilised a fluorescent derivative of the antimicrobial peptide, tachyplesin-1-nitrobenzoxadiazole (tachyplesin-NBD) (<xref ref-type="bibr" rid="bib22">Blaskovich et al., 2019</xref>) in combination with a flow cytometry assay adapted from previously reported protocols (<xref ref-type="bibr" rid="bib162">Zhang et al., 2023b</xref>; <xref ref-type="bibr" rid="bib165">Zhou et al., 2015</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> and Methods).</p><p>As expected, we found that bacterial fluorescence, due to accumulation of tachyplesin-NBD in individual stationary phase <italic>E. coli</italic> BW25113 cells, increased an order of magnitude when the extracellular concentration of tachyplesin-NBD increased from 0 to 8 μg mL<sup>–1</sup> (0–3.2 μM). At the latter concentration, the single-cell fluorescence distribution displayed a median value of 2400 a.u. after 60 min treatment at 37 °C (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). However, a further increase in the extracellular concentration of tachyplesin-NBD to 16 μg mL<sup>–1</sup> (6.3 μM) revealed a noticeable bimodal distribution in single-cell fluorescence. We classified bacteria in the distribution with a median value of 2400 a.u. as low accumulators and those in the distribution with a median value of 28,000 a.u. as high accumulators (blue and red shaded areas, respectively, in <xref ref-type="fig" rid="fig1">Figure 1A</xref> and S1D-J).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Tachyplesin accumulates heterogeneously within clonal <italic>E. coli</italic> and <italic>P. aeruginosa</italic> populations.</title><p>(<bold>A</bold>) Tachyplesin-nitrobenzoxadiazole (NBD) accumulation in stationary phase <italic>E. coli</italic> BW25113 treated with increasing concentrations of tachyplesin-NBD for 60 min (0, 8, 16, 32, 46, 64, 128, and 256 μg mL<sup>–1</sup> or 0.0, 3.2, 6.3, 12.7, 18.2, 25.4, 50.7, and 101.5 μM). Shaded regions show low (blue) and high (red) tachyplesin-NBD accumulation within an isogenic <italic>E. coli</italic> BW25113 population. Each histogram reports 10,000 recorded events and is a representative example of accumulation data from three independent biological replicates (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). (<bold>B</bold>) Tachyplesin-NBD accumulation in nine stationary phase <italic>E. coli</italic> clinical isolates treated with 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD for 60 min. Accumulation data for <italic>E. coli</italic> BW25113 is reproduced from panel A. (<bold>C</bold>) Heatmap showing the presence of antimicrobial resistance (AMR) genes and phylogenetic data of the clinical isolates. Corresponding gene products and the antimicrobials these genes confer resistance to are reported in <xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>. (<bold>D–F</bold>) Tachyplesin-NBD accumulation in <italic>P. aeruginosa</italic> (<bold>D</bold>), <italic>K. pneumoniae</italic> (<bold>E</bold>), and <italic>S. aureus</italic> (<bold>F</bold>) treated with 0 or 46 μg mL<sup>–1</sup> (0 or 18.2 μM) tachyplesin-NBD for 60 min. Each histogram in each panel shows a representative example of accumulation data from three independent biological replicates. (<bold>G</bold>) Representative fluorescence images depicting low and high tachyplesin-NBD accumulators within an <italic>E. coli</italic> BW25113 population. Bacteria were continuously exposed to 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD for 60 min in a microfluidic mother machine device. Blue stars and red diamonds indicate low and high accumulators, respectively. Scale bar: 3 μm. (<bold>H, I</bold>) Representative fluorescence images of individual low (<bold>H</bold>) and high (<bold>I</bold>) tachyplesin-NBD accumulators, respectively. Blue and red lines show a 2.2 μm-long cross-sectional line used for measuring fluorescence profile values in J and K, with the origin on the left side. (<bold>J, K</bold>) Normalised median (solid line), lower and upper quartiles (dotted lines) of fluorescence profile values of <italic>E. coli</italic> BW25113 cells plotted against the distance along the left side origin of a 2.2-μm-long straight line in low (<bold>J</bold>) and high (<bold>K</bold>) tachyplesin-NBD accumulators, respectively. Phenotype assignment was further verified via propidium iodide staining (see <xref ref-type="fig" rid="fig2">Figure 2G</xref>). Inset: each dot represents the corresponding membrane-to-cell centre fluorescence ratio measured at the points indicated in H and I, dashed lines indicate the median and quartiles of each distribution. Statistical significance was assessed using an unpaired nonparametric Mann-Whitney U test with a two-tailed p-value and confidence level at 95%. ****p&lt;0.0001. Data were collected from three independent biological replicates.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Flow cytometry, genomics, and microscopy data were used to generate the graphs presented in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99752-fig1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Antimicrobial resistance genes within clinical isolates.</title><p>This table reports the strains displaying each antimicrobial resistance gene, the name of the gene, its product, and the antimicrobials it confers resistance to.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99752-fig1-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99752-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Gating strategy and dose-dependent response to tachyplesin-nitrobenzoxadiazole (NBD) treatment.</title><p>(<bold>A–C</bold>) Gating strategy for all flow cytometric assays. Bacteria were gated and separated from cellular debris using forward scatter and violet side scatter (<bold>A</bold>). Background noise was then further separated based on cellular autofluorescence measured on the fluorescein isothiocyanate (FITC)-A channel for cells not treated with fluorescent peptides (<bold>B</bold>). An additional gate on the FITC-A channel was then used for cells treated with fluorescent peptides to further separate background noise (<bold>C</bold>). (<bold>D–J</bold>) Median fluorescence and proportion of low (blue) and high (red) tachyplesin-NBD accumulators within <italic>E. coli</italic> BW25113 stationary phase populations treated with 8 μg mL<sup>–1</sup> (3.2 μM) (<bold>D</bold>), 16 μg mL<sup>–1</sup> (6.3 μM) (<bold>E</bold>), 32 μg mL<sup>–1</sup> (12.7 μM) (<bold>F</bold>), 46 μg mL<sup>–1</sup> (18.2 μM) (<bold>G</bold>), 64 μg mL<sup>–1</sup> (25.4 μM) (<bold>H</bold>), 128 μg mL<sup>–1</sup> (50.7 μM) (<bold>I</bold>), or 256 μg mL<sup>–1</sup> (101.5 μM) (<bold>J</bold>) tachyplesin-NBD in M9 at 37 °C for 60 min. Each of the three graphs in each panel shows data for 10,000 events collected from an independent biological replicate. The horizontal lines in each graph represent the manual gating applied.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99752-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Tachyplesin-nitrobenzoxadiazole (NBD) accumulation in stationary and exponential phase <italic>E. coli</italic> BW25113.</title><p>Stationary (<bold>A</bold>) and exponential (<bold>B</bold>) phase <italic>E. coli</italic> BW25113 were treated with 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD in M9 at 37 °C for 60 min and single-cell fluorescence was measured via flow cytometry. The blue and red horizontal lines in each graph represent the gating applied and the median fluorescence and proportion of cells in the corresponding gate are reported within each graph. Each of the three graphs in each panel shows data collected from an independent biological replicate.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99752-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Dose-dependent response to arenicin-nitrobenzoxadiazole (NBD), polymyxin-B-NBD, and octapeptin-NBD treatment.</title><p>(<bold>A–C</bold>) Stationary phase <italic>E. coli</italic> BW25113 was treated with 0, 8, 16, 32, 46, or 64 μg mL<sup>–1</sup> of arenicin-NBD (0.0, 2.8, 5.7, 11.3, 16.3, 22.7, 45.4, or 90.7 μM) (<bold>A</bold>), polymyxin-B-NBD (0.0, 7.0, 13.9, 27.9, 40.0, 55.7, 111.4, or 222.8 μM) (<bold>B</bold>), and octapeptin-NBD (0.0, 6.1, 12.3, 24.5, 35.3, 49.1, 98.2, or 196.3 μM) (<bold>C</bold>) in M9 at 37 °C for 60 min. Data are representative of data collected from three biological replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99752-fig1-figsupp3-v1.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Impact of environmental temperature and proteinase K on tachyplesin-nitrobenzoxadiazole (NBD) accumulation.</title><p>(<bold>A</bold>) Stationary phase <italic>E. coli</italic> BW25113 were treated with 0 or 46 μg mL<sup>–1</sup> (0 or 18.2 μM) tachyplesin-NBD in M9 at 37 °C or on ice for 60 min. Each panel shows data representative of three independent biological replicates. (<bold>B, C</bold>) Stationary phase <italic>E. coli</italic> BW25113 were treated with 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD in M9 at 37 °C for 60 min. Cells were washed and then incubated in either M9 (<bold>B</bold>) or 20 μg mL<sup>–1</sup> (0.7 μΜ) proteinase K in M9 (<bold>C</bold>) at 37 °C for 120 min. Each panel shows data representative of three independent biological replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99752-fig1-figsupp4-v1.tif"/></fig><fig id="fig1s5" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 5.</label><caption><title>Distribution of single-cell tachyplesin-nitrobenzoxadiazole (NBD) accumulation in the microfluidic mother machine.</title><p>Distribution of tachyplesin-NBD accumulation in stationary phase <italic>E. coli</italic> BW25113 treated with 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD in M9 at 37 °C for 60 min then washed with M9 at 37 °C for 60 min in the microfluidic mother machine.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99752-fig1-figsupp5-v1.tif"/></fig><fig id="fig1s6" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 6.</label><caption><title>Representative live-cell confocal microscopy images of <italic>E. coli</italic> treated with tachyplesin-nitrobenzoxadiazole (NBD) and FM 4–64 FX.</title><p>Exponential phase <italic>E. coli</italic> ATCC 25922 were treated with 16 μg mL<sup>–1</sup> (6.3 μM) tachyplesin-NBD at 37 °C for 30 min, followed by staining with 5 μg mL<sup>–1</sup> (6.3 μM) FM 4–64 FX, a membrane-specific dye on ice. The samples were then visualised using confocal microscopy. (<bold>A</bold>) Image showing tachyplesin-NBD fluorescence (green), indicating antimicrobial peptides (AMP) accumulation in the cells. (<bold>B</bold>) Image showing FM 4–64 FX fluorescence (red), highlighting the bacterial cell membrane. (<bold>C</bold>) Merged images from panels A and B, showing the intracellular accumulation of tachyplesin-NBD. Blue stars and red diamonds indicate representative low and high accumulators, respectively. Scale bars represent 5 μm. Data were collected from three independent biological replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99752-fig1-figsupp6-v1.tif"/></fig><fig id="fig1s7" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 7.</label><caption><title>Comparison of cell sizes between low and high tachyplesin-nitrobenzoxadiazole (NBD) accumulators.</title><p>(<bold>A, B</bold>) Distribution of forward scatter (<bold>A</bold>) and violet side scatter (<bold>B</bold>) of low (blue) and high (red) accumulators after treatment with 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD in M9 at 37 °C for 60 min. Corresponding medians reported in each graph. Each histogram in each panel shows data collected from an independent biological replicate. (<bold>C</bold>) Distribution of cell lengths of low and high tachyplesin-NBD accumulators measured by using the microfluidics-based microscopy platform. Stationary phase <italic>E. coli</italic> was treated with 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD in M9 at 37 °C for 60 min, then washed with M9 at 37 °C for 60 min in the microfluidic mother machine. Classification of low and high tachyplesin-NBD accumulators was further validated by propidium iodide staining (see <xref ref-type="fig" rid="fig2">Figure 2G</xref>). Statistical significance was assessed using an unpaired two-tailed nonparametric Mann-Whitney U test. p-value: ***p=0.0002. Data were collected from three independent biological replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99752-fig1-figsupp7-v1.tif"/></fig></fig-group><p>A further increase in the extracellular concentration of tachyplesin-NBD to 46 μg mL<sup>–1</sup> (18.2 μM) still yielded a bimodal distribution in single-cell fluorescence, 43% of the population being low accumulators; in contrast, only 5% of the population were low accumulators when tachyplesin-NBD treatment at 46 μg mL<sup>–1</sup> (18.2 μM) was carried out against exponential phase <italic>E. coli</italic> (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>). Notably, the minimum inhibitory concentration (MIC) of tachyplesin-NBD against exponential phase <italic>E. coli</italic> is 1 μg mL<sup>–1</sup> (0.4 μM) (<xref ref-type="bibr" rid="bib70">Łapińska et al., 2022</xref>). Therefore, our data suggest that even at extracellular concentrations surpassing growth-inhibitory levels, stationary phase <italic>E. coli</italic> populations harbour two distinct phenotypes with differing physiological states that respond to treatment differently with high accumulators displaying over 10-fold greater fluorescence than low accumulators.</p><p>Subsequently, we tested whether this newly observed bimodal distribution of tachyplesin-NBD accumulation was unique to the <italic>E. coli</italic> BW25113 strain. We found that the bimodal distribution in single-cell fluorescence was also present in nine <italic>E. coli</italic> clinical isolates (treated with tachyplesin-NBD at 46 μg mL<sup>–1</sup> or 18.2 μM for 60 min) characterised by a diverse genetic background and various AMR genes, such as the polymyxin-E resistance gene <italic>mcr1</italic> (<xref ref-type="bibr" rid="bib92">Majewski et al., 2021</xref> <xref ref-type="fig" rid="fig1">Figure 1B and C</xref>, <xref ref-type="supplementary-material" rid="fig1sdata2">Figure 1—source data 2</xref>). The median fluorescence of low accumulators in strains JS1147 and MC04960 was shifted to the left and to the right, respectively, compared to BW25113, whereas the median fluorescence of high accumulators for strain JS1060 was shifted to the left compared to BW25113. Remarkably, all isolates tested harboured low accumulators of tachyplesin-NBD.</p><p>Furthermore, to examine whether the bimodal distribution of tachyplesin-NBD accumulation also occurred in other highly virulent bacterial pathogens, we treated three members of the ESKAPE pathogens with 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD for 60 min while in their stationary phase of growth. In <italic>P. aeruginosa</italic> populations, we observed a bimodal distribution of tachyplesin-NBD accumulation with the presence of low accumulators (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). In contrast, we did not find evidence of low tachyplesin-NBD accumulators in <italic>K. pneumoniae</italic> (<xref ref-type="fig" rid="fig1">Figure 1E</xref>) and recorded only low levels of tachyplesin-NBD accumulation in <italic>S. aureus</italic> (<xref ref-type="fig" rid="fig1">Figure 1F</xref>) in accordance with previous reports (<xref ref-type="bibr" rid="bib39">Edwards et al., 2017</xref>). Finally, we tested whether this newly observed bimodal distribution was a feature unique to tachyplesin or is widespread across different AMPs. We found that <italic>E. coli</italic> BW25113 displayed only low accumulators of another β-hairpin AMP, arenicin-NBD, and only high accumulators of cyclic lipopeptide AMPs, polymyxin-B-NBD and octapeptin-NBD (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>).</p><p>These data demonstrate that two key pathogens display bimodal accumulation of tachyplesin, although only limited evolution of genetic resistance against tachyplesin has been previously observed (<xref ref-type="bibr" rid="bib131">Spohn et al., 2019</xref>), but not towards polymyxin-B against which they develop genetic resistance (<xref ref-type="bibr" rid="bib131">Spohn et al., 2019</xref>).</p></sec><sec id="s2-2"><title>Tachyplesin accumulates primarily on the membranes of low accumulators</title><p>Next, we set out to characterise the differences between low and high tachyplesin accumulators. First, we found that <italic>E. coli</italic> low accumulators treated with 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD for 60 min at 37 °C exhibited a fluorescence distribution akin to the entire population of cells treated with 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD at 0 °C (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). At this low temperature, antimicrobials adhere non-specifically to bacterial surfaces as the passive and active transport across bacterial membranes is significantly diminished (<xref ref-type="bibr" rid="bib165">Zhou et al., 2015</xref>). Furthermore, post-binding peptide-lipid interactions are significantly diminished at 0 °C, but not the primary binding step (<xref ref-type="bibr" rid="bib38">Eckert et al., 2006</xref>; <xref ref-type="bibr" rid="bib76">Lehrer et al., 1985</xref>). Moreover, we found that the fluorescence of high accumulators did not decrease over time when tachyplesin-NBD was removed from the extracellular environment and bacteria were treated with 20 μg mL<sup>–1</sup> (0.7 μM) proteinase K, a widely occurring serine protease that can cleave the peptide bonds of AMPs (<xref ref-type="bibr" rid="bib11">Bajorath et al., 1988</xref>; <xref ref-type="bibr" rid="bib49">Glibowicka et al., 2022</xref>; <xref ref-type="bibr" rid="bib130">Song et al., 2021</xref>; <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). These data suggest that tachyplesin-NBD primarily accumulates intracellularly in high accumulators.</p><p>Next, we measured tachyplesin-NBD accumulation in individual <italic>E. coli</italic> cells using our microfluidics-based microscopy platform (<xref ref-type="bibr" rid="bib69">Łapińska et al., 2019</xref>; <xref ref-type="bibr" rid="bib29">Cama et al., 2020</xref>; <xref ref-type="bibr" rid="bib50">Glover et al., 2022</xref>) with the well-established mother machine device (<xref ref-type="bibr" rid="bib144">Wang et al., 2010</xref>; <xref ref-type="bibr" rid="bib18">Bergmiller et al., 2017</xref>). The mother machine is equipped with thousands of microfluidic channels that trap and host individual <italic>E. coli</italic> cells, enabling controlled medium exchange via pressure-driven microfluidics. Consistent with our flow cytometry data, we observed a bimodal accumulation of tachyplesin-NBD (<xref ref-type="fig" rid="fig1s5">Figure 1—figure supplement 5</xref>), with the presence of low and high accumulators (<xref ref-type="fig" rid="fig1">Figure 1G–I</xref>, blue stars and red diamonds, respectively). However, the relative abundance of low accumulators was lower in the microfluidics experiments possibly due to lower cell densities. Low accumulators exhibited a significantly higher membrane-to-cell centre fluorescence ratio compared to high accumulators (p-value &lt;0.0001, <xref ref-type="fig" rid="fig1">Figure 1J and K</xref>) and confocal microscopy further confirmed that tachyplesin-NBD is present only on the cell membranes of low accumulators and primarily intracellularly in high accumulators (<xref ref-type="fig" rid="fig1s6">Figure 1—figure supplement 6</xref>).</p><p>We also compared the forward scatter and violet side scatter values, and cell lengths between low and high tachyplesin-NBD accumulators. We found that these two phenotypes had similar forward and violet side scatter values (<xref ref-type="fig" rid="fig1s7">Figure 1—figure supplement 7</xref>), and high accumulators were significantly smaller than low accumulators in the microfluidics platform (p-value &lt;0.0001, <xref ref-type="fig" rid="fig1s7">Figure 1—figure supplement 7</xref>). These data clearly exclude the possibility that high tachyplesin-NBD fluorescence is attributed to larger cell sizes.</p></sec><sec id="s2-3"><title>Tachyplesin accumulation on the bacterial membranes is insufficient for bacterial eradication</title><p>To test the hypothesis that the accumulation of tachyplesin on the bacterial membranes may be insufficient for bacterial eradication, we conducted measurements of tachyplesin-NBD accumulation and efficacy in bacterial eradication.</p><p>Stationary phase <italic>E. coli</italic> was treated with 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD for 60 min followed by fluorescence-activated cell sorting to separate low and high accumulators, alongside untreated control cells (<xref ref-type="fig" rid="fig2">Figure 2A, B</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, and Methods). Subsequently, we assessed the survival of each sorted sample via colony-forming unit assays and found that the survival fraction of low accumulators was not significantly different from that measured for untreated cells, whereas the survival fraction of high accumulators was significantly lower (p-value &lt;0.0001, <xref ref-type="fig" rid="fig2">Figure 2C</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Intracellular tachyplesin accumulation is essential for its antimicrobial efficacy.</title><p>(<bold>A, B</bold>) Fluorescence and side scatter values of individual <italic>E. coli</italic> treated with M9 at 37 °C for 60 min (<bold>A</bold>) and 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-nitrobenzoxadiazole (NBD) in M9 at 37 °C for 60 min (<bold>B</bold>). The black rectangles show the gates used to sort approximately one million untreated control cells, low and high tachyplesin-NBD accumulators for subsequent analysis. Data collected from four independent biological replicates. (<bold>C</bold>) Survival fraction of cells sorted through the untreated control, low, and high tachyplesin-NBD accumulator gates presented in A and B. Bars and error bars represent the mean and standard deviation of data obtained from four biological replicates, each comprising three technical replicates. Statistical significance was assessed using an ordinary one-way ANOVA with Tukey’s multiple comparisons test and confidence level at 95%. ****p&lt;0.0001, ns: p&gt;0.05. (<bold>D–F</bold>) Representative microscopic images depicting brightfield (<bold>D</bold>), tachyplesin-NBD fluorescence (<bold>E</bold>), and propidium iodide (PI) fluorescence (<bold>F</bold>) after exposure to 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD in M9 for 60 min, followed by a M9 wash for 60 min, then 30 µM PI staining for 15 min at 37 °C in the microfluidic mother machine. Blue stars and red diamonds indicate low and high accumulators, respectively. Scale bar indicates 2.5 μm. The left part of (<bold>E</bold>) is reproduced from part of <xref ref-type="fig" rid="fig1">Figure 1G</xref>. (<bold>G</bold>) Correlation between tachyplesin-NBD and PI fluorescence of N=371 individual <italic>E. coli</italic> cells collected from three independent biological replicates. The purple dashed line shows a nonlinear regression (semi-log) of the data (r<sup>2</sup>=0.70). (<bold>H</bold>) Correlation between the proportion of low accumulators as a percentage of the whole bacterial population measured via flow cytometry and survival fraction measured via colony-forming unit assays. Symbols and error bars represent the mean and standard deviation of three independent biological replicates, each comprising three technical replicates. Tachyplesin-NBD treatment concentration indicated by colour gradient. Some error bars are masked by the data points. The purple dashed line illustrates a linear regression of the data (r<sup>2</sup>=0.98, p-value &lt;0.0001).</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>FACS, colony-forming unit, and microscopy data were used to generate the graphs presented in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99752-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99752-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Fluorescence-activated cell sorting of untreated cells, low and high tachyplesin-nitrobenzoxadiazole (NBD) accumulators.</title><p>(<bold>A</bold>) Gating on side scatter width against side scatter height was applied on all events to separate single cells from cell aggregates. (<bold>B–H</bold>) Representative plots of fluorescence and side scatter of: M9 only (<bold>B</bold>); individual <italic>E. coli</italic> incubated in M9 at 37 °C for 60 min (<bold>C</bold>); post-sort analysis of <italic>E. coli</italic> sorted through control gate in C (<bold>D</bold>); individual <italic>E. coli</italic> incubated in 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD at 37 °C for 60 min (<bold>E</bold>); post-sort analysis of <italic>E. coli</italic> sorted through the low gate in E (<bold>F</bold>); post-sort analysis of a 1:1 mixture of <italic>E. coli</italic> sorted through the low and high gates in E (<bold>G</bold>); post-sort analysis of <italic>E. coli</italic> sorted through the high gate in E (<bold>H</bold>). Data were collected from four independent biological replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99752-fig2-figsupp1-v1.tif"/></fig></fig-group><p>To investigate the hypothesis that tachyplesin causes less membrane damage to low accumulators, we employed our microfluidics-based microscopy platform to simultaneously measure tachyplesin-NBD accumulation and bacterial membrane integrity via propidium iodide (PI) (<xref ref-type="bibr" rid="bib161">Zhang et al., 2023a</xref>). We found a strong positive semi-log correlation between tachyplesin-NBD fluorescence and PI fluorescence (r<sup>2</sup>=0.70, p-value &lt;0.0001): all bacteria exhibiting PI staining had a tachyplesin-NBD fluorescence greater than 800 a.u. and were high accumulators characterised by tachyplesin-NBD localisation both on the bacterial membranes and intracellularly; by contrast, low accumulators, where tachyplesin-NBD is primarily localised on the bacterial membranes, did not stain with PI (<xref ref-type="fig" rid="fig2">Figure 2D–G</xref>).</p><p>Finally, we set out to determine the contribution of low accumulators to the overall population survival. We exposed stationary phase <italic>E. coli</italic> to increasing concentrations of tachyplesin-NBD for 60 min, while measuring tachyplesin-NBD accumulation in individual bacteria and the bacterial eradication efficacy of tachyplesin-NBD at the population level. We used the accumulation data to measure the proportion of low accumulators relative to the whole population of bacteria at increasing tachyplesin-NBD concentrations and found a strong positive linear correlation with the population survival fraction (r<sup>2</sup>=0.98, p-value &lt;0.0001, <xref ref-type="fig" rid="fig2">Figure 2H</xref>). Taken together with PI staining data indicating membrane damage caused by high tachyplesin accumulation, these data demonstrate that low accumulators, which primarily retain tachyplesin-NBD on the bacterial membranes, maintain membrane integrity and strongly contribute to the survival of the bacterial population in response to tachyplesin treatment.</p></sec><sec id="s2-4"><title>Enhanced efflux, membrane lipid alterations, and increased secretion of outer membrane vesicles associated with low accumulation of tachyplesin</title><p>Next, we set out to investigate the mechanisms underpinning low accumulation of tachyplesin. Following our established protocols (<xref ref-type="bibr" rid="bib128">Smith et al., 2018</xref>; <xref ref-type="bibr" rid="bib51">Goode et al., 2021a</xref>), we performed genome-wide comparative transcriptome analysis between low accumulators, a 1:1 (<italic>v/v</italic>) mixture of low and high accumulators, high accumulators, and untreated stationary phase bacteria that were sorted via fluorescence-activated cell sorting. Principal component analysis revealed clustering of the replicate transcriptomes of low tachyplesin-NBD accumulators, the 1:1 mixture of low and high accumulators, high accumulators, and untreated control cells with a distinct separation between these groups on the PC1 plane (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>).</p><p>Our analysis revealed significant differential expression of 1,563 genes in at least one of the three groups compared to untreated cells (<xref ref-type="supplementary-material" rid="fig3sdata2">Figure 3—source data 2</xref>). By performing cluster analysis of these genes (<xref ref-type="bibr" rid="bib50">Glover et al., 2022</xref>; <xref ref-type="bibr" rid="bib51">Goode et al., 2021a</xref>) (see Methods), we identified five distinct clusters of genes based on their expression profile across the three groups relative to the control population (<xref ref-type="fig" rid="fig3">Figure 3A, B</xref>, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). Gene ontology enrichment revealed significant enrichment of biological processes in clusters 2, 4, and 5 (<xref ref-type="fig" rid="fig3">Figure 3C and D</xref>). Genes in clusters 2 and 5 were downregulated to a greater extent in low accumulators; genes in cluster 4 were upregulated to a greater extent in low accumulators. This analysis enabled the identification of major transcriptional differences between low and high accumulators of tachyplesin.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Biological processes associated with low tachyplesin accumulation.</title><p>(<bold>A, B</bold>) Log<sub>2</sub> fold changes in transcript reads of genes in low and high tachyplesin-nitrobenzoxadiazole (NBD) accumulators (blue and red violin plots, respectively) relative to untreated stationary phase <italic>E. coli</italic> bacteria in cluster 2 (<bold>A</bold>) and cluster 4 (<bold>B</bold>). Each dot represents a single gene, dashed lines indicate the median and quartiles of each distribution. Dotted lines represent a log<sub>2</sub> fold change of 0. Statistical significance was tested using a paired two-tailed Wilcoxon nonparametric test (due to non-normally distributed data) with a two-tailed p-value and confidence level at 95%. ****p-value &lt;0.0001. The full list of genes belonging to each cluster is reported in <xref ref-type="supplementary-material" rid="fig3sdata2">Figure 3—source data 2</xref> and the violin plots of log<sub>2</sub> fold changes for all clusters are shown in <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>. Data were collected from four independent biological replicates, then pooled for analysis. (<bold>C, D</bold>) Corresponding gene ontology enrichment plots of biological processes enriched in cluster 2 (<bold>C</bold>) and 4 (<bold>D</bold>). Each dot represents a biological process with its size indicating the number of genes associated with each process and the colour indicating the false discovery rate (FDR). The lines and their thickness represent the abundance of mutual genes present within the connected biological processes. The enrichment plot for cluster 5 is not shown as only one biological process, ‘response to biotic stimulus,’ was enriched. Full details about each process are reported in <xref ref-type="supplementary-material" rid="fig3sdata3">Figure 3—source data 3</xref>. (<bold>E</bold>) Relative abundance of lipid classes (PG, phosphatidylglycerol; FA, fatty acids; PE, phosphatidylethanolamine; LPE, lysophosphatidylethanolamine) in untreated bacteria and bacteria treated with 46 µg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD for 60 min.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Transcriptomic and lipidomic data used to generate the graphs presented in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99752-fig3-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3—source data 2.</label><caption><title>Differential gene expression in low, 1:1 mix, and high tachyplesin-nitrobenzoxadiazole (NBD) accumulators.</title><p>Gene name and product, cluster and accumulator phenotype it belongs to, its log<sub>2</sub> fold change compared with the transcript copy number measured of untreated bacteria. These data are reported only for the 1,563 genes with significant differential expression in at least one of either low, 1:1 mix, or high accumulators compared to untreated bacteria.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99752-fig3-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3—source data 3.</label><caption><title>Biological processes are significantly enriched in each transcriptomic cluster.</title><p>Full and simplified list of biological processes that were significantly enriched in each cluster together with their gene ontology (GO) ID, description and shortened term, the corresponding ratio of number of genes annotated with the process term within the cluster over the total number of genes within the cluster (generation), the ratio of number of all genes annotated with the process term over the total number of genes annotated with any process term (bgratio), the p-value, adjusted p-value, and q-value, and the list of genes contained in each biological process.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99752-fig3-data3-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata4"><label>Figure 3—source data 4.</label><caption><title>Differential transcription factor activity between low and high tachyplesin-nitrobenzoxadiazole (NBD) accumulators.</title><p>Name and inferred activity of each transcription factor together with the list of genes it regulates.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99752-fig3-data4-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99752-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Principal component analysis of transcriptomes.</title><p>Cells were analysed after 60 min treatment in M9 only (black) or 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-nitrobenzoxadiazole (NBD), then sorted for low (blue) and high (red) accumulators, and 1:1 mix (purple) accumulators (generated by a 1:1 mixture of low and high accumulators). Circles, squares, diamonds, and triangles indicate four separate biological replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99752-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Clustering of differentially regulated genes in low, 1:1 mix, and high accumulators of tachyplesin-nitrobenzoxadiazole (NBD).</title><p>(<bold>A–E</bold>) Log<sub>2</sub> fold changes in transcript reads of genes in cluster 1 (<bold>A</bold>), 2 (<bold>B</bold>), 3 (<bold>C</bold>), 4 (<bold>D</bold>), and 5 (<bold>E</bold>) in low (blue), 1:1 mix (purple), and high (red) tachyplesin-NBD accumulators relative to the control treatment. Each point represents a single gene, dashed lines indicate the median and quartiles of each distribution. Dotted lines represent a log<sub>2</sub> fold change of 0. Statistical significance was tested using a paired Wilcoxon nonparametric test (due to non-normally distributed data) with a two-tailed p-value and confidence level at 95%. ****p&lt;0.0001. The full list of genes belonging to each cluster is reported in <xref ref-type="supplementary-material" rid="fig3sdata2">Figure 3—source data 2</xref>. Data were collected from four independent biological replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99752-fig3-figsupp2-v1.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Clustering of lipidomes of low and high accumulators of tachyplesin-nitrobenzoxadiazole (NBD).</title><p>Orthogonal partial least squares-discriminant analysis of the lipidomes measured for bacteria treated in M9 only (black) or sorted low (blue) or high (red) accumulators after 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD treatment for 60 min. Circles, squares, and diamonds indicate three separate biological replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99752-fig3-figsupp3-v1.tif"/></fig><fig id="fig3s4" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 4.</label><caption><title>Inferred transcription factor (TF) activity for the ten TFs with highest inferred activity in low and high tachyplesin-nitrobenzoxadiazole (NBD) accumulators.</title><p>TF activity reported as normalised enrichment scores (NES), for low and high accumulators (blue and red bars, respectively). Activity was inferred using <xref ref-type="supplementary-material" rid="fig3sdata2">Figure 3—source data 2</xref> and a full list of TFs and the genes they regulate within each cluster is reported in <xref ref-type="supplementary-material" rid="fig3sdata4">Figure 3—source data 4</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99752-fig3-figsupp4-v1.tif"/></fig></fig-group><p>Cluster 2 included processes involved in protein synthesis, energy production, and gene expression that were downregulated to a greater extent in low accumulators than high accumulators (see <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref> and <xref ref-type="supplementary-material" rid="fig3sdata3">Figure 3—source data 3</xref> for a short and complete list of genes involved in these processes, respectively).</p><p>Cluster 4 included processes involved in the transport of organic substances that were upregulated to a greater extent in low accumulators than high accumulators (<xref ref-type="fig" rid="fig3">Figure 3B and D</xref>). Notably, genes encoding major facilitator superfamily (MFS) and resistance-nodulation-division (RND) efflux pump components, such as <italic>emrK</italic>, <italic>mdtM</italic>, <italic>mdtE</italic>, and <italic>mdtF</italic>, were upregulated in low accumulators (<xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref> and <xref ref-type="supplementary-material" rid="fig3sdata3">Figure 3—source data 3</xref>).</p><p>Low and high accumulators displayed differential expression of biological pathways facilitating the synthesis and assembly of the lipopolysaccharides (LPS), which is the first site of interaction between gram-negative bacteria and AMPs (<xref ref-type="bibr" rid="bib68">Kushibiki et al., 2014</xref>). For example, <italic>clsB</italic>, encoding cardiolipin synthase B, was contained in cluster 2 and downregulated in low accumulators (<xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref> and <xref ref-type="supplementary-material" rid="fig3sdata3">Figure 3—source data 3</xref>), suggesting that low accumulators might display a lower content of cardiolipin that could bind tachyplesin due to its negative charge (<xref ref-type="bibr" rid="bib39">Edwards et al., 2017</xref>; <xref ref-type="bibr" rid="bib93">Matsuzaki et al., 1991</xref>). Moreover, we performed a comparative lipidomic analysis of untreated versus tachyplesin-NBD-treated stationary phase <italic>E. coli</italic> using ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry <xref ref-type="bibr" rid="bib32">Casula et al., 2023</xref>. In accordance with our transcriptomic data, we found that treatment with tachyplesin-NBD caused a strong decrease in phosphatidylglycerol (PG from 37% to 3%, i.e. the main constituent of cardiolipin), along with the emergence of lysophosphatidylethanolamines (LPE, 10%) and slight increases in PE and FA (<xref ref-type="fig" rid="fig3">Figure 3E</xref>, <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>, and <xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref>).</p><p><italic>ompA</italic>, <italic>ompC</italic>, <italic>degP</italic>, <italic>mcrB</italic>, <italic>tolA</italic>, <italic>tolB</italic>, and <italic>pal</italic> were downregulated in low accumulators, and their deletion has previously been associated with increased secretion of outer membrane vesicles (OMVs) that can confer resistance to AMPs and small molecule antibiotics (<xref ref-type="bibr" rid="bib102">Murray et al., 2020</xref>; <xref ref-type="bibr" rid="bib13">Balhuizen et al., 2021</xref>). Moreover, <italic>nlpA</italic>, <italic>lysS</italic>, <italic>waaC</italic>, and <italic>waaF</italic> were upregulated in low accumulators, and their overexpression has been previously associated with enhanced OMV secretion (<xref ref-type="bibr" rid="bib96">McBroom and Kuehn, 2007</xref>; <xref ref-type="bibr" rid="bib82">Liu et al., 2016</xref>; <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref> and <xref ref-type="supplementary-material" rid="fig3sdata3">Figure 3—source data 3</xref>).</p><p>Finally, low accumulators displayed an upregulation of peptidases and proteases compared to high accumulators, suggesting a potential mechanism for degrading tachyplesin (<xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref> and <xref ref-type="supplementary-material" rid="fig3sdata3">Figure 3—source data 3</xref>).</p><p>Noteworthy, tachyplesin-NBD has antibiotic efficacy (see <xref ref-type="fig" rid="fig2">Figure 2</xref>) and has an impact on the <italic>E. coli</italic> transcriptome (<xref ref-type="fig" rid="fig3">Figure 3</xref>). Therefore, we cannot conclude whether the transcriptomic differences reported above between low and high accumulators of tachyplesin-NBD are causative for the distinct accumulation patterns or if they are a consequence of differential accumulation and downstream phenotypic effects.</p><p>Next, we sought to infer transcription factor (TF) activities via differential expression of their known regulatory targets (<xref ref-type="bibr" rid="bib4">Alvarez et al., 2016</xref>). A total of 126 TFs were inferred to exhibit differential activity between low and high accumulators (<xref ref-type="supplementary-material" rid="fig3sdata4">Figure 3—source data 4</xref> and <xref ref-type="bibr" rid="bib75">Lee et al., 2025</xref>). Among the top ten TFs displaying higher inferred activity in low accumulators compared to high accumulators, four regulate transport systems, i.e., Nac, EvgA, Cra, and NtrC (<xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>). However, further experiments should be carried out to directly measure the activity of these TFs.</p><p>Taken together, these data suggest that phenotypic variants within clonal bacterial populations display a differential regulation of lipid composition, efflux, outer membrane vesicle secretion, and proteolytic processes that affect tachyplesin accumulation levels.</p></sec><sec id="s2-5"><title>Low accumulators display enhanced efflux activity</title><p>Next, we set out to delve deeper into the specific molecular mechanisms utilised by low accumulators in response to tachyplesin exposure. We investigated the accumulation kinetics of tachyplesin-NBD in individual stationary phase <italic>E. coli</italic> cells after different durations of tachyplesin-NBD treatment. Strikingly, within just 15 min of treatment, we observed high levels of tachyplesin-NBD accumulation in all cells, placing the whole population in the high accumulator group with a median fluorescence of 15,000 a.u. (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). However, after 30 min of treatment, a subpopulation began to display lower fluorescence, and after 60 min, the low accumulator fluorescence distribution became evident with a median fluorescence of 3600 a.u. (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). By contrast, the median fluorescence of high accumulators increased from 15,000 a.u. at 15 min to 32,000 a.u. after 120 min (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Taken together, these data demonstrate that the entire isogenic <italic>E. coli</italic> population initially accumulates tachyplesin-NBD to high levels, but a subpopulation can reduce intracellular accumulation of the drug in response to treatment while the other subpopulation continues to accumulate the drug to higher levels. Reduced intracellular accumulation of tachyplesin-NBD in the presence of extracellular tachyplesin-NBD could be due to decreased drug influx, increased drug efflux, increased proteolytic activity, or increased secretion of OMVs.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Low accumulators of tachyplesin-NBD display enhanced efflux activity.</title><p>(<bold>A</bold>) Distribution of tachyplesin-nitrobenzoxadiazole (NBD) accumulation in stationary phase <italic>E. coli</italic> BW25113 over 240 min of treatment with 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD in M9 at 37 °C. (<bold>B</bold>) Tachyplesin-NBD accumulation in <italic>E. coli</italic> BW25113 single or double gene-deletion mutants lacking efflux components or regulators of efflux components. Stationary phase populations of each mutant were treated with 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD at 37 °C for 60 min and single-cell fluorescence was measured via flow cytometry. (<bold>C, D</bold>) Efflux of tachyplesin-NBD over 240 min, after an initial 15 min preloading with 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD in M9 then washed and transferred into either M9 (<bold>C</bold>), or sertraline (30 μg mL<sup>–1</sup> or 98 μM) (<bold>D</bold>). The top histograms of panels B-D are reproduced from the 10 min histogram of panel A. Histograms in panels A-D are representative of three independent biological replicates and report 10,000 events. (<bold>E, F</bold>) Correlation of tachyplesin-NBD and PI fluorescence of individual stationary phase <italic>E. coli</italic> BW25113 cells measured in the microfluidic mother machine after 60 min of 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD treatment (N=108) (<bold>E</bold>), or 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD cotreatment with 30 μg mL<sup>–1</sup> (98 μM) sertraline (N=108) (<bold>F</bold>). Purple dashed lines show nonlinear (semi-log) regressions (r<sup>2</sup>=0.74 and 0.38, respectively). (<bold>G</bold>) Survival fraction of stationary phase <italic>E. coli</italic> BW25113 over 240 min treatment with tachyplesin-1 (46 μg mL<sup>–1</sup> or 20.3 μM, magenta squares), sertraline (30 μg mL<sup>–1</sup> or 98 μM, green circles), tachyplesin-1 (46 μg mL<sup>–1</sup> or 20.3 μM) cotreatment with sertraline (30 μg mL<sup>–1</sup> or 98 μM) (purple triangles), or incubation in M9 (black diamonds). Symbols and error bars indicate the mean and standard deviation of measurements performed in three independent biological replicates comprising three technical replicates each. Some error bars are masked behind the symbols.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Flow cytometry, microscopy, and colony-forming unit data used to generate the graphs presented in <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99752-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99752-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Ethidium bromide efflux in the presence and absence of unlabelled tachyplesin-1.</title><p><italic>E. coli</italic> cells were pre-loaded with ethidium bromide (EtBr) by adding 100 μg mL<sup>–1</sup> (254 μM) EtBr to a stationary phase culture 90 min before reaching 17 hr incubation at 37 °C and 200 rpm. Cells were then washed to remove extracellular EtBr before resuspending in either M9 (<bold>A</bold>) or 46 μg mL<sup>–1</sup> (20.3 μM) unlabelled tachyplesin. Single-cell EtBr fluorescence was then measured via flow cytometry over 120 min. Histograms are representative of three independent biological replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99752-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Impact of efflux component and transcription factor deletion on tachyplesin-nitrobenzoxadiazole (NBD) accumulation.</title><p>Tachyplesin-NBD accumulation in <italic>E. coli</italic> BW25113 single or double gene-deletion mutants lacking either efflux components or regulators of efflux components or the transcription factors reported in <xref ref-type="fig" rid="fig3s4">Figure 3—figure supplement 4</xref>. Stationary phase populations of each mutant were treated with 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD at 37 °C for 60 min and single-cell fluorescence was measured via flow cytometry. Histograms are representative of three independent biological replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99752-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Tachyplesin-nitrobenzoxadiazole (NBD) efflux in the presence of different efflux pump inhibitors.</title><p>(<bold>A–I</bold>) Temporal dependence of the distribution of tachyplesin-NBD accumulation in stationary phase <italic>E. coli</italic> treated in 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD in M9 for 15 min, then washed to remove extracellular tachyplesin-NBD and transferred into M9 (<bold>A</bold>), CCCP (50 μg mL<sup>–1</sup> or 244 μM) (<bold>B</bold>), sertraline (30 μg mL<sup>–1</sup> or 98 μM) (<bold>C</bold>), verapamil (50 μg mL<sup>–1</sup> or 110 μM) (<bold>D</bold>), berberine (250 μg mL<sup>–1</sup> or 743 μΜ) (<bold>E</bold>), baicalein (25 μg mL<sup>–1</sup> or 93 μM) (<bold>F</bold>), phenylalanine-arginine beta-naphthylamide (PAβN; 20 μg mL<sup>–1</sup> or 53 μM) (<bold>G</bold>), reserpine (20 μg mL<sup>–1</sup> or 33 μM) (<bold>H</bold>) and 1-(1-naphthylmethyl)piperazine (NMP; 100 μg mL<sup>–1</sup> or 442 μM) (<bold>I</bold>). Each distribution is representative of three independent biological replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99752-fig4-figsupp3-v1.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>Differences in metabolic activity of low and high tachyplesin-nitrobenzoxadiazole (NBD) accumulators.</title><p>Stationary phase <italic>E. coli</italic> BW25113 were treated with 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD in carbon-free M9 at 37 °C for 60 min. Cells were washed and then incubated in 1 μM resazurin and 50 μM CCCP in carbon-free M9 at 37 °C for 15 min. Single-cell fluorescence of resorufin and tachyplesin-NBD fluorescence was measured simultaneously with flow cytometry. (<bold>A</bold>) Single-cell resorufin fluorescence in all cells. The blue (low) and red (high) horizontal lines in each graph represent the gating applied and the median resorufin fluorescence of cells in the corresponding gate is reported within each gate. (<bold>B</bold>) Single-cell tachyplesin-NBD fluorescence measured in all cells (top panel); cells measured with low resorufin fluorescence (middle panel, showing cells only within the low resorufin gate in panel A); cells measured with high resorufin fluorescence (bottom panel, showing cells only within the high resorufin gate in panel A).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99752-fig4-figsupp4-v1.tif"/></fig></fig-group><p>Next, we performed efflux assays using ethidium bromide (EtBr) by adapting a previously described protocol (<xref ref-type="bibr" rid="bib148">Whittle et al., 2019</xref>). Briefly, we preloaded stationary phase <italic>E. coli</italic> with EtBr by incubating cells at a concentration of 254 µM EtBr in LB for 90 min. Cells were then pelleted and resuspended in M9 to remove extracellular EtBr. Single-cell EtBr fluorescence was measured at regular time points in the absence of extracellular EtBr using flow cytometry. This analysis revealed a progressive homogeneous decrease of EtBr fluorescence due to efflux from all cells within the stationary phase <italic>E. coli</italic> population (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). In contrast, when we performed efflux assays by preloading cells with tachyplesin-NBD (46 μg mL<sup>–1</sup> or 18.2 μM), followed by pelleting and resuspension in M9 to remove extracellular tachyplesin-NBD, we observed a heterogeneous decrease in tachyplesin-NBD fluorescence in the absence of extracellular tachyplesin-NBD: a subpopulation retained high tachyplesin-NBD fluorescence, i.e., high accumulators; whereas another subpopulation displayed decreased tachyplesin-NBD fluorescence, 60 min after the removal of extracellular tachyplesin-NBD (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Since these assays were performed in the absence of extracellular tachyplesin-NBD, decreased tachyplesin-NBD fluorescence could not be ascribed to decreased drug influx or increased secretion of OMVs in low accumulators, but could be due to either enhanced efflux or proteolytic activity in low accumulators.</p><p>Next, we repeated efflux assays using EtBr in the presence of 46 μg mL<sup>–1</sup> (or 20.3 µM) extracellular tachyplesin-1. We observed a heterogeneous decrease in EtBr fluorescence with a subpopulation retaining high EtBr fluorescence (i.e. high tachyplesin accumulators) and another population displaying reduced EtBr fluorescence (i.e. low tachyplesin accumulators, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>) when extracellular tachyplesin-1 was present. Moreover, we repeated tachyplesin-NBD efflux assays in the presence of M9 containing 50 μg mL<sup>–1</sup> (244 μM) carbonyl cyanide m-chlorophenyl hydrazone (CCCP), an ionophore that disrupts the proton motive force (PMF) and is commonly employed to abolish efflux and found that all cells retained tachyplesin-NBD fluorescence (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). However, it is important to note that CCCP does not only abolish efflux but also other respiration-associated and energy-driven processes (<xref ref-type="bibr" rid="bib126">Sharma et al., 2019</xref>).</p><p>Taken together, our data demonstrate that in the absence of extracellular tachyplesin, stationary phase <italic>E. coli</italic> homogeneously efflux EtBr, whereas only low accumulators are capable of performing efflux of intracellular tachyplesin after initial tachyplesin accumulation. In the presence of extracellular tachyplesin, only low accumulators can perform efflux of both intracellular tachyplesin and intracellular EtBr. However, it is also conceivable that besides enhanced efflux, low accumulators employ proteolytic activity, OMV secretion, and variations to their bacterial membrane to hinder further uptake and intracellular accumulation of tachyplesin in the presence of extracellular tachyplesin.</p><p>Next, we performed tachyplesin-NBD accumulation assays using 28 single and four double <italic>E. coli</italic> BW25113 gene-deletion mutants of efflux components and transcription factors regulating efflux. While for the majority of the mutants we recorded bimodal distributions of tachyplesin-NBD accumulation similar to the distribution recorded for the <italic>E. coli</italic> BW25113 parental strain (<xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>), we found unimodal distributions of tachyplesin-NBD accumulation constituted only of high accumulators for both <italic>ΔqseB</italic> and <italic>ΔqseBΔqseC</italic> mutants as well as reduced numbers of low accumulators for the <italic>ΔacrAΔtolC</italic> mutant (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Considering that the AcrAB-TolC tripartite RND efflux system is known to confer genetic resistance against AMPs like protamine and polymyxin-B (<xref ref-type="bibr" rid="bib147">Weatherspoon-Griffin et al., 2014</xref>; <xref ref-type="bibr" rid="bib81">Lister et al., 2012</xref>) and that the quorum sensing regulators <italic>qseBC</italic> might control the expression of <italic>acrA</italic> (<xref ref-type="bibr" rid="bib80">Li et al., 2020</xref>), these data further corroborate the hypothesis that low accumulators can efflux tachyplesin and survive treatment with this AMP.</p></sec><sec id="s2-6"><title>Tachyplesin accumulation and efficacy can be boosted with the addition of efflux pump inhibitors or nutrients</title><p>Next, we screened a panel of seven alternative efflux pump inhibitors (EPIs) to identify compounds capable of preventing the formation of low accumulators of tachyplesin-NBD. Interestingly, M9 containing 30 µg mL<sup>–1</sup> (98 μM) sertraline (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>), an antidepressant which inhibits efflux activity of RND pumps, potentially through direct binding to efflux pumps (<xref ref-type="bibr" rid="bib24">Bohnert et al., 2011</xref>) and decreasing the PMF (<xref ref-type="bibr" rid="bib78">Li et al., 2017</xref>), or 50 µg mL<sup>–1</sup> (110 μM) verapamil (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>), a calcium channel blocker that inhibits MATE transporters <xref ref-type="bibr" rid="bib115">Radchenko et al., 2015</xref> by a generally accepted mechanism of PMF generation interference (<xref ref-type="bibr" rid="bib118">Rodrigues et al., 2012</xref>; <xref ref-type="bibr" rid="bib91">Mahamoud et al., 2007</xref>), was able to prevent the emergence of low accumulators. Furthermore, tachyplesin-NBD cotreatment with sertraline simultaneously increased tachyplesin-NBD accumulation levels in individual cells and the proportion of PI-stained cells (<xref ref-type="fig" rid="fig4">Figure 4E and F</xref>). The use of berberine, a natural isoquinoline alkaloid that inhibits MFS transporters (<xref ref-type="bibr" rid="bib156">Ying and Xizhen, 2023</xref>) and RND pumps (<xref ref-type="bibr" rid="bib101">Morita et al., 2016</xref>), potentially by inhibiting conformational changes required for efflux activity (<xref ref-type="bibr" rid="bib156">Ying and Xizhen, 2023</xref>), and baicalein, a natural flavonoid compound that inhibits ABC (<xref ref-type="bibr" rid="bib145">Wang et al., 2019</xref>) and MFS (<xref ref-type="bibr" rid="bib46">Fujita et al., 2005</xref>; <xref ref-type="bibr" rid="bib33">Chan et al., 2011</xref>) transporters, potentially through PMF dissipation (<xref ref-type="bibr" rid="bib146">Wang et al., 2023</xref>), led to the formation of a unimodal distribution of low accumulators of tachyplesin (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>). Phenylalanine-arginine beta-naphthylamide (PAβN), a synthetic peptidomimetic compound that inhibits RND pumps (<xref ref-type="bibr" rid="bib35">Cortez-Cordova and Kumar, 2011</xref>) through competitive inhibition (<xref ref-type="bibr" rid="bib34">Compagne et al., 2023</xref>), reserpine, an indole alkaloid that inhibits ABC and MFS transporters, and RND pumps (<xref ref-type="bibr" rid="bib125">Shaheen et al., 2019</xref>), by altering the generation of the PMF (<xref ref-type="bibr" rid="bib91">Mahamoud et al., 2007</xref>), and 1-(1-naphthylmethyl)piperazine (NMP), a synthetic piperazine derivative that inhibits RND pumps (<xref ref-type="bibr" rid="bib23">Bohnert and Kern, 2005</xref>), through non-competitive inhibition (<xref ref-type="bibr" rid="bib142">Vargiu et al., 2014</xref>), did not prevent the emergence of low accumulators (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>).</p><p>Next, we investigated whether sertraline could enhance the bactericidal activity of the parent drug, tachyplesin-1. Using colony-forming unit assays, we measured the survival fraction of stationary phase <italic>E. coli</italic> treated with either tachyplesin-1 at 46 μg mL<sup>–1</sup> (20.3 μM) (which has an MIC value of 1 µg mL<sup>–1</sup> or 0.43 μM against <italic>E. coli</italic> <xref ref-type="bibr" rid="bib70">Łapińska et al., 2022</xref>) or sertraline at 30 μg mL<sup>–1</sup> (98 μM) (for which we determined an MIC value of 128 μg mL<sup>–1</sup> or 418 μM against <italic>E. coli</italic>, see <xref ref-type="supplementary-material" rid="fig4sdata1">Figure 4—source data 1</xref>), or a combination of both compounds, and compared these data to untreated <italic>E. coli</italic> incubated in M9. The survival fraction after treatment with sertraline was comparable to that measured for untreated <italic>E. coli</italic>, whereas the survival fraction measured after the combination treatment was fivefold lower than that measured after tachyplesin-1 treatment (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). Increased tachyplesin efficacy in the presence of sertraline is likely due to efflux inhibition. However, it is also conceivable that increased tachyplesin efficacy is due to metabolic and transcriptomic changes induced by sertraline.</p><p>Our transcriptomics analysis also showed that low tachyplesin accumulators downregulated genes associated with protein synthesis, energy production, and gene expression compared to high accumulators. To gain further insight into the metabolic state of low tachyplesin accumulators, we employed the membrane-permeable redox-sensitive dye, resazurin, which is reduced to the highly fluorescent resorufin in metabolically active cells. We first treated stationary phase <italic>E. coli</italic> with 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD for 60 min, then washed the cells, and then incubated them in 1 μM resazurin and 50 μM CCCP for 15 min and measured single-cell fluorescence of resorufin and tachyplesin-NBD simultaneously via flow cytometry. CCCP was included to minimise differences in efflux activity and preserve resorufin retention between low and high accumulators, though some variability in efflux may still persist. We found that low tachyplesin-NBD accumulators also displayed low fluorescence of resorufin, whereas high tachyplesin-NBD accumulators also displayed high fluorescence of resorufin (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>), suggesting lower metabolic activity in low tachyplesin-NBD accumulators.</p><p>Therefore, we set out to test the hypothesis that the formation of low accumulators could be prevented by manipulating the nutrient environment around the bacteria. We treated stationary phase <italic>E. coli</italic> with 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD either in M9, or M9 supplemented with 0.4% glucose and 0.2% casamino acids. After 15 min of treatment, both conditions resulted in a unimodal fluorescence distribution, with median values of 15,000 a.u. and 18,000 a.u., respectively (<xref ref-type="fig" rid="fig4">Figures 4A</xref> and <xref ref-type="fig" rid="fig5">5A</xref>, respectively). However, upon extending the treatment to 30 min, we observed distinct responses to tachyplesin-NBD treatment. For <italic>E. coli</italic> treated with tachyplesin-NBD in M9, the emergence of low accumulators led to a bimodal distribution of single-cell fluorescence (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). In contrast, when <italic>E. coli</italic> was treated with tachyplesin-NBD in M9 supplemented with nutrients, the fluorescence of the entire population increased, resulting in a unimodal distribution of single-cell fluorescence with a median of 35,000 a.u. (<xref ref-type="fig" rid="fig5">Figure 5A</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Impact of nutritional environment and growth phase on tachyplesin-nitrobenzoxadiazole (NBD) accumulation and efficacy.</title><p>(<bold>A, B</bold>) Temporal dependence of the distribution of tachyplesin-NBD accumulation in stationary phase <italic>E. coli</italic> in M9 supplemented with 0.4% glucose and 0.2% casamino acids (<bold>A</bold>) and exponential phase <italic>E. coli</italic> in M9 only (<bold>B</bold>) treated with 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD. Each distribution is representative of three independent biological replicates. (<bold>C</bold>) Survival fraction of untreated stationary phase <italic>E. coli</italic> in M9 only (black diamonds), and bacteria treated with 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD over 240 min in stationary phase <italic>E. coli</italic> in M9 only (green circles), stationary phase <italic>E. coli</italic> treated in M9 supplemented with 0.4% glucose and 0.2% casamino acids (purple triangles), exponential phase <italic>E. coli</italic> treated in M9 only (magenta squares). Symbols and error bars indicate the mean and standard deviation of three biological replicates measured from three technical replicates each. Some error bars are masked behind the symbols.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Flow cytometry and colony-forming unit data were used to generate the graphs presented in <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-99752-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99752-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Impact of the bacterial phase of growth on cell size.</title><p>(<bold>A, B</bold>) Histograms showing the forward scatter (<bold>A</bold>) and side scatter (<bold>B</bold>) of high tachyplesin-nitrobenzoxadiazole (NBD) accumulators in stationary (blue) and exponential (red) phase cells after treatment in 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD in M9 at 37 °C for 60 min with the corresponding median values reported for each distribution. Each distribution is representative of three independent biological replicates.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-99752-fig5-figsupp1-v1.tif"/></fig></fig-group><p>Similarly, <italic>E. coli</italic> incubated in LB for 3 h before drug treatment, and therefore in the exponential phase of growth, displayed a unimodal fluorescence distribution with a median of 80,000 a.u. after 10 min treatment in tachyplesin-NBD in M9 (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). These exponential phase bacteria also displayed a modest increase in cell size compared to stationary phase <italic>E. coli</italic> (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Interestingly, a small subpopulation of low accumulators emerged within exponential phase <italic>E. coli</italic> after 120 min tachyplesin-NBD treatment in M9, with a median of 4700 a.u. (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). This subpopulation contributed to 10% of the entire isogenic <italic>E. coli</italic> population, five-fold less abundant compared to stationary phase <italic>E. coli</italic> treated in tachyplesin-NBD in M9 (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Finally, we investigated whether preventing the formation of low accumulators via nutrient supplementation could enhance the efficacy of tachyplesin treatment by performing colony-forming unit assays. We observed that tachyplesin exhibited enhanced efficacy in eradicating <italic>E. coli</italic> both when M9 was supplemented with nutrients, and against exponential phase <italic>E. coli</italic> compared to stationary phase <italic>E. coli</italic> without nutrient supplementation (<xref ref-type="fig" rid="fig5">Figure 5C</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The link between antimicrobial accumulation and efficacy has not been widely investigated, especially in the context of AMPs (<xref ref-type="bibr" rid="bib119">Rybenkov et al., 2021</xref>). In fact, it has been widely accepted that the cell membrane is the primary target of most AMPs and that their main mechanism of action is membrane disruption. However, emerging evidence suggests that AMPs may also enter the intracellular environment and target intracellular processes, creating opportunities for the development of bacterial resistance (<xref ref-type="bibr" rid="bib116">Rima et al., 2021</xref>; <xref ref-type="bibr" rid="bib100">Mookherjee et al., 2020</xref>; <xref ref-type="bibr" rid="bib90">Magana et al., 2020</xref>; <xref ref-type="bibr" rid="bib17">Bechinger and Gorr, 2017</xref>).</p><p>Here, we demonstrate for the first time that there is a strong correlation between tachyplesin intracellular accumulation and efficacy. We show that after an initial homogeneous tachyplesin accumulation within a stationary phase <italic>E. coli</italic> population, tachyplesin is retained intracellularly by bacteria that do not survive tachyplesin exposure, whereas tachyplesin is retained only in the membrane of bacteria that survive tachyplesin exposure.</p><p>These findings align with evidence showing that modifications to tachyplesin that preserve membrane disruption but reduce membrane translocation, such as linear analogues or PEGylation, result in diminished antimicrobial activity (<xref ref-type="bibr" rid="bib61">Imura et al., 2007</xref>; <xref ref-type="bibr" rid="bib94">Matsuzaki et al., 1997</xref>). Furthermore, tachyplesin has also been reported to interact with intracellular targets such as the minor groove of DNA (<xref ref-type="bibr" rid="bib61">Imura et al., 2007</xref>; <xref ref-type="bibr" rid="bib157">Yonezawa et al., 1992</xref>), intracellular esterases (<xref ref-type="bibr" rid="bib57">Hong et al., 2015</xref>), or the 3-ketoacyl carrier protein reductase FabG (<xref ref-type="bibr" rid="bib83">Liu et al., 2018</xref>). However, our transcriptomic analysis did not reveal differential regulation of any of these pathways between low and high accumulators of tachyplesin, suggesting that bacteria likely employ alternative mechanisms rather than target downregulation to survive tachyplesin treatment, a point on which we expand below.</p><p>The emergence of genetic resistance to AMPs is strikingly lower compared to resistance to small molecule antibiotics (<xref ref-type="bibr" rid="bib131">Spohn et al., 2019</xref>; <xref ref-type="bibr" rid="bib17">Bechinger and Gorr, 2017</xref>; <xref ref-type="bibr" rid="bib64">Kintses et al., 2019a</xref>). However, research on AMP resistance has often focused on whole population responses (<xref ref-type="bibr" rid="bib131">Spohn et al., 2019</xref>; <xref ref-type="bibr" rid="bib17">Bechinger and Gorr, 2017</xref>; <xref ref-type="bibr" rid="bib64">Kintses et al., 2019a</xref>; <xref ref-type="bibr" rid="bib60">Hong et al., 2022</xref>), overlooking heterogeneous responses to drug treatment in isogenic bacteria. Crucially, phenotypic variants can survive treatment with small molecule antibiotics through several distinct phenomena, including persistence (<xref ref-type="bibr" rid="bib12">Balaban et al., 2019</xref>), the viable but nonculturable state (<xref ref-type="bibr" rid="bib8">Ayrapetyan et al., 2018</xref>), heteroresistance (<xref ref-type="bibr" rid="bib5">Andersson et al., 2019</xref>), tolerance (<xref ref-type="bibr" rid="bib151">Windels et al., 2019b</xref>), and perseverance (<xref ref-type="bibr" rid="bib27">Brandis et al., 2023</xref>).</p><p>Here, we report the first observation of phenotypic resistance to tachyplesin within isogenic <italic>E. coli</italic> and <italic>P. aeruginosa</italic> populations. This novel phenomenon is characterised by a bimodal distribution of tachyplesin accumulation, revealing two distinct subpopulations: low (surviving) and high (susceptible) accumulators. This bimodal distribution draws similarities to the perseverance phenomenon identified for two antimicrobials possessing intracellular targets, rifampicin and nitrofurantoin. Perseverance is characterised by a bimodal distribution of single-cell growth rates, where the slower-growing subpopulation maintains growth during drug treatment (<xref ref-type="bibr" rid="bib27">Brandis et al., 2023</xref>).</p><p>Bacteria can reduce the intracellular concentration of antimicrobials via active efflux, allowing them to survive in the presence of high extracellular antimicrobial concentrations (<xref ref-type="bibr" rid="bib19">Blair et al., 2015</xref>). Efflux as a mechanism of tachyplesin resistance has been shown at the population level in tachyplesin-resistant <italic>P. aeruginosa</italic> via transcriptome analysis (<xref ref-type="bibr" rid="bib60">Hong et al., 2022</xref>; <xref ref-type="bibr" rid="bib59">Hong et al., 2020</xref>), whereas phenotypic resistance to tachyplesin has not been investigated. Heterogeneous expression of efflux pumps within isogenic bacterial populations has been reported (<xref ref-type="bibr" rid="bib113">Pu et al., 2016</xref>; <xref ref-type="bibr" rid="bib42">El Meouche and Dunlop, 2018</xref>; <xref ref-type="bibr" rid="bib70">Łapińska et al., 2022</xref>; <xref ref-type="bibr" rid="bib18">Bergmiller et al., 2017</xref>; <xref ref-type="bibr" rid="bib41">El Meouche et al., 2016</xref>; <xref ref-type="bibr" rid="bib74">Le et al., 2021</xref>). However, recent reports have suggested that efflux is not the primary mechanism of antimicrobial resistance within stationary phase bacteria (<xref ref-type="bibr" rid="bib149">Whittle et al., 2021</xref>; <xref ref-type="bibr" rid="bib99">Mitchell et al., 2017</xref>) and the impact of heterogeneous efflux pump expression on AMP accumulation is unknown. Here, we show for the first time the upregulation of a range of MFS, ABC, and RND efflux pumps in a stationary phase subpopulation that exhibited low accumulation of tachyplesin with corresponding enhanced survival and that the deletion of two components of the AcrAB-TolC efflux pump or the quorum sensing regulator QseBC leads to a dramatic decrease in the numbers of low accumulators.</p><p>Moreover, whether certain resistance mechanisms utilised by phenotypic variants surviving antimicrobial treatment are preemptive or induced by drug treatment is underinvestigated (<xref ref-type="bibr" rid="bib12">Balaban et al., 2019</xref>; <xref ref-type="bibr" rid="bib44">Fernández and Hancock, 2012</xref>) primarily due to the requirement of prior selection for phenotypic variants (<xref ref-type="bibr" rid="bib113">Pu et al., 2016</xref>). As our accumulation assay did not require the prior selection for phenotypic variants, we have demonstrated that low accumulators emerge subsequent to the initial high accumulation of tachyplesin-NBD, suggesting enhanced efflux as an induced response. However, it is conceivable that other pre-existing traits of low accumulators also contribute to reduced tachyplesin accumulation. For example, reduced protein synthesis, energy production, and gene expression in low accumulators could slow down tachyplesin efficacy, giving low accumulators more time to mount efflux as an additional protective response.</p><p>Furthermore, most AMPs are cationic and interact electrostatically with the negatively charged LPS in the bacterial outer membrane (<xref ref-type="bibr" rid="bib77">Lei et al., 2019</xref>). To reduce affinity to AMPs, bacteria can modify their membrane charge, thickness, fluidity, or curvature (<xref ref-type="bibr" rid="bib87">MacDermott-Opeskin et al., 2022</xref>). At the population level, bacteria have been reported to add positively charged <sc>L</sc>-Ara4N or phosphoethanolamine (pEtN) to LPS lipid-A to resist AMPs (<xref ref-type="bibr" rid="bib17">Bechinger and Gorr, 2017</xref>). Accordingly, our transcriptomics analysis revealed the upregulation in the low accumulator subpopulation of the <italic>arn</italic> operon that is involved in the biosynthesis and attachment of the positively charged <sc>L</sc>-Ara4N to lipid-A (<xref ref-type="bibr" rid="bib155">Yan et al., 2007</xref>). Furthermore, tachyplesin has been shown to bind strongly to negatively charged PG lipids (<xref ref-type="bibr" rid="bib93">Matsuzaki et al., 1991</xref>). Accordingly, our lipidomics data revealed that tachyplesin-treated bacteria were composed of significantly lower abundance of PG lipids compared to the untreated bacteria.</p><p>OMVs, nano-sized proteoliposomes secreted by Gram-negative bacteria, are a less studied system that allows bacteria to remove AMPs from the cell (<xref ref-type="bibr" rid="bib67">Kulp and Kuehn, 2010</xref>). Increased secretion of OMVs has also been shown to be induced by AMP exposure (<xref ref-type="bibr" rid="bib13">Balhuizen et al., 2021</xref>). OMVs are suggested to counteract AMPs via at least three mechanisms: the adsorption of extracellular AMPs to decrease AMP concentrations in the environment <xref ref-type="bibr" rid="bib102">Murray et al., 2020</xref>; <xref ref-type="bibr" rid="bib13">Balhuizen et al., 2021</xref>; removal of parts of the bacterial outer membrane affected by AMPs <xref ref-type="bibr" rid="bib13">Balhuizen et al., 2021</xref>; and export of antimicrobials from the intracellular compartment (<xref ref-type="bibr" rid="bib97">Medvedeva et al., 2014</xref>). Our transcriptomic data revealed the downregulation in low accumulators of genes, such as <italic>ompA</italic> and <italic>ompC</italic>, known to increase the secretion of OMVs upon deletion, and the upregulation of genes, such as <italic>nlpA</italic>, whose overexpression has been linked to enhanced OMV secretion (<xref ref-type="bibr" rid="bib107">Nevermann et al., 2019</xref>; <xref ref-type="bibr" rid="bib88">MacNair and Tan, 2023</xref>).</p><p>Bacteria also employ extracellular or intracellular proteases <xref ref-type="bibr" rid="bib20">Blair et al., 2022</xref>; <xref ref-type="bibr" rid="bib17">Bechinger and Gorr, 2017</xref> and peptidases <xref ref-type="bibr" rid="bib79">Li et al., 2018</xref>; <xref ref-type="bibr" rid="bib95">Mattiuzzo et al., 2014</xref> to cleave and neutralise the activity of AMPs, including tachyplesin (<xref ref-type="bibr" rid="bib58">Hong et al., 2016</xref>). Our transcriptomic analysis revealed the simultaneous upregulation in low accumulators of proteases and peptidases that could potentially degrade tachyplesin either extracellularly or intracellularly.</p><p>Responses to extrinsic environmental cues, such as the starvation-induced stringent response, have been shown to induce failure in antimicrobial treatment (<xref ref-type="bibr" rid="bib112">Podlesek and Žgur Bertok, 2020</xref>). These responses are typically mediated by two-component regulatory systems (TCSs) sensing external stimuli via sensor kinases and altering gene expression via response regulators (<xref ref-type="bibr" rid="bib55">Hirakawa et al., 2020</xref>). Additionally, nucleoid-associated proteins (NAPs) influence bacterial chromosome organisation and gene transcription in response to intracellular or extracellular stress factors (<xref ref-type="bibr" rid="bib56">Hołówka and Zakrzewska-Czerwińska, 2020</xref>). Finally, transcriptional regulators such as regulators of the LysR family and histone-like proteins (H-NS) also modulate gene expression (<xref ref-type="bibr" rid="bib152">Wójcicki et al., 2021</xref>). One such TCS, QseBC, was previously inferred to mediate resistance to a tachyplesin analogue by upregulating efflux genes based on transcriptomic analysis and hypersusceptibility of Δ<italic>qseB</italic>Δ<italic>qseC</italic> mutants (<xref ref-type="bibr" rid="bib159">Yu et al., 2020</xref>). Accordingly, we demonstrated that Δ<italic>qseBΔqseC</italic> mutants display only high accumulators of tachyplesin-NBD, suggesting that this TCS might play an important role in the control of tachyplesin efflux, possibly by regulating the expression of AcrA and TolC or other efflux components (<xref ref-type="bibr" rid="bib80">Li et al., 2020</xref>). This data provides experimental support for the involvement of QseBC-mediated efflux of tachyplesin, extending previous transcription-based inferences. However, it is also conceivable that the deletion of QseBC has pleiotropic effects on other cellular mechanisms involved in tachyplesin accumulation. We also acknowledge that our data do not take into account post-transcriptional modifications that represent a second control point to survive external stressors.</p><p>Drugs that inhibit the efflux activity of bacterial pathogens have been shown to be a promising strategy for repurposing antimicrobials (<xref ref-type="bibr" rid="bib21">Blanco et al., 2018</xref>; <xref ref-type="bibr" rid="bib138">Turner et al., 2019</xref>; <xref ref-type="bibr" rid="bib3">AlMatar et al., 2021</xref>). An FDA-approved drug, sertraline, was found to be effective in preventing the formation of the low accumulator phenotype by inhibiting tachyplesin efflux and enhancing the eradication of stationary phase bacteria, although it is also conceivable that sertraline prevented the formation of the low accumulator phenotype via efflux-independent mechanisms. These data strongly suggest that EPIs are a promising approach for developing new combination therapies against stationary phase bacteria, contrary to previous evidence suggesting their ineffectiveness against stationary phase bacteria (<xref ref-type="bibr" rid="bib149">Whittle et al., 2021</xref>). However, it should be noted that the concentration of sertraline in the plasma of patients using sertraline as an antidepressant is below the concentration that we employed in our study (<xref ref-type="bibr" rid="bib114">Rácz and Spengler, 2023</xref>). This limitation underscores the broader challenge of identifying EPIs that are both effective and minimally toxic within clinically achievable concentrations, while also meeting key therapeutic criteria such as broad-spectrum efficacy against diverse efflux pumps, high specificity for bacterial targets, and non-inducers of AMR (<xref ref-type="bibr" rid="bib163">Zhang et al., 2023c</xref>). However, advances in biochemical, computational, and structural methodologies hold the potential to guide rational drug design, making the search for effective EPIs more promising (<xref ref-type="bibr" rid="bib109">Opperman and Nguyen, 2015</xref>). Therefore, more investigation should be carried out to further optimise the use of sertraline or other EPIs in combination with tachyplesin and other AMPs.</p><p>Moreover, growth rate and metabolism have been shown to influence antimicrobial efficacy (<xref ref-type="bibr" rid="bib85">Lopatkin et al., 2019</xref>), with starved or slow growing stationary phase bacteria becoming transiently insensitive to antimicrobials when metabolites or ATP become unavailable (<xref ref-type="bibr" rid="bib135">Tamer et al., 2021</xref>). For example, the expression of efflux genes has been shown to be increased in <italic>E. coli</italic> in minimal media compared to rich media (<xref ref-type="bibr" rid="bib10">Bailey et al., 2006</xref>). Due to the heightened resistance of starved and stationary phase cells, successful attempts have been made to selectively target metabolically dormant bacteria (<xref ref-type="bibr" rid="bib164">Zheng et al., 2024</xref>) or to sensitise recalcitrant cells via metabolites as a potential therapeutic strategy (<xref ref-type="bibr" rid="bib2">Allison et al., 2011</xref>; <xref ref-type="bibr" rid="bib98">Meylan et al., 2017</xref>; <xref ref-type="bibr" rid="bib54">Gutierrez et al., 2017</xref>). Likewise, we found that stationary phase cells supplemented with glucose and casamino acids were more sensitive to treatment with tachyplesin. However, nutrient supplementation may potentially lead to an increase in bacterial cell count and disease burden, as well as an escalation in selection pressure on surviving cells. Moreover, nutrient supplementation as a therapeutic strategy may not be viable in many infection contexts, as host density and the immune system often regulate access to nutrients (<xref ref-type="bibr" rid="bib134">Tamer and Toprak, 2017</xref>). It may be worthwhile to test other metabolites such as fumarate, which has received FDA approval in several drugs and has been shown to potentiate antimicrobial efficacy (<xref ref-type="bibr" rid="bib98">Meylan et al., 2017</xref>). Therefore, we conclude that the use of EPIs in combination with tachyplesin represents a more viable antimicrobial treatment against antimicrobial-refractory stationary phase bacteria.</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Chemicals and cell culture</title><p>All chemicals were purchased from Fisher Scientific or Sigma-Aldrich unless otherwise stated. LB medium (10 g L<sup>–1</sup> tryptone, 5 g L<sup>–1</sup> yeast extract, and 10 g L<sup>–1</sup> NaCl) and LB agar plates (LB with 15 g L<sup>–1</sup> agar) were used for planktonic growth and streak plates, respectively. Tachyplesin-1 and tachyplesin-1-NBD were synthesised by WuXi AppTech (Shanghai, China). Stock solutions of antimicrobials (1.28 mg mL<sup>–1</sup>), PI (1.5 mM), proteinase K (20 mg mL<sup>–1</sup>), and EtBr (1 mg mL<sup>–1</sup>) were obtained by dissolving in Milli-Q water. All EPIs and C<sub>12</sub>-resazurin were obtained by dissolving in dimethyl sulfoxide at a concentration of 1 mg mL<sup>–1</sup>. Carbon-free M9-minimal medium used for dilution of antimicrobials, PI, proteinase K, EtBr, EPIs, C<sub>12</sub>-resazurin, and bacteria was prepared using 5×M9 minimal salts (Merck, Germany), with an additional 2 mM MgSO<sub>4</sub> and 0.1 mM CaCl<sub>2</sub> in Milli-Q water. 0.4% glucose and 0.2% casamino acids were added to yield nutrient-supplemented M9. M9 was then filtered through a 0.22 μm Minisart Syringe Filter (Sartorius, Germany).</p><p><italic>E. coli</italic> BW25113 and <italic>S. aureus</italic> ATCC 25923 were purchased from Dharmacon (Horizon Discovery, UK). <italic>E. coli</italic> and <italic>K. pneumoniae</italic> (JS1187) clinical isolates were kindly provided by Fernanda Paganelli, UMC Utrecht, the Netherlands. <italic>P. aeruginosa</italic> (PA14 <italic>flgK</italic>::Tn5B30(Tc)) was kindly provided by George O’Toole, Dartmouth College, USA. <italic>E. coli</italic> single-gene deletion KO mutants were obtained from the Keio collection (<xref ref-type="bibr" rid="bib9">Baba et al., 2006</xref>). To construct double gene-deletion mutants, the antibiotic resistance gene flanked by flippase recognition target sequences was removed from the chromosome using the pCP20 plasmid which encodes the flippase enzyme. The resulting transformants were then treated as described previously (<xref ref-type="bibr" rid="bib36">Datsenko and Wanner, 2000</xref>). Double gene-deletion mutants were then subsequently constructed by P1vir transduction of alleles from the Keio collection, as previously detailed (<xref ref-type="bibr" rid="bib137">Thomason et al., 2007</xref>). All strains were stored in a 50% glycerol stock at –80 °C. Streak plates for each strain were produced by thawing a small aliquot of the corresponding glycerol stock every week and plated onto LB agar plates. Stationary phase cultures were prepared by inoculating 100 mL fresh LB medium with a single bacterial colony from a streak plate and incubated on a shaking platform at 200 rpm and 37 °C for 17 h (<xref ref-type="bibr" rid="bib132">Stie et al., 2020</xref>). Exponential phase cultures were prepared by transferring 100 μL of a stationary phase culture into 100 mL LB and incubated on a shaking platform at 200 rpm and 37 °C for 3 h.</p></sec><sec id="s4-2"><title>Synthesis of fluorescent antimicrobial derivatives</title><p>Fluorescent antimicrobial derivatives of tachyplesin (<xref ref-type="bibr" rid="bib22">Blaskovich et al., 2019</xref>; <xref ref-type="bibr" rid="bib39">Edwards et al., 2017</xref>), arenicin (<xref ref-type="bibr" rid="bib40">Elliott et al., 2020</xref>), polymyxin-B (<xref ref-type="bibr" rid="bib47">Gallardo-Godoy et al., 2016</xref>), and octapeptin <xref ref-type="bibr" rid="bib143">Velkov et al., 2018</xref> were designed and synthesised based on structure-activity-relationship studies and synthetic protocols reported in previous publications (<xref ref-type="bibr" rid="bib160">Zhang et al., 2022</xref>), substituting a non-critical amino acid residue with an azidolysine residue that was then employed for the subsequent Cu-catalysed azide-alkyne cycloaddition ‘click’ reactions with nitrobenzoxadiazole (NBD)-alkyne. Detailed synthesis and characterisation of these probes will be reported in due course.</p></sec><sec id="s4-3"><title>Phylogenetic and AMR genes analyses</title><p>The <italic>E. coli</italic> BW25113 genome sequence was downloaded from the National Center for Biotechnology Information’s (NCBI) GenBank (<xref ref-type="bibr" rid="bib53">Grenier et al., 2014</xref>). <italic>E. coli</italic> clinical isolates MA02514, MA07534, MA08141, MC04960, and MC42862 were collected and sequenced by UMC Utrecht, the Netherlands (<xref ref-type="bibr" rid="bib141">van den Bunt, 2014</xref>). Briefly, genomic DNA libraries were prepared using the Nextera XT Library Prep Kit (Illumina, USA) and sequenced on either the Illumina MiSeq or NextSeq (Illumina, USA). Contigs were assembled using SPAdes Genome Assembler version 3.6.2 (<xref ref-type="bibr" rid="bib15">Bankevich et al., 2012</xref>), and contigs larger than 500  bp with at least 10× coverage were further analysed. <italic>E. coli</italic> clinical isolates JS1060, JS1073, JS1147, and JS1147 were collected by UMC Utrecht, the Netherlands, and were sequenced by a microbial genome sequencing service (MicrobesNG, UK). Briefly, genomic DNA libraries were prepared using the Nextera XT Library Prep Kit (Illumina, USA) following the manufacturer’s protocol with the following modifications: input DNA was increased twofold, and PCR elongation time was increased to 45 s. DNA quantification and library preparation were carried out on a Hamilton Microlab STAR automated liquid handling system (Hamilton Bonaduz AG, Switzerland). Libraries were sequenced on an Illumina NovaSeq 6000 (Illumina, USA) using a 250 bp paired-end protocol. Reads and adapters trimmed using Trimmomatic version 0.30 (<xref ref-type="bibr" rid="bib25">Bolger et al., 2014</xref>) with a sliding window quality cutoff of Q15. De novo assembly was performed on samples using SPAdes version 3.7 (<xref ref-type="bibr" rid="bib15">Bankevich et al., 2012</xref>), and contigs were annotated using Prokka 1.11 (<xref ref-type="bibr" rid="bib123">Seemann, 2014</xref>).</p><p>Genomic data for AMR genes were screened through ABRicate (<xref ref-type="bibr" rid="bib124">Seemann, 2016</xref>) and the NCBI’s AMRFinderPlus databases (<xref ref-type="bibr" rid="bib43">Feldgarden et al., 2021</xref>). A rooted phylogenetic tree was created from the genomic data by pairwise distance estimation of all genomes and an outgroup genome (NCBI’s reference genome for <italic>Escherichia fergusonii</italic>) with the <italic>dist</italic> function from the Mash package (<xref ref-type="bibr" rid="bib108">Ondov et al., 2016</xref>), with a k-mer size of 21. Unrooted phylogenetic trees were created from the resulting pairwise distance matrices using the <italic>nj</italic> (neighbour joining) function in APE (<xref ref-type="bibr" rid="bib111">Paradis et al., 2004</xref>). These trees were then rooted to the outgroup (<italic>ape::root</italic>). The phylogenetic tree was plotted against presence/absence heatmaps of AMR genes using <italic>ggtree</italic> (<xref ref-type="bibr" rid="bib154">Xu et al., 2022</xref>).</p></sec><sec id="s4-4"><title>Flow cytometric assays</title><p>Bacterial cultures were prepared as described above. For all flow cytometric assays, bacterial cultures (stationary and exponential phase) were adjusted to an OD<sub>600</sub> of four for <italic>E. coli</italic> and <italic>K. pneumoniae</italic>, five for <italic>S. aureus</italic>, and two for <italic>P. aeruginosa</italic> (<xref ref-type="bibr" rid="bib72">Łapińska et al., 2025</xref>). Cultures were pelleted by centrifugation in a SLS4600 microcentrifuge (Scientific Laboratory Supplies, UK) at 4000 ×<italic>g</italic> and room temperature for 5 min. The supernatant was then removed, and cells were resuspended in the appropriate volume of the treatment solution for incubation, with a final volume between 50 and 550 μL depending on the experiment. All treatments were incubated at 37 °C and 1000 rpm on a ThermoMixer C (Eppendorf, Germany), except for cold treatments, which were incubated on ice, for the stated duration. All wash steps were performed to remove any unaccumulated compounds by centrifugation at 4000 ×<italic>g</italic> for 5 min, after which the supernatant was removed to eliminate any extracellular drug.</p><p>For AMP accumulation assays, bacteria were incubated with the stated concentration of peptide in either carbon-free or nutrient-supplemented M9. For proteinase K degradation and C<sub>12</sub>-resazurin metabolic activity assays, <italic>E. coli</italic> was first incubated in 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD for 60 min followed by a wash step. Cells were then incubated in either 20 μg mL<sup>–1</sup> (0.7 μM) proteinase K, or 1 μM C<sub>12</sub>-resazurin and 50 μM CCCP, all diluted in carbon-free M9. For tachyplesin-NBD efflux assays, <italic>E. coli</italic> was incubated in 46 μg mL<sup>–1</sup> (18.2 μM) tachyplesin-NBD for 5 min, followed by a wash step and incubation in EPI diluted in carbon-free M9. For EtBr efflux assays, <italic>E. coli</italic> was preloaded with EtBr by adding 100 μg mL<sup>–1</sup> (254 μM) EtBr to the stationary phase culture 90 min before a total of 17 h incubation (i.e. 15.5 h post-inoculation). Cells were then washed and incubated in 46 μg mL<sup>–1</sup> (20.3 μM) unlabelled tachyplesin-1 diluted in carbon-free M9. Carbon-free M9 was used as the untreated control in all flow cytometric assays.</p><p>At the stated incubation time points, a 30 μL sacrificial aliquot was transferred to microcentrifuge tubes. A wash step was immediately performed, after which cells were resuspended and diluted 500x in carbon-free M9 before flow cytometry measurements. For the accumulation assays, to account for the time between sample collection and flow cytometry measurements, 10 min was added to the reported incubation time for the first two time points (i.e. the sacrificial aliquot taken immediately after tachyplesin-NBD addition was reported as 10 min).</p><p>Flow cytometric measurements were performed on the CytoFLEX S Flow Cytometer (Beckman Coulter, USA) equipped with a 488 nm (50 mW) and a 405 nm (80 mW) laser. Fluorescence of individual bacteria was measured using the fluorescein isothiocyanate (FITC) channel (488 nm 525/40 BP) for fluorescent peptides and phycoerythrin (PE) channel (488 nm 585/42 BP) for EtBr and C<sub>12</sub>-resorufin. Cell size was measured using FSC (forward scatter) and Violet SSC (side scatter) channels. Avalanche photodiode gains of FSC: 1000, SSC: 500, Violet SSC: 1, FITC: 250, and a threshold value of SSC-A: 10,000 to limit background noise was used. Bacteria were gated to separate cells from background noise by plotting FSC-A and Violet SSC-A. Background noise was then further separated based on cellular autofluorescence measured on the FITC-A channel for cells not treated with fluorescent peptides. An additional gate on the FITC-A channel was then used for cells treated with fluorescent peptides to further separate background noise. CytoFLEX Sheath Fluid (Beckman Coulter, USA) was used as sheath fluid. Data were collected using CytExpert software (Beckman Coulter, USA) and exported to FlowJo version 10.9 software (BD Biosciences, USA) for analysis.</p></sec><sec id="s4-5"><title>Microfluidic mother machine device fabrication</title><p>Microfluidic mother machine devices were fabricated by pouring a 10:1 (base:curing agent) polydimethylsiloxane (PDMS) mixture (<xref ref-type="bibr" rid="bib71">Łapińska et al., 2023</xref>) into an epoxy mould kindly provided by S. Jun (<xref ref-type="bibr" rid="bib144">Wang et al., 2010</xref>). Each mother machine device contains approximately 6000 bacterial hosting channels with a width, height, and length of 1, 1.5, and 25 µm, respectively. These channels are connected to a main microfluidic chamber with a width and height of 25 and 100 µm, respectively. After degassing the PDMS mixture in a vacuum desiccator (SP Bel-Art, USA) with a two-stage rotary vane pump FRVP series (Fisher Scientific, USA), the PDMS was cured at 70 °C for 2 h and peeled from the epoxy mould to obtain 12 individual chips (<xref ref-type="bibr" rid="bib110">Pagliara et al., 2011</xref>). Fluidic inlet and outlet were achieved using a 0.75 mm biopsy punch (WellTech Labs, Taiwan) at the two ends of the main chamber of the mother machine. The PDMS chip was then washed with ethanol and dried with nitrogen gas, followed by removal of small particles using adhesive tape (3M, USA) along with a rectangular glass coverslip (Fisher Scientific, USA). The microfluidic device was assembled by exposing the PDMS chip and glass coverslip to air plasma treatment at 30 W plasma power for 10 s with the Zepto One plasma cleaner (Diener Electronic, Germany) and then placed in contact to irreversibly bind the PDMS chip and glass coverslip (<xref ref-type="bibr" rid="bib37">Dettmer et al., 2014</xref>). The mother machine was then filled with 5 μL of 50 mg mL <sup>–1</sup> (752 μM) bovine serum albumin and incubated at 37 °C for 1 h to passivate the charge within the channels after plasma treatment, screening electrostatic interaction between bacterial membranes, PDMS, and glass surfaces (<xref ref-type="bibr" rid="bib28">Cama et al., 2016</xref>).</p></sec><sec id="s4-6"><title>Microfluidics-microscopy assay to measure tachyplesin-NBD accumulation and PI staining in individual <italic>E. coli</italic></title><p>A stationary phase <italic>E. coli</italic> culture was prepared as described above. The culture was adjusted to OD<sub>600</sub> 75 by centrifuging 50 mL of culture in a conical tube at 3220×<italic>g</italic> at room temperature for 5 min in a 5810 R centrifuge (Eppendorf, Germany). The supernatant was removed, and the pellet was resuspended in carbon-free M9 and vortexed. 5 μL of bacterial suspension was then injected into the mother machine device using a pipette and incubated at 37 °C for 30–60 min to allow for filling of ~80% of bacteria hosting channels (<xref ref-type="bibr" rid="bib52">Goode et al., 2021b</xref>). The loaded microfluidic device was then mounted on an Olympus IX73 inverted microscope (Olympus, Japan) connected to a 60x, 1.2 N.A. objective UPLSAPO60XW/1.20 (Olympus, Japan) and a Zyla 4.2 sCMOS camera (Andor, UK) for visual inspection. Each region of interest was adjusted to visualise 23 bacteria hosting channels and a mean of 11 regions of interest were selected for imaging for each experiment via automated stages M-545.USC and P-545.3C7 (Physik Instrumente, Germany) for coarse and fine movements, respectively. Fluorinated ethylene propylene tubing (1/32’×0.0008’) was then inserted into both inlet and outlet accesses as previously reported (<xref ref-type="bibr" rid="bib84">Locatelli et al., 2016</xref>). The inlet tubing was connected to a Flow Unit S flow rate sensor (Fluigent, France) and MFCS-4C pressure control system (Fluigent, France) controlled via MAESFLO 3.3.1 software (Fluigent, France) allowing for computerised, accurate regulation of fluid flow into the microfluidic device. A 300 μL h<sup>–1</sup> flow of carbon-free M9 for 8 min was used to clear the main channel of excess bacteria that had not entered the bacterial hosting channels. Tachyplesin-NBD (46 μg mL<sup>–1</sup> or 18.2 μM) with or without sertraline (30 μg mL<sup>–1</sup> or 98 μM) in carbon-free M9 was then flowed through the microfluidic device at 300 μL h<sup>–1</sup> for 8 min, before reducing to 100 μL h<sup>–1</sup> until 240 min. Carbon-free M9 was then flushed through the device at 300 μL h<sup>–1</sup> for 60 min to wash away unaccumulated tachyplesin-NBD. PI staining was performed by flowing PI (1.5 mM) at 300 μL h<sup>–1</sup> for 15 min. Brightfield and fluorescence images were captured consecutively every 10 min until the end of the experiment by switching between brightfield and fluorescence mode using LabVIEW (National Instruments, USA). Fluorescence images were captured by illuminating bacteria with a pE-300<sup>white</sup> broad-spectrum LED (CoolLED, UK) for 0.06 s on the blue excitation band at 20% intensity with a FITC filter for tachyplesin-NBD and green excitation band at 100% intensity with a DAPI/TEXAS filter for PI. The entire experiment was performed at 37 °C in an environmental chamber (Solent Scientific, UK) enclosing the microscope and microfluidics equipment. A step-by-step guide to the process above can be found in <xref ref-type="bibr" rid="bib30">Cama and Pagliara, 2021</xref>.</p></sec><sec id="s4-7"><title>Image and data analyses</title><p>Images were processed using ImageJ software as previously described (<xref ref-type="bibr" rid="bib129">Smith et al., 2019</xref>). Each individual bacterium was tracked throughout the 240 min tachyplesin-NBD treatment, 60 min carbon-free M9 wash, and 15 min PI staining. To measure tachyplesin-NBD and PI accumulation, a rectangle was drawn around each bacterium in each brightfield image at every time point, obtaining its length, width, and relative position in the microfluidic hosting channel. The same rectangle was then overlaid onto the corresponding fluorescence image to measure the mean fluorescence intensity, which represents the total fluorescence normalised by cell size (i.e. the area covered by each bacterium in the 2D images), thus accounting for variations in tachyplesin-NBD and PI accumulation due to the cell cycle (<xref ref-type="bibr" rid="bib136">Taniguchi et al., 2010</xref>). The same rectangle was then shifted to the nearest adjacent channel that did not contain any bacteria to measure the mean background fluorescence from extracellular tachyplesin-NBD in the media. This mean background fluorescence value was subsequently subtracted from the bacterium’s mean fluorescence value. To measure tachyplesin-NBD fluorescence profiles, the fluorescence values of a straight horizontal line spanning 20 pixels (left to right) were recorded, then converted and presented in μm. The membrane over cell centre fluorescence ratios were calculated by dividing the fluorescence of the membrane by the fluorescence value of the centre of the cell. The mean membrane fluorescence was obtained using the fluorescence of the seventh and thirteenth pixel, and the cell centre fluorescence using the tenth pixel along the profile measurements. To measure cell sizes of low and high accumulators, the vertical length of the rectangles drawn to measure fluorescence was taken for each cell then converted and presented in μm. All data were then analysed and plotted in Prism version 10.2.0 (GraphPad Software, USA).</p><p>Statistical significance tests, including the ordinary one-way ANOVA with Tukey’s multiple comparisons tests, paired two-tailed Wilcoxon nonparametric test, unpaired two-tailed nonparametric Mann-Whitney U test, as well as linear and nonlinear (semi-log) regressions were calculated using Prism version 10.2.0 (GraphPad Software, USA).</p></sec><sec id="s4-8"><title>Fluorescence-activated cell sorting</title><p>Samples for fluorescence-activated cell sorting were generated following the same protocol as flow cytometry accumulation assays. Cells were incubated for 60 min and a wash step carried out before performing a 30x dilution on 500 μL of treated cells for cell sorting. Cell sorting was performed on a BD FACSAria Fusion Flow Cytometer, equipped with a 488 nm (50 mW) laser (BD Biosciences, USA). Drops were generated at 70 psi sheath pressure, 87.0 kHz frequency, and 5.6 amplitude using a 70 μm nozzle. BD FACSFlow (BD Biosciences, USA) was used as sheath fluid and the instrument was set up for sorting with the BD Cytometer Setup &amp; Tracking Beads Kit, and BD FACS Accudrop Beads reagents (BD Biosciences, USA), following the manufacturer’s instructions. Cells were sorted based on their fluorescence measured on the 488 nm 530/30 BP channel with photomultiplier tubes (PMT) voltages of FSC: 452, SSC: 302, and 488 nm 530/30 BP: 444, and a threshold value of 200 was applied on the SSC channel to limit background noise. Cell aggregates were excluded by plotting SSC-W against SSC-H. Tachyplesin-NBD-treated cells were sorted into two groups (low and high accumulators) and the untreated control treatment through a control gate. A one-drop sorting envelope with purity rules was used. Approximately 1,000,000 million cells for each group were sorted directly into RNAprotect (Qiagen, Germany) to stabilise RNA in preparation for extraction and into carbon-free M9 for lipid Folch extractions. An additional combined sample containing a 1:1, <italic>v/v</italic> mixture of sorted low and high accumulators was generated (referred to as 1:1 mix accumulators) to aid and validate downstream transcriptomics analyses. Cells were sorted into carbon-free M9 for cell viability measurements following the same protocol above. Data were collected via BD FACSDiva version 8.0.1 (BD Biosciences, USA) software and analysed using FlowJo version 10.9 software (BD Biosciences, USA). Post-sort analyses revealed high levels of purity and very low occurrences of events measured outside of the sorting gate for sorted cells. Increased events measured in the M9 gate in post-sort samples are due to a reduced concentration of cells in post-sort analyses.</p></sec><sec id="s4-9"><title>Cell viability assays</title><p>Cell viability was assessed by diluting cells in carbon-free M9, then plating on LB agar plates. Plates were then incubated at 37 °C for 17 h followed by colony-forming unit counts. For flow cytometry accumulation and time-kill assays, sacrificial 30 µL aliquots of cells were obtained from the treatment microcentrifuge tube at their respective time points for dilution and spread plating. For cells sorted via fluorescence-activated cell sorting, low and high tachyplesin-NBD accumulators, and untreated control cells were sorted into carbon-free M9 before dilution and spread plating.</p></sec><sec id="s4-10"><title>RNA extraction and sequencing</title><p>RNA extractions were performed on cells sorted into RNAprotect (Qiagen, Germany). Enzymatic lysis and proteinase K digestion of bacteria was performed following protocol 4 in the RNAprotect Bacteria Reagent Handbook (Qiagen, Germany). Purification of total RNA from bacterial lysate using the RNeasy Mini Kit (Qiagen, Germany) following protocol 7 in the handbook. Due to the small quantity of initial material from cell sorting, RNeasy MinElute spin columns were used instead of RNeasy Mini spin columns. A further on-column DNase digestion using the RNase-Free DNase set (Qiagen, Germany) was performed following appendix B in the handbook. RNA concentration and quality were assessed using the Agilent High Sensitivity RNA ScreenTape System (Agilent, USA) following the provided protocol. Samples returned a mean RNA concentration of 2.5 ng μL<sup>–1</sup> and mean RNA integrity number equivalent (RIN<sup>e</sup>) score of 7.1. rRNA depletion was performed with the Illumina Stranded Total RNA Prep, Ligation with Ribo-Zero Plus kit (Illumina, USA) following the manufacturer’s instructions and sequencing carried out on the Illumina NovaSeq 6000 (Illumina, USA). Transcript abundance was quantified using Salmon for each gene in all samples. Differential gene expression was performed with DESeq2 in R software to quantify the log<sub>2</sub> fold change in transcript reads (<xref ref-type="bibr" rid="bib86">Love et al., 2014</xref>) for each gene and subsequent principal component analysis using DESeq2 and a built-in R method (prcomp) (<xref ref-type="bibr" rid="bib128">Smith et al., 2018</xref>).</p></sec><sec id="s4-11"><title>Cluster and gene ontology analyses</title><p>For cluster and gene ontology analysis, differential expression was tested with edgeR (version 3.28.1) (<xref ref-type="bibr" rid="bib117">Robinson et al., 2010</xref>). Predicted log fold changes were positively correlated between replicates; however, a batch effect was detected, and replicate number was retained as a model term. Transcripts with low expression were filtered out of the data via edgeR before fitting the differential expression models. Clustering analysis was performed using the mclust package (version 5.4.7) for R (<xref ref-type="bibr" rid="bib122">Scrucca et al., 2016</xref>). Only transcripts with differential expression FDR &lt;0.05 in at least one cell type were subjected to clustering analysis (<xref ref-type="bibr" rid="bib66">Kraus et al., 2024</xref>). All variance structures were tested for a range of 2–20 clusters, and the minimal, best-fitting model was identified by the Bayes information criterion. Gene ontology enrichment analysis was performed using the clusterProfiler package (version 4.10.0) for R (<xref ref-type="bibr" rid="bib158">Yu et al., 2012</xref>; <xref ref-type="bibr" rid="bib153">Wu et al., 2021</xref>). Enrichment in terms belonging to the ‘Biological Process’ ontology was calculated for each gene cluster, relative to the set of all genes quantified in the experiment, via a one-sided Fisher exact test (hypergeometric test). p-values were adjusted for false discovery by using the method of Benjamini and Hochberg. Finally, the lists of significantly enriched terms were simplified to remove redundant terms, as assessed via their semantic similarity to other enriched terms, using clusterProfiler’s simplify function.</p></sec><sec id="s4-12"><title>Transcription factor activity</title><p>Relative activities of transcription factors were estimated from differential expression results (generated in edgeR) using VIPER (version 1.2.0) for R (<xref ref-type="bibr" rid="bib4">Alvarez et al., 2016</xref>). Transcription factor regulons were derived from the full RegulonDB database (version 10.9) (<xref ref-type="bibr" rid="bib121">Santos-Zavaleta et al., 2019</xref>), fixing the likelihood to 1. Only transcripts with differential expression FDR &lt;0.05 in at least one cell type were used to estimate transcription factor activities. VIPER was run with a minimum allowed regulon size of 20 (<italic>minsize = 20</italic>), on the full gene data set (<italic>eset.filter=FALSE</italic>), and was set to normalised enrichment scores (<italic>nes = TRUE</italic>).</p></sec><sec id="s4-13"><title>Lipid extraction and lipidomic analysis</title><p>Lipid extractions were performed following a modified version of the Folch extraction (<xref ref-type="bibr" rid="bib32">Casula et al., 2023</xref>; <xref ref-type="bibr" rid="bib45">Folch et al., 1951</xref>). Briefly, 100 μL of sample was added to 250 μL of methanol and 125 μL of chloroform in a microcentrifuge tube. Samples were incubated for 60 min and vortexed every 15 min. Then, 380 μL of chloroform and 90 μL of 0.2 M potassium chloride were added to each sample. Cells were centrifuged at 14,000×<italic>g</italic> for 10 min to obtain a lipophilic phase which was transferred to a glass vial and dried under a nitrogen stream.</p><p>The lipophilic phase was then resuspended in 20 μL of a methanol:chloroform solution (1:1 <italic>v/v</italic>), then 980 μL of an isopropanol:acetonitrile:water solution (2:1:1, <italic>v/v/v</italic>) was added. Samples were analysed on the Agilent 6560 Q-TOF-MS (Agilent, USA) coupled with the Agilent 1290 Infinity II LC system (Agilent, USA). An aliquot of 0.5 μL for positive ionisation mode and 2 μL for negative ionisation mode from each sample was injected into a Kinetex 5 μm EVO C18 100 A, 150 mm ×2.1 μm column (Phenomenex, USA). The column was maintained at 50 °C at a flow rate of 0.3 mL min<sup>–1</sup>. For the positive ionisation mode, the mobile phases consisted of (A) acetonitrile:water (2:3 <italic>v/v</italic>) with ammonium formate (10 mM) and (B) acetonitrile:isopropanol (1:9, <italic>v/v</italic>) with ammonium formate (10 mM). For the negative ionisation mode, the mobile phases consisted of (A) acetonitrile:water (2:3 <italic>v/v</italic>) with ammonium acetate (10 mM) and (B) acetonitrile:isopropanol (1:9, <italic>v/v</italic>) with ammonium acetate (10 mM). The chromatographic separation was obtained with the following gradient: 0–1 min 70% B; 1–3.5 min 86% B; 3.5–10 min 86% B; 10.1–17 min 100% B; 17.1–10 min 70% B. The mass spectrometry platform was equipped with an Agilent Jet Stream Technology Ion Source (Agilent, USA), which was operated in both positive and negative ion modes with the following parameters: gas temperature (200 °C); gas flow (nitrogen), 10 L min<sup>–1</sup>; nebuliser gas (nitrogen), 50 psig; sheath gas temperature (300 °C); sheath gas flow, 12 L min<sup>–1</sup>; capillary voltage 3500 V for positive, and 3000 V for negative; nozzle voltage 0 V; fragmentor 150 V; skimmer 65 V, octupole RF 7550 V; mass range, 40–1,700 <italic>m/z</italic>; capillary voltage, 3.5 kV; collision energy 20 eV in positive, and 25 eV in negative mode. MassHunter software (Agilent, USA) was used for instrument control.</p><p>Low and high tachyplesin-NBD accumulators, and untreated control cells sorted via cell sorting were analysed using quadrupole time-of-flight liquid chromatography/mass spectrometry (Q-TOF-LC/MS). Mass Profiler 10.0 (Agilent, USA) was used to generate a matrix containing lipid features across all samples, then filtered by standard deviation, and normalised by sum calculations. Multivariate statistical analyses were performed on these features using SIMCA software 15.0 (Sartorius, Germany). First, a principal component analysis (PCA) was performed, followed by a partial least square-discriminant analysis (PLS-DA) with its orthogonal extension (OPLS-DA), which was used to visualise differences between low and high tachyplesin-NBD accumulators and untreated control samples.</p><p>Tachyplesin-NBD-treated and untreated cells were analysed using ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF-MS) and detected a mean of 1000 mass spectrometry features in positive and negative ionisation modes. Lipid annotation was performed following COSMOS consortium guidelines (<xref ref-type="bibr" rid="bib120">Salek et al., 2015</xref>) with the CEU Mass Mediator version 3.0 online tool (<xref ref-type="bibr" rid="bib48">Gil-de-la-Fuente et al., 2019</xref>). Lipid Annotator software (Agilent, USA) was then used to identify the lipid classes and their relative abundances (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Lipids with variable importance in projection (VIP) scores above 1 were annotated.</p></sec><sec id="s4-14"><title>Determination of minimum inhibitory concentration</title><p>Exponential phase bacterial cultures were prepared as described above and grown to an OD<sub>600</sub> of 0.5. 100 μL LB broth was added to all wells of a 96-well microtiter plate (Sarstedt, Germany). Then, 100 μL of a 2048 μg mL<sup>–1</sup> (6693.5 μM) sertraline solution was added to the first nine wells of the top row and mixed. Sertraline was then serially diluted to 8 μg mL<sup>–1</sup> (26.1 μM) by transferring 100 μL to the next row, mixing thoroughly after each transfer, using a multi-channel pipette. After the final dilution step, 100 μL was discarded to maintain equal volumes across wells. Exponential phase bacterial cultures were then diluted to yield 10<sup>6</sup> colony-forming units (CFU) mL<sup>–1</sup> and added to all wells containing sertraline. Each plate included 9 positive control wells (i.e. bacteria in LB without sertraline), and 15 negative control wells (i.e. LB only, without bacteria or sertraline). Plates were covered with a lid and incubated at 37 °C for 24 h. The MIC of sertraline against <italic>E. coli</italic> BW25113 was determined using the CLARIOstar microplate reader (BMG Labtech, Germany) by measuring OD<sub>600</sub> after incubation. The MIC was defined as the lowest concentration of sertraline at which no visible growth was observed, as determined by comparison to positive control wells.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>is affiliated with PIPA LLC</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Supervision, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Resources, Data curation, Software, Formal analysis, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Data curation, Formal analysis, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Resources, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Data curation, Software, Formal analysis, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Resources, Supervision, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con17"><p>Resources, Supervision, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Data curation, Supervision, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con19"><p>Formal analysis, Supervision, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con20"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Visualization, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-99752-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files; source data files have been provided for all figures; omics data have been deposited at <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1096674">https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1096674</ext-link>.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KK</given-names></name><name><surname>Łapińska</surname><given-names>U</given-names></name><name><surname>Tolle</surname><given-names>M</given-names></name><name><surname>Micaletto</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Phetsang</surname><given-names>W</given-names></name><name><surname>Verderosa</surname><given-names>AD</given-names></name><name><surname>Invergo</surname><given-names>BM</given-names></name><name><surname>Westley</surname><given-names>J</given-names></name><name><surname>Bebes</surname><given-names>A</given-names></name><name><surname>Yuecel</surname><given-names>R</given-names></name><name><surname>O’Neill</surname><given-names>PA</given-names></name><name><surname>Farbos</surname><given-names>A</given-names></name><name><surname>Jeffries</surname><given-names>AR</given-names></name><name><surname>Houte</surname><given-names>VS</given-names></name><name><surname>Caboni</surname><given-names>P</given-names></name><name><surname>Blaskovich</surname><given-names>MAT</given-names></name><name><surname>Housden</surname><given-names>BE</given-names></name><name><surname>Tsaneva-Atanasova</surname><given-names>K</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Heterogeneous efflux pump expression underpins phenotypic resistance to antimicrobial peptides</data-title><source>NCBI BioProject</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1096674">PRJNA1096674</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors thank Lisa Butt and Rob Beardmore, University of Exeter, for providing strains of their Keio collection. This work was supported by the BBSRC through a grant awarded to SP, KTA, and UL (BB/V008021/1), the EPSRC and the MRC through two grants awarded to S.P. (EP/Y023528/1 and MR/Y033892/1). KKL was supported by a Living Systems Institute PhD studentship. SP, KTA, and MATB acknowledge further support from the QUEX Institute. KTA and BMI gratefully acknowledge the financial support of the EPSRC (EP/T017856/1). BEH gratefully acknowledges financial support from the MRC (MR/V009583/1). This project utilised equipment funded by a Wellcome Trust Institutional Strategic Support Fund (WT097835MF), a Wellcome Trust Multi-User Equipment Award (WT101650MA) and a BBSRC LoLa award (BB/K003240/1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising from this submission.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>M</given-names></name><name><surname>Aduru</surname><given-names>SV</given-names></name><name><surname>Smith</surname><given-names>RP</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Lopatkin</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>The role of bacterial metabolism in antimicrobial resistance</article-title><source>Nature Reviews. Microbiology</source><volume>23</volume><fpage>439</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1038/s41579-025-01155-0</pub-id><pub-id pub-id-type="pmid">39979446</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allison</surname><given-names>KR</given-names></name><name><surname>Brynildsen</surname><given-names>MP</given-names></name><name><surname>Collins</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Metabolite-enabled eradication of bacterial persisters by aminoglycosides</article-title><source>Nature</source><volume>473</volume><fpage>216</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1038/nature10069</pub-id><pub-id pub-id-type="pmid">21562562</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>AlMatar</surname><given-names>M</given-names></name><name><surname>Albarri</surname><given-names>O</given-names></name><name><surname>Makky</surname><given-names>EA</given-names></name><name><surname>Köksal</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Efflux pump inhibitors: new updates</article-title><source>Pharmacological Reports</source><volume>73</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1007/s43440-020-00160-9</pub-id><pub-id pub-id-type="pmid">32946075</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez</surname><given-names>MJ</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Giorgi</surname><given-names>FM</given-names></name><name><surname>Lachmann</surname><given-names>A</given-names></name><name><surname>Ding</surname><given-names>BB</given-names></name><name><surname>Ye</surname><given-names>BH</given-names></name><name><surname>Califano</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Functional characterization of somatic mutations in cancer using network-based inference of protein activity</article-title><source>Nature Genetics</source><volume>48</volume><fpage>838</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1038/ng.3593</pub-id><pub-id pub-id-type="pmid">27322546</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>DI</given-names></name><name><surname>Nicoloff</surname><given-names>H</given-names></name><name><surname>Hjort</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mechanisms and clinical relevance of bacterial heteroresistance</article-title><source>Nature Reviews. Microbiology</source><volume>17</volume><fpage>479</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1038/s41579-019-0218-1</pub-id><pub-id pub-id-type="pmid">31235888</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attrill</surname><given-names>EL</given-names></name><name><surname>Claydon</surname><given-names>R</given-names></name><name><surname>Łapińska</surname><given-names>U</given-names></name><name><surname>Recker</surname><given-names>M</given-names></name><name><surname>Meaden</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>AT</given-names></name><name><surname>Westra</surname><given-names>ER</given-names></name><name><surname>Harding</surname><given-names>SV</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Individual bacteria in structured environments rely on phenotypic resistance to phage</article-title><source>PLOS Biology</source><volume>19</volume><elocation-id>e3001406</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3001406</pub-id><pub-id pub-id-type="pmid">34637438</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Attrill</surname><given-names>EL</given-names></name><name><surname>Łapińska</surname><given-names>U</given-names></name><name><surname>Westra</surname><given-names>ER</given-names></name><name><surname>Harding</surname><given-names>SV</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Slow growing bacteria survive bacteriophage in isolation</article-title><source>ISME Communications</source><volume>3</volume><elocation-id>95</elocation-id><pub-id pub-id-type="doi">10.1038/s43705-023-00299-5</pub-id><pub-id pub-id-type="pmid">37684358</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ayrapetyan</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>T</given-names></name><name><surname>Oliver</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Relationship between the viable but nonculturable state and antibiotic persister cells</article-title><source>Journal of Bacteriology</source><volume>200</volume><elocation-id>e00249-18</elocation-id><pub-id pub-id-type="doi">10.1128/JB.00249-18</pub-id><pub-id pub-id-type="pmid">30082460</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baba</surname><given-names>T</given-names></name><name><surname>Ara</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>M</given-names></name><name><surname>Takai</surname><given-names>Y</given-names></name><name><surname>Okumura</surname><given-names>Y</given-names></name><name><surname>Baba</surname><given-names>M</given-names></name><name><surname>Datsenko</surname><given-names>KA</given-names></name><name><surname>Tomita</surname><given-names>M</given-names></name><name><surname>Wanner</surname><given-names>BL</given-names></name><name><surname>Mori</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Construction of <italic>Escherichia coli</italic> K-12 in-frame, single-gene knockout mutants: the Keio collection</article-title><source>Molecular Systems Biology</source><volume>2</volume><elocation-id>2006.0008</elocation-id><pub-id pub-id-type="doi">10.1038/msb4100050</pub-id><pub-id pub-id-type="pmid">16738554</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>AM</given-names></name><name><surname>Webber</surname><given-names>MA</given-names></name><name><surname>Piddock</surname><given-names>LJV</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Medium plays a role in determining expression of acrB, marA, and soxS in <italic>Escherichia coli</italic></article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>50</volume><fpage>1071</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1128/AAC.50.3.1071-1074.2006</pub-id><pub-id pub-id-type="pmid">16495271</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajorath</surname><given-names>J</given-names></name><name><surname>Hinrichs</surname><given-names>W</given-names></name><name><surname>Saenger</surname><given-names>W</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>The enzymatic activity of proteinase K is controlled by calcium</article-title><source>European Journal of Biochemistry</source><volume>176</volume><fpage>441</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1988.tb14301.x</pub-id><pub-id pub-id-type="pmid">3166426</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balaban</surname><given-names>NQ</given-names></name><name><surname>Helaine</surname><given-names>S</given-names></name><name><surname>Lewis</surname><given-names>K</given-names></name><name><surname>Ackermann</surname><given-names>M</given-names></name><name><surname>Aldridge</surname><given-names>B</given-names></name><name><surname>Andersson</surname><given-names>DI</given-names></name><name><surname>Brynildsen</surname><given-names>MP</given-names></name><name><surname>Bumann</surname><given-names>D</given-names></name><name><surname>Camilli</surname><given-names>A</given-names></name><name><surname>Collins</surname><given-names>JJ</given-names></name><name><surname>Dehio</surname><given-names>C</given-names></name><name><surname>Fortune</surname><given-names>S</given-names></name><name><surname>Ghigo</surname><given-names>J-M</given-names></name><name><surname>Hardt</surname><given-names>W-D</given-names></name><name><surname>Harms</surname><given-names>A</given-names></name><name><surname>Heinemann</surname><given-names>M</given-names></name><name><surname>Hung</surname><given-names>DT</given-names></name><name><surname>Jenal</surname><given-names>U</given-names></name><name><surname>Levin</surname><given-names>BR</given-names></name><name><surname>Michiels</surname><given-names>J</given-names></name><name><surname>Storz</surname><given-names>G</given-names></name><name><surname>Tan</surname><given-names>M-W</given-names></name><name><surname>Tenson</surname><given-names>T</given-names></name><name><surname>Van Melderen</surname><given-names>L</given-names></name><name><surname>Zinkernagel</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Definitions and guidelines for research on antibiotic persistence</article-title><source>Nature Reviews. Microbiology</source><volume>17</volume><fpage>441</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1038/s41579-019-0196-3</pub-id><pub-id pub-id-type="pmid">30980069</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balhuizen</surname><given-names>MD</given-names></name><name><surname>van Dijk</surname><given-names>A</given-names></name><name><surname>Jansen</surname><given-names>JWA</given-names></name><name><surname>van de Lest</surname><given-names>CHA</given-names></name><name><surname>Veldhuizen</surname><given-names>EJA</given-names></name><name><surname>Haagsman</surname><given-names>HP</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Outer membrane vesicles protect gram-negative bacteria against host defense peptides</article-title><source>mSphere</source><volume>6</volume><elocation-id>e0052321</elocation-id><pub-id pub-id-type="doi">10.1128/mSphere.00523-21</pub-id><pub-id pub-id-type="pmid">34232080</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bamford</surname><given-names>RA</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Metz</surname><given-names>J</given-names></name><name><surname>Glover</surname><given-names>G</given-names></name><name><surname>Titball</surname><given-names>RW</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Investigating the physiology of viable but non-culturable bacteria by microfluidics and time-lapse microscopy</article-title><source>BMC Biology</source><volume>15</volume><elocation-id>121</elocation-id><pub-id pub-id-type="doi">10.1186/s12915-017-0465-4</pub-id><pub-id pub-id-type="pmid">29262826</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bankevich</surname><given-names>A</given-names></name><name><surname>Nurk</surname><given-names>S</given-names></name><name><surname>Antipov</surname><given-names>D</given-names></name><name><surname>Gurevich</surname><given-names>AA</given-names></name><name><surname>Dvorkin</surname><given-names>M</given-names></name><name><surname>Kulikov</surname><given-names>AS</given-names></name><name><surname>Lesin</surname><given-names>VM</given-names></name><name><surname>Nikolenko</surname><given-names>SI</given-names></name><name><surname>Pham</surname><given-names>S</given-names></name><name><surname>Prjibelski</surname><given-names>AD</given-names></name><name><surname>Pyshkin</surname><given-names>AV</given-names></name><name><surname>Sirotkin</surname><given-names>AV</given-names></name><name><surname>Vyahhi</surname><given-names>N</given-names></name><name><surname>Tesler</surname><given-names>G</given-names></name><name><surname>Alekseyev</surname><given-names>MA</given-names></name><name><surname>Pevzner</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing</article-title><source>Journal of Computational Biology</source><volume>19</volume><fpage>455</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1089/cmb.2012.0021</pub-id><pub-id pub-id-type="pmid">22506599</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>TC</given-names></name><name><surname>Mok</surname><given-names>WWK</given-names></name><name><surname>Murawski</surname><given-names>AM</given-names></name><name><surname>Brynildsen</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Enhanced antibiotic resistance development from fluoroquinolone persisters after a single exposure to antibiotic</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>1177</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-09058-4</pub-id><pub-id pub-id-type="pmid">30862812</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bechinger</surname><given-names>B</given-names></name><name><surname>Gorr</surname><given-names>SU</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Antimicrobial peptides: mechanisms of action and resistance</article-title><source>Journal of Dental Research</source><volume>96</volume><fpage>254</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1177/0022034516679973</pub-id><pub-id pub-id-type="pmid">27872334</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergmiller</surname><given-names>T</given-names></name><name><surname>Andersson</surname><given-names>AMC</given-names></name><name><surname>Tomasek</surname><given-names>K</given-names></name><name><surname>Balleza</surname><given-names>E</given-names></name><name><surname>Kiviet</surname><given-names>DJ</given-names></name><name><surname>Hauschild</surname><given-names>R</given-names></name><name><surname>Tkačik</surname><given-names>G</given-names></name><name><surname>Guet</surname><given-names>CC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Biased partitioning of the multidrug efflux pump AcrAB-TolC underlies long-lived phenotypic heterogeneity</article-title><source>Science</source><volume>356</volume><fpage>311</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1126/science.aaf4762</pub-id><pub-id pub-id-type="pmid">28428424</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blair</surname><given-names>JMA</given-names></name><name><surname>Webber</surname><given-names>MA</given-names></name><name><surname>Baylay</surname><given-names>AJ</given-names></name><name><surname>Ogbolu</surname><given-names>DO</given-names></name><name><surname>Piddock</surname><given-names>LJV</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Molecular mechanisms of antibiotic resistance</article-title><source>Nature Reviews. Microbiology</source><volume>13</volume><fpage>42</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3380</pub-id><pub-id pub-id-type="pmid">25435309</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blair</surname><given-names>JMA</given-names></name><name><surname>Zeth</surname><given-names>K</given-names></name><name><surname>Bavro</surname><given-names>VN</given-names></name><name><surname>Sancho-Vaello</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The role of bacterial transport systems in the removal of host antimicrobial peptides in Gram-negative bacteria</article-title><source>FEMS Microbiology Reviews</source><volume>46</volume><elocation-id>fuac032</elocation-id><pub-id pub-id-type="doi">10.1093/femsre/fuac032</pub-id><pub-id pub-id-type="pmid">35749576</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanco</surname><given-names>P</given-names></name><name><surname>Sanz-García</surname><given-names>F</given-names></name><name><surname>Hernando-Amado</surname><given-names>S</given-names></name><name><surname>Martínez</surname><given-names>JL</given-names></name><name><surname>Alcalde-Rico</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The development of efflux pump inhibitors to treat Gram-negative infections</article-title><source>Expert Opinion on Drug Discovery</source><volume>13</volume><fpage>919</fpage><lpage>931</lpage><pub-id pub-id-type="doi">10.1080/17460441.2018.1514386</pub-id><pub-id pub-id-type="pmid">30198793</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Blaskovich</surname><given-names>MA</given-names></name><name><surname>Phetsang</surname><given-names>W</given-names></name><name><surname>Stone</surname><given-names>MR</given-names></name><name><surname>Lapinska</surname><given-names>U</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name><name><surname>Bhalla</surname><given-names>R</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Antibiotic-derived molecular probes for bacterial imaging</article-title><conf-name>Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections and Inflammatory Diseases 2019</conf-name><conf-loc>San Francisco, United States</conf-loc><pub-id pub-id-type="doi">10.1117/12.2507329</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohnert</surname><given-names>JA</given-names></name><name><surname>Kern</surname><given-names>WV</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Selected arylpiperazines are capable of reversing multidrug resistance in <italic>Escherichia coli</italic> overexpressing RND efflux pumps</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>49</volume><fpage>849</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1128/AAC.49.2.849-852.2005</pub-id><pub-id pub-id-type="pmid">15673787</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohnert</surname><given-names>JA</given-names></name><name><surname>Szymaniak-Vits</surname><given-names>M</given-names></name><name><surname>Schuster</surname><given-names>S</given-names></name><name><surname>Kern</surname><given-names>WV</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Efflux inhibition by selective serotonin reuptake inhibitors in <italic>Escherichia coli</italic></article-title><source>The Journal of Antimicrobial Chemotherapy</source><volume>66</volume><fpage>2057</fpage><lpage>2060</lpage><pub-id pub-id-type="doi">10.1093/jac/dkr258</pub-id><pub-id pub-id-type="pmid">21700628</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolger</surname><given-names>AM</given-names></name><name><surname>Lohse</surname><given-names>M</given-names></name><name><surname>Usadel</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Trimmomatic: a flexible trimmer for Illumina sequence data</article-title><source>Bioinformatics</source><volume>30</volume><fpage>2114</fpage><lpage>2120</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu170</pub-id><pub-id pub-id-type="pmid">24695404</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bollen</surname><given-names>C</given-names></name><name><surname>Louwagie</surname><given-names>E</given-names></name><name><surname>Verstraeten</surname><given-names>N</given-names></name><name><surname>Michiels</surname><given-names>J</given-names></name><name><surname>Ruelens</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Environmental, mechanistic and evolutionary landscape of antibiotic persistence</article-title><source>EMBO Reports</source><volume>24</volume><elocation-id>e57309</elocation-id><pub-id pub-id-type="doi">10.15252/embr.202357309</pub-id><pub-id pub-id-type="pmid">37395716</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandis</surname><given-names>G</given-names></name><name><surname>Larsson</surname><given-names>J</given-names></name><name><surname>Elf</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Antibiotic perseverance increases the risk of resistance development</article-title><source>PNAS</source><volume>120</volume><elocation-id>e2216216120</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2216216120</pub-id><pub-id pub-id-type="pmid">36595701</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cama</surname><given-names>J</given-names></name><name><surname>Schaich</surname><given-names>M</given-names></name><name><surname>Al Nahas</surname><given-names>K</given-names></name><name><surname>Hernández-Ainsa</surname><given-names>S</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name><name><surname>Keyser</surname><given-names>UF</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Direct optofluidic measurement of the lipid permeability of fluoroquinolones</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>32824</elocation-id><pub-id pub-id-type="doi">10.1038/srep32824</pub-id><pub-id pub-id-type="pmid">27604156</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cama</surname><given-names>J</given-names></name><name><surname>Voliotis</surname><given-names>M</given-names></name><name><surname>Metz</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Iannucci</surname><given-names>J</given-names></name><name><surname>Keyser</surname><given-names>UF</given-names></name><name><surname>Tsaneva-Atanasova</surname><given-names>K</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Single-cell microfluidics facilitates the rapid quantification of antibiotic accumulation in Gram-negative bacteria</article-title><source>Lab on a Chip</source><volume>20</volume><fpage>2765</fpage><lpage>2775</lpage><pub-id pub-id-type="doi">10.1039/d0lc00242a</pub-id><pub-id pub-id-type="pmid">32613221</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cama</surname><given-names>J</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Microfluidic single-cell phenotyping of the activity of peptide-based antimicrobials</article-title><source>Methods in Molecular Biology</source><volume>2208</volume><fpage>237</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-0928-6_16</pub-id><pub-id pub-id-type="pmid">32856267</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campey</surname><given-names>A</given-names></name><name><surname>Łapińska</surname><given-names>U</given-names></name><name><surname>Chait</surname><given-names>R</given-names></name><name><surname>Tsaneva-Atanasova</surname><given-names>K</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Antibiotic resistant bacteria survive treatment by doubling while shrinking</article-title><source>mBio</source><volume>15</volume><elocation-id>e0237524</elocation-id><pub-id pub-id-type="doi">10.1128/mbio.02375-24</pub-id><pub-id pub-id-type="pmid">39565111</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casula</surname><given-names>M</given-names></name><name><surname>Scano</surname><given-names>P</given-names></name><name><surname>Manis</surname><given-names>C</given-names></name><name><surname>Tolle</surname><given-names>G</given-names></name><name><surname>Nudda</surname><given-names>A</given-names></name><name><surname>Carta</surname><given-names>S</given-names></name><name><surname>Pulina</surname><given-names>G</given-names></name><name><surname>Caboni</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>UHPLC-QTOF/MS untargeted lipidomics and caffeine carry-over in milk of goats under spent coffee ground enriched diet</article-title><source>Applied Sciences</source><volume>13</volume><elocation-id>2477</elocation-id><pub-id pub-id-type="doi">10.3390/app13042477</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>BCL</given-names></name><name><surname>Ip</surname><given-names>M</given-names></name><name><surname>Lau</surname><given-names>CBS</given-names></name><name><surname>Lui</surname><given-names>SL</given-names></name><name><surname>Jolivalt</surname><given-names>C</given-names></name><name><surname>Ganem-Elbaz</surname><given-names>C</given-names></name><name><surname>Litaudon</surname><given-names>M</given-names></name><name><surname>Reiner</surname><given-names>NE</given-names></name><name><surname>Gong</surname><given-names>H</given-names></name><name><surname>See</surname><given-names>RH</given-names></name><name><surname>Fung</surname><given-names>KP</given-names></name><name><surname>Leung</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Synergistic effects of baicalein with ciprofloxacin against NorA over-expressed methicillin-resistant <italic>Staphylococcus aureus</italic> (MRSA) and inhibition of MRSA pyruvate kinase</article-title><source>Journal of Ethnopharmacology</source><volume>137</volume><fpage>767</fpage><lpage>773</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2011.06.039</pub-id><pub-id pub-id-type="pmid">21782012</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Compagne</surname><given-names>N</given-names></name><name><surname>Vieira Da Cruz</surname><given-names>A</given-names></name><name><surname>Müller</surname><given-names>RT</given-names></name><name><surname>Hartkoorn</surname><given-names>RC</given-names></name><name><surname>Flipo</surname><given-names>M</given-names></name><name><surname>Pos</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Update on the discovery of efflux pump inhibitors against critical priority gram-negative bacteria</article-title><source>Antibiotics</source><volume>12</volume><elocation-id>180</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics12010180</pub-id><pub-id pub-id-type="pmid">36671381</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortez-Cordova</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Activity of the efflux pump inhibitor phenylalanine-arginine β-naphthylamide against the AdeFGH pump of Acinetobacter baumannii</article-title><source>International Journal of Antimicrobial Agents</source><volume>37</volume><fpage>420</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2011.01.006</pub-id><pub-id pub-id-type="pmid">21377839</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Datsenko</surname><given-names>KA</given-names></name><name><surname>Wanner</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>One-step inactivation of chromosomal genes in <italic>Escherichia coli</italic> K-12 using PCR products</article-title><source>PNAS</source><volume>97</volume><fpage>6640</fpage><lpage>6645</lpage><pub-id pub-id-type="doi">10.1073/pnas.120163297</pub-id><pub-id pub-id-type="pmid">10829079</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dettmer</surname><given-names>SL</given-names></name><name><surname>Keyser</surname><given-names>UF</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Local characterization of hindered Brownian motion by using digital video microscopy and 3D particle tracking</article-title><source>Review of Scientific Instruments</source><volume>85</volume><elocation-id>4865552</elocation-id><pub-id pub-id-type="doi">10.1063/1.4865552</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eckert</surname><given-names>R</given-names></name><name><surname>Qi</surname><given-names>F</given-names></name><name><surname>Yarbrough</surname><given-names>DK</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>MH</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Adding selectivity to antimicrobial peptides: rational design of a multidomain peptide against Pseudomonas spp</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>50</volume><fpage>1480</fpage><lpage>1488</lpage><pub-id pub-id-type="doi">10.1128/AAC.50.4.1480-1488.2006</pub-id><pub-id pub-id-type="pmid">16569868</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>IA</given-names></name><name><surname>Elliott</surname><given-names>AG</given-names></name><name><surname>Kavanagh</surname><given-names>AM</given-names></name><name><surname>Blaskovich</surname><given-names>MAT</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Structure-activity and -toxicity relationships of the antimicrobial peptide tachyplesin-1</article-title><source>ACS Infectious Diseases</source><volume>3</volume><fpage>917</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.7b00123</pub-id><pub-id pub-id-type="pmid">28960954</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>AG</given-names></name><name><surname>Huang</surname><given-names>JX</given-names></name><name><surname>Neve</surname><given-names>S</given-names></name><name><surname>Zuegg</surname><given-names>J</given-names></name><name><surname>Edwards</surname><given-names>IA</given-names></name><name><surname>Cain</surname><given-names>AK</given-names></name><name><surname>Boinett</surname><given-names>CJ</given-names></name><name><surname>Barquist</surname><given-names>L</given-names></name><name><surname>Lundberg</surname><given-names>CV</given-names></name><name><surname>Steen</surname><given-names>J</given-names></name><name><surname>Butler</surname><given-names>MS</given-names></name><name><surname>Mobli</surname><given-names>M</given-names></name><name><surname>Porter</surname><given-names>KM</given-names></name><name><surname>Blaskovich</surname><given-names>MAT</given-names></name><name><surname>Lociuro</surname><given-names>S</given-names></name><name><surname>Strandh</surname><given-names>M</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>An amphipathic peptide with antibiotic activity against multidrug-resistant Gram-negative bacteria</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>3184</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-16950-x</pub-id><pub-id pub-id-type="pmid">32576824</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Meouche</surname><given-names>I</given-names></name><name><surname>Siu</surname><given-names>Y</given-names></name><name><surname>Dunlop</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Stochastic expression of a multiple antibiotic resistance activator confers transient resistance in single cells</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>19538</elocation-id><pub-id pub-id-type="doi">10.1038/srep19538</pub-id><pub-id pub-id-type="pmid">26758525</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Meouche</surname><given-names>I</given-names></name><name><surname>Dunlop</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Heterogeneity in efflux pump expression predisposes antibiotic-resistant cells to mutation</article-title><source>Science</source><volume>362</volume><fpage>686</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1126/science.aar7981</pub-id><pub-id pub-id-type="pmid">30409883</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feldgarden</surname><given-names>M</given-names></name><name><surname>Brover</surname><given-names>V</given-names></name><name><surname>Gonzalez-Escalona</surname><given-names>N</given-names></name><name><surname>Frye</surname><given-names>JG</given-names></name><name><surname>Haendiges</surname><given-names>J</given-names></name><name><surname>Haft</surname><given-names>DH</given-names></name><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Pettengill</surname><given-names>JB</given-names></name><name><surname>Prasad</surname><given-names>AB</given-names></name><name><surname>Tillman</surname><given-names>GE</given-names></name><name><surname>Tyson</surname><given-names>GH</given-names></name><name><surname>Klimke</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>AMRFinderPlus and the Reference Gene Catalog facilitate examination of the genomic links among antimicrobial resistance, stress response, and virulence</article-title><source>Scientific Reports</source><volume>11</volume><elocation-id>12728</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-91456-0</pub-id><pub-id pub-id-type="pmid">34135355</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernández</surname><given-names>L</given-names></name><name><surname>Hancock</surname><given-names>REW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance</article-title><source>Clinical Microbiology Reviews</source><volume>25</volume><fpage>661</fpage><lpage>681</lpage><pub-id pub-id-type="doi">10.1128/CMR.00043-12</pub-id><pub-id pub-id-type="pmid">23034325</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folch</surname><given-names>J</given-names></name><name><surname>Ascoli</surname><given-names>I</given-names></name><name><surname>Lees</surname><given-names>M</given-names></name><name><surname>Meath</surname><given-names>JA</given-names></name><name><surname>Lebaron</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1951">1951</year><article-title>Preparation of lipide extracts from brain tissue</article-title><source>The Journal of Biological Chemistry</source><volume>191</volume><fpage>833</fpage><lpage>841</lpage><pub-id pub-id-type="pmid">14861228</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname><given-names>M</given-names></name><name><surname>Shiota</surname><given-names>S</given-names></name><name><surname>Kuroda</surname><given-names>T</given-names></name><name><surname>Hatano</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Mizushima</surname><given-names>T</given-names></name><name><surname>Tsuchiya</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Remarkable synergies between baicalein and tetracycline, and baicalein and beta-lactams against methicillin-resistant <italic>Staphylococcus aureus</italic></article-title><source>Microbiology and Immunology</source><volume>49</volume><fpage>391</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1111/j.1348-0421.2005.tb03732.x</pub-id><pub-id pub-id-type="pmid">15840965</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallardo-Godoy</surname><given-names>A</given-names></name><name><surname>Muldoon</surname><given-names>C</given-names></name><name><surname>Becker</surname><given-names>B</given-names></name><name><surname>Elliott</surname><given-names>AG</given-names></name><name><surname>Lash</surname><given-names>LH</given-names></name><name><surname>Huang</surname><given-names>JX</given-names></name><name><surname>Butler</surname><given-names>MS</given-names></name><name><surname>Pelingon</surname><given-names>R</given-names></name><name><surname>Kavanagh</surname><given-names>AM</given-names></name><name><surname>Ramu</surname><given-names>S</given-names></name><name><surname>Phetsang</surname><given-names>W</given-names></name><name><surname>Blaskovich</surname><given-names>MAT</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Activity and predicted nephrotoxicity of synthetic antibiotics based on polymyxin B</article-title><source>Journal of Medicinal Chemistry</source><volume>59</volume><fpage>1068</fpage><lpage>1077</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.5b01593</pub-id><pub-id pub-id-type="pmid">26734854</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gil-de-la-Fuente</surname><given-names>A</given-names></name><name><surname>Godzien</surname><given-names>J</given-names></name><name><surname>Saugar</surname><given-names>S</given-names></name><name><surname>Garcia-Carmona</surname><given-names>R</given-names></name><name><surname>Badran</surname><given-names>H</given-names></name><name><surname>Wishart</surname><given-names>DS</given-names></name><name><surname>Barbas</surname><given-names>C</given-names></name><name><surname>Otero</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CEU mass mediator 3.0: A metabolite annotation tool</article-title><source>Journal of Proteome Research</source><volume>18</volume><fpage>797</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.8b00720</pub-id><pub-id pub-id-type="pmid">30574788</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glibowicka</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>S</given-names></name><name><surname>Deber</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Enhanced proteolytic resistance of cationic antimicrobial peptides through lysine side chain analogs and cyclization</article-title><source>Biochemical and Biophysical Research Communications</source><volume>612</volume><fpage>105</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2022.04.113</pub-id><pub-id pub-id-type="pmid">35512459</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glover</surname><given-names>G</given-names></name><name><surname>Voliotis</surname><given-names>M</given-names></name><name><surname>Łapińska</surname><given-names>U</given-names></name><name><surname>Invergo</surname><given-names>BM</given-names></name><name><surname>Soanes</surname><given-names>D</given-names></name><name><surname>O’Neill</surname><given-names>P</given-names></name><name><surname>Moore</surname><given-names>K</given-names></name><name><surname>Nikolic</surname><given-names>N</given-names></name><name><surname>Petrov</surname><given-names>PG</given-names></name><name><surname>Milner</surname><given-names>DS</given-names></name><name><surname>Roy</surname><given-names>S</given-names></name><name><surname>Heesom</surname><given-names>K</given-names></name><name><surname>Richards</surname><given-names>TA</given-names></name><name><surname>Tsaneva-Atanasova</surname><given-names>K</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Nutrient and salt depletion synergistically boosts glucose metabolism in individual <italic>Escherichia coli</italic> cells</article-title><source>Communications Biology</source><volume>5</volume><elocation-id>385</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-022-03336-6</pub-id><pub-id pub-id-type="pmid">35444215</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goode</surname><given-names>O</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Zarkan</surname><given-names>A</given-names></name><name><surname>Cama</surname><given-names>J</given-names></name><name><surname>Invergo</surname><given-names>BM</given-names></name><name><surname>Belgami</surname><given-names>D</given-names></name><name><surname>Caño-Muñiz</surname><given-names>S</given-names></name><name><surname>Metz</surname><given-names>J</given-names></name><name><surname>O’Neill</surname><given-names>P</given-names></name><name><surname>Jeffries</surname><given-names>A</given-names></name><name><surname>Norville</surname><given-names>IH</given-names></name><name><surname>David</surname><given-names>J</given-names></name><name><surname>Summers</surname><given-names>D</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Persister <italic>Escherichia coli</italic> cells have a lower intracellular ph than susceptible cells but maintain Their pH in response to antibiotic treatment</article-title><source>mBio</source><volume>12</volume><elocation-id>e0090921</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00909-21</pub-id><pub-id pub-id-type="pmid">34281389</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goode</surname><given-names>O</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Łapińska</surname><given-names>U</given-names></name><name><surname>Bamford</surname><given-names>R</given-names></name><name><surname>Kahveci</surname><given-names>Z</given-names></name><name><surname>Glover</surname><given-names>G</given-names></name><name><surname>Attrill</surname><given-names>E</given-names></name><name><surname>Carr</surname><given-names>A</given-names></name><name><surname>Metz</surname><given-names>J</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Heterologous protein expression favors the formation of protein aggregates in persister and viable but nonculturable bacteria</article-title><source>ACS Infectious Diseases</source><volume>7</volume><fpage>1848</fpage><lpage>1858</lpage><pub-id pub-id-type="doi">10.1021/acsinfecdis.1c00154</pub-id><pub-id pub-id-type="pmid">34000805</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grenier</surname><given-names>F</given-names></name><name><surname>Matteau</surname><given-names>D</given-names></name><name><surname>Baby</surname><given-names>V</given-names></name><name><surname>Rodrigue</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Complete genome sequence of <italic>Escherichia coli</italic> BW25113</article-title><source>Genome Announcements</source><volume>2</volume><elocation-id>e01038-14</elocation-id><pub-id pub-id-type="doi">10.1128/genomeA.01038-14</pub-id><pub-id pub-id-type="pmid">25323716</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutierrez</surname><given-names>A</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Bhargava</surname><given-names>P</given-names></name><name><surname>Hamblin</surname><given-names>M</given-names></name><name><surname>Lobritz</surname><given-names>MA</given-names></name><name><surname>Collins</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Understanding and sensitizing density-dependent persistence to quinolone antibiotics</article-title><source>Molecular Cell</source><volume>68</volume><fpage>1147</fpage><lpage>1154</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2017.11.012</pub-id><pub-id pub-id-type="pmid">29225037</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirakawa</surname><given-names>H</given-names></name><name><surname>Kurushima</surname><given-names>J</given-names></name><name><surname>Hashimoto</surname><given-names>Y</given-names></name><name><surname>Tomita</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Progress overview of bacterial two-component regulatory systems as potential targets for antimicrobial chemotherapy</article-title><source>Antibiotics</source><volume>9</volume><elocation-id>635</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics9100635</pub-id><pub-id pub-id-type="pmid">32977461</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hołówka</surname><given-names>J</given-names></name><name><surname>Zakrzewska-Czerwińska</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Nucleoid associated proteins: the small organizers that help to cope with stress</article-title><source>Frontiers in Microbiology</source><volume>11</volume><elocation-id>590</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2020.00590</pub-id><pub-id pub-id-type="pmid">32373086</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Guan</surname><given-names>W</given-names></name><name><surname>Jin</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Dai</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mechanism of tachyplesin I injury to bacterial membranes and intracellular enzymes, determined by laser confocal scanning microscopy and flow cytometry</article-title><source>Microbiological Research</source><volume>170</volume><fpage>69</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.micres.2014.08.012</pub-id><pub-id pub-id-type="pmid">25267486</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Ke</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Experimental induction of bacterial resistance to the antimicrobial peptide tachyplesin I and investigation of the resistance mechanisms</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>60</volume><fpage>6067</fpage><lpage>6075</lpage><pub-id pub-id-type="doi">10.1128/AAC.00640-16</pub-id><pub-id pub-id-type="pmid">27480861</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Transcriptome analysis reveals the resistance mechanism of <italic>Pseudomonas aeruginosa</italic> to tachyplesin I</article-title><source>Infection and Drug Resistance</source><volume>13</volume><fpage>155</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.2147/IDR.S226687</pub-id><pub-id pub-id-type="pmid">32021330</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>M</given-names></name><name><surname>Hong</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Co-expression mechanism analysis of different tachyplesin I-resistant strains in <italic>Pseudomonas aeruginosa</italic> based on transcriptome sequencing</article-title><source>Frontiers in Microbiology</source><volume>13</volume><elocation-id>871290</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2022.871290</pub-id><pub-id pub-id-type="pmid">35464984</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imura</surname><given-names>Y</given-names></name><name><surname>Nishida</surname><given-names>M</given-names></name><name><surname>Ogawa</surname><given-names>Y</given-names></name><name><surname>Takakura</surname><given-names>Y</given-names></name><name><surname>Matsuzaki</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Action mechanism of tachyplesin I and effects of PEGylation</article-title><source>Biochimica et Biophysica Acta - Biomembranes</source><volume>1768</volume><fpage>1160</fpage><lpage>1169</lpage><pub-id pub-id-type="doi">10.1016/j.bbamem.2007.01.005</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jangir</surname><given-names>PK</given-names></name><name><surname>Ogunlana</surname><given-names>L</given-names></name><name><surname>MacLean</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Evolutionary constraints on the acquisition of antimicrobial peptide resistance in bacterial pathogens</article-title><source>Trends in Microbiology</source><volume>29</volume><fpage>1058</fpage><lpage>1061</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2021.03.007</pub-id><pub-id pub-id-type="pmid">33836929</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kepiro</surname><given-names>IE</given-names></name><name><surname>Marzuoli</surname><given-names>I</given-names></name><name><surname>Hammond</surname><given-names>K</given-names></name><name><surname>Ba</surname><given-names>X</given-names></name><name><surname>Lewis</surname><given-names>H</given-names></name><name><surname>Shaw</surname><given-names>M</given-names></name><name><surname>Gunnoo</surname><given-names>SB</given-names></name><name><surname>De Santis</surname><given-names>E</given-names></name><name><surname>Łapińska</surname><given-names>U</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name><name><surname>Holmes</surname><given-names>MA</given-names></name><name><surname>Lorenz</surname><given-names>CD</given-names></name><name><surname>Hoogenboom</surname><given-names>BW</given-names></name><name><surname>Fraternali</surname><given-names>F</given-names></name><name><surname>Ryadnov</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Engineering chirally blind protein pseudocapsids into antibacterial persisters</article-title><source>ACS Nano</source><volume>14</volume><fpage>1609</fpage><lpage>1622</lpage><pub-id pub-id-type="doi">10.1021/acsnano.9b06814</pub-id><pub-id pub-id-type="pmid">31794180</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kintses</surname><given-names>B</given-names></name><name><surname>Jangir</surname><given-names>PK</given-names></name><name><surname>Fekete</surname><given-names>G</given-names></name><name><surname>Számel</surname><given-names>M</given-names></name><name><surname>Méhi</surname><given-names>O</given-names></name><name><surname>Spohn</surname><given-names>R</given-names></name><name><surname>Daruka</surname><given-names>L</given-names></name><name><surname>Martins</surname><given-names>A</given-names></name><name><surname>Hosseinnia</surname><given-names>A</given-names></name><name><surname>Gagarinova</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Phanse</surname><given-names>S</given-names></name><name><surname>Csörgő</surname><given-names>B</given-names></name><name><surname>Györkei</surname><given-names>Á</given-names></name><name><surname>Ari</surname><given-names>E</given-names></name><name><surname>Lázár</surname><given-names>V</given-names></name><name><surname>Nagy</surname><given-names>I</given-names></name><name><surname>Babu</surname><given-names>M</given-names></name><name><surname>Pál</surname><given-names>C</given-names></name><name><surname>Papp</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019a</year><article-title>Chemical-genetic profiling reveals limited cross-resistance between antimicrobial peptides with different modes of action</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>5731</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-13618-z</pub-id><pub-id pub-id-type="pmid">31844052</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kintses</surname><given-names>B</given-names></name><name><surname>Méhi</surname><given-names>O</given-names></name><name><surname>Ari</surname><given-names>E</given-names></name><name><surname>Számel</surname><given-names>M</given-names></name><name><surname>Györkei</surname><given-names>Á</given-names></name><name><surname>Jangir</surname><given-names>PK</given-names></name><name><surname>Nagy</surname><given-names>I</given-names></name><name><surname>Pál</surname><given-names>F</given-names></name><name><surname>Fekete</surname><given-names>G</given-names></name><name><surname>Tengölics</surname><given-names>R</given-names></name><name><surname>Nyerges</surname><given-names>Á</given-names></name><name><surname>Likó</surname><given-names>I</given-names></name><name><surname>Bálint</surname><given-names>A</given-names></name><name><surname>Molnár</surname><given-names>T</given-names></name><name><surname>Bálint</surname><given-names>B</given-names></name><name><surname>Vásárhelyi</surname><given-names>BM</given-names></name><name><surname>Bustamante</surname><given-names>M</given-names></name><name><surname>Papp</surname><given-names>B</given-names></name><name><surname>Pál</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019b</year><article-title>Phylogenetic barriers to horizontal transfer of antimicrobial peptide resistance genes in the human gut microbiota</article-title><source>Nature Microbiology</source><volume>4</volume><fpage>447</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1038/s41564-018-0313-5</pub-id><pub-id pub-id-type="pmid">30559406</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraus</surname><given-names>S</given-names></name><name><surname>Fletcher</surname><given-names>ML</given-names></name><name><surname>Łapińska</surname><given-names>U</given-names></name><name><surname>Chawla</surname><given-names>K</given-names></name><name><surname>Baker</surname><given-names>E</given-names></name><name><surname>Attrill</surname><given-names>EL</given-names></name><name><surname>O’Neill</surname><given-names>P</given-names></name><name><surname>Farbos</surname><given-names>A</given-names></name><name><surname>Jeffries</surname><given-names>A</given-names></name><name><surname>Galyov</surname><given-names>EE</given-names></name><name><surname>Korbsrisate</surname><given-names>S</given-names></name><name><surname>Barnes</surname><given-names>KB</given-names></name><name><surname>Harding</surname><given-names>SV</given-names></name><name><surname>Tsaneva-Atanasova</surname><given-names>K</given-names></name><name><surname>Blaskovich</surname><given-names>MAT</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Phage-induced efflux down-regulation boosts antibiotic efficacy</article-title><source>PLOS Pathogens</source><volume>20</volume><elocation-id>e1012361</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1012361</pub-id><pub-id pub-id-type="pmid">38941361</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulp</surname><given-names>A</given-names></name><name><surname>Kuehn</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Biological functions and biogenesis of secreted bacterial outer membrane vesicles</article-title><source>Annual Review of Microbiology</source><volume>64</volume><fpage>163</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1146/annurev.micro.091208.073413</pub-id><pub-id pub-id-type="pmid">20825345</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kushibiki</surname><given-names>T</given-names></name><name><surname>Kamiya</surname><given-names>M</given-names></name><name><surname>Aizawa</surname><given-names>T</given-names></name><name><surname>Kumaki</surname><given-names>Y</given-names></name><name><surname>Kikukawa</surname><given-names>T</given-names></name><name><surname>Mizuguchi</surname><given-names>M</given-names></name><name><surname>Demura</surname><given-names>M</given-names></name><name><surname>Kawabata</surname><given-names>S</given-names></name><name><surname>Kawano</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Interaction between tachyplesin I, an antimicrobial peptide derived from horseshoe crab, and lipopolysaccharide</article-title><source>Biochimica et Biophysica Acta- Proteins and Proteomics</source><volume>1844</volume><fpage>527</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1016/j.bbapap.2013.12.017</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Łapińska</surname><given-names>U</given-names></name><name><surname>Glover</surname><given-names>G</given-names></name><name><surname>Capilla-Lasheras</surname><given-names>P</given-names></name><name><surname>Young</surname><given-names>AJ</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Bacterial ageing in the absence of external stressors</article-title><source>Philosophical Transactions of the Royal Society B</source><volume>374</volume><elocation-id>20180442</elocation-id><pub-id pub-id-type="doi">10.1098/rstb.2018.0442</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Łapińska</surname><given-names>U</given-names></name><name><surname>Voliotis</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>KK</given-names></name><name><surname>Campey</surname><given-names>A</given-names></name><name><surname>Stone</surname><given-names>MRL</given-names></name><name><surname>Tuck</surname><given-names>B</given-names></name><name><surname>Phetsang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Tsaneva-Atanasova</surname><given-names>K</given-names></name><name><surname>Blaskovich</surname><given-names>MAT</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Fast bacterial growth reduces antibiotic accumulation and efficacy</article-title><source>eLife</source><volume>11</volume><elocation-id>e74062</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.74062</pub-id><pub-id pub-id-type="pmid">35670099</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Łapińska</surname><given-names>U</given-names></name><name><surname>Glover</surname><given-names>G</given-names></name><name><surname>Kahveci</surname><given-names>Z</given-names></name><name><surname>Irwin</surname><given-names>NAT</given-names></name><name><surname>Milner</surname><given-names>DS</given-names></name><name><surname>Tourte</surname><given-names>M</given-names></name><name><surname>Albers</surname><given-names>SV</given-names></name><name><surname>Santoro</surname><given-names>AE</given-names></name><name><surname>Richards</surname><given-names>TA</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Systematic comparison of unilamellar vesicles reveals that archaeal core lipid membranes are more permeable than bacterial membranes</article-title><source>PLOS Biology</source><volume>21</volume><elocation-id>e3002048</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3002048</pub-id><pub-id pub-id-type="pmid">37014915</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Łapińska</surname><given-names>U</given-names></name><name><surname>Chandran</surname><given-names>G</given-names></name><name><surname>Tunstall</surname><given-names>T</given-names></name><name><surname>Zborowsky</surname><given-names>S</given-names></name><name><surname>Tolle</surname><given-names>G</given-names></name><name><surname>Verderosa</surname><given-names>AD</given-names></name><name><surname>García-Castillo</surname><given-names>M</given-names></name><name><surname>O’Neill</surname><given-names>PA</given-names></name><name><surname>Farbos</surname><given-names>A</given-names></name><name><surname>Jeffries</surname><given-names>AR</given-names></name><name><surname>Young</surname><given-names>AJ</given-names></name><name><surname>Canton</surname><given-names>R</given-names></name><name><surname>Caboni</surname><given-names>P</given-names></name><name><surname>Blaskovich</surname><given-names>MAT</given-names></name><name><surname>Warris</surname><given-names>A</given-names></name><name><surname>Tsaneva-Atanasova</surname><given-names>K</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2025">2025</year><article-title>Competition with <italic>Pseudomonas aeruginosa</italic> induces <italic>Staphylococcus aureus</italic> in an antibiotic-tolerant viable but non culturable state</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2025.04.30.651255</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazzaro</surname><given-names>BP</given-names></name><name><surname>Zasloff</surname><given-names>M</given-names></name><name><surname>Rolff</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Antimicrobial peptides: Application informed by evolution</article-title><source>Science</source><volume>368</volume><elocation-id>eaau5480</elocation-id><pub-id pub-id-type="doi">10.1126/science.aau5480</pub-id><pub-id pub-id-type="pmid">32355003</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>D</given-names></name><name><surname>Krasnopeeva</surname><given-names>E</given-names></name><name><surname>Sinjab</surname><given-names>F</given-names></name><name><surname>Pilizota</surname><given-names>T</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Active efflux leads to heterogeneous dissipation of proton motive force by protonophores in bacteria</article-title><source>mBio</source><volume>12</volume><elocation-id>e0067621</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00676-21</pub-id><pub-id pub-id-type="pmid">34253054</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KK</given-names></name><name><surname>Housden</surname><given-names>B</given-names></name><name><surname>Tsaneva-Atanasova</surname><given-names>K</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2025">2025</year><source>Dissecting the Mechanisms Underlying Heterogeneous Antimicrobial Accumulation in Isogenic Bacterial Populations</source><publisher-name>University of Exeter</publisher-name></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehrer</surname><given-names>RI</given-names></name><name><surname>Szklarek</surname><given-names>D</given-names></name><name><surname>Ganz</surname><given-names>T</given-names></name><name><surname>Selsted</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>Correlation of binding of rabbit granulocyte peptides to Candida albicans with candidacidal activity</article-title><source>Infection and Immunity</source><volume>49</volume><fpage>207</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1128/iai.49.1.207-211.1985</pub-id><pub-id pub-id-type="pmid">3891625</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lei</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Mackey</surname><given-names>V</given-names></name><name><surname>Coy</surname><given-names>DH</given-names></name><name><surname>He</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The antimicrobial peptides and their potential clinical applications</article-title><source>American Journal of Translational Research</source><volume>11</volume><fpage>3919</fpage><lpage>3931</lpage><pub-id pub-id-type="pmid">31396309</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Kromann</surname><given-names>S</given-names></name><name><surname>Olsen</surname><given-names>JE</given-names></name><name><surname>Svenningsen</surname><given-names>SW</given-names></name><name><surname>Olsen</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Insight into synergetic mechanisms of tetracycline and the selective serotonin reuptake inhibitor, sertraline, in a tetracycline-resistant strain of <italic>Escherichia coli</italic></article-title><source>The Journal of Antibiotics</source><volume>70</volume><fpage>944</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.1038/ja.2017.78</pub-id><pub-id pub-id-type="pmid">28698674</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>YX</given-names></name><name><surname>Zhong</surname><given-names>Z</given-names></name><name><surname>Hou</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>WP</given-names></name><name><surname>Qian</surname><given-names>PY</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Resistance to nonribosomal peptide antibiotics mediated by D-stereospecific peptidases</article-title><source>Nature Chemical Biology</source><volume>14</volume><fpage>381</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1038/s41589-018-0009-4</pub-id><pub-id pub-id-type="pmid">29483640</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Xue</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Qi</surname><given-names>K</given-names></name><name><surname>Ni</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>R</given-names></name><name><surname>Shang</surname><given-names>F</given-names></name><name><surname>Xue</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>QseBC is involved in the biofilm formation and antibiotic resistance in <italic>Escherichia coli</italic> isolated from bovine mastitis</article-title><source>PeerJ</source><volume>8</volume><elocation-id>e8833</elocation-id><pub-id pub-id-type="doi">10.7717/peerj.8833</pub-id><pub-id pub-id-type="pmid">32257646</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lister</surname><given-names>IM</given-names></name><name><surname>Raftery</surname><given-names>C</given-names></name><name><surname>Mecsas</surname><given-names>J</given-names></name><name><surname>Levy</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Yersinia pestis AcrAB-TolC in antibiotic resistance and virulence</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>56</volume><fpage>1120</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1128/AAC.05338-11</pub-id><pub-id pub-id-type="pmid">22083483</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Yi</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Roland</surname><given-names>KL</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Kong</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Outer membrane vesicles derived from <italic>Salmonella</italic> Typhimurium mutants with truncated LPS induce cross-protective immune responses against infection of <italic>Salmonella enterica</italic> serovars in the mouse model</article-title><source>International Journal of Medical Microbiology</source><volume>306</volume><fpage>697</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1016/j.ijmm.2016.08.004</pub-id><pub-id pub-id-type="pmid">27578609</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Shan</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Tachyplesin causes membrane instability that kills multidrug-resistant bacteria by inhibiting the 3-ketoacyl carrier protein reductase FabG</article-title><source>Frontiers in Microbiology</source><volume>9</volume><elocation-id>825</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2018.00825</pub-id><pub-id pub-id-type="pmid">29765362</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Locatelli</surname><given-names>E</given-names></name><name><surname>Pierno</surname><given-names>M</given-names></name><name><surname>Baldovin</surname><given-names>F</given-names></name><name><surname>Orlandini</surname><given-names>E</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Single-file escape of colloidal particles from microfluidic channels</article-title><source>Physical Review Letters</source><volume>117</volume><elocation-id>038001</elocation-id><pub-id pub-id-type="doi">10.1103/PhysRevLett.117.038001</pub-id><pub-id pub-id-type="pmid">27472142</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopatkin</surname><given-names>AJ</given-names></name><name><surname>Stokes</surname><given-names>JM</given-names></name><name><surname>Zheng</surname><given-names>EJ</given-names></name><name><surname>Yang</surname><given-names>JH</given-names></name><name><surname>Takahashi</surname><given-names>MK</given-names></name><name><surname>You</surname><given-names>L</given-names></name><name><surname>Collins</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Bacterial metabolic state more accurately predicts antibiotic lethality than growth rate</article-title><source>Nature Microbiology</source><volume>4</volume><fpage>2109</fpage><lpage>2117</lpage><pub-id pub-id-type="doi">10.1038/s41564-019-0536-0</pub-id><pub-id pub-id-type="pmid">31451773</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacDermott-Opeskin</surname><given-names>HI</given-names></name><name><surname>Gupta</surname><given-names>V</given-names></name><name><surname>O’Mara</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Lipid-mediated antimicrobial resistance: a phantom menace or a new hope?</article-title><source>Biophysical Reviews</source><volume>14</volume><fpage>145</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1007/s12551-021-00912-8</pub-id><pub-id pub-id-type="pmid">35251360</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacNair</surname><given-names>CR</given-names></name><name><surname>Tan</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The role of bacterial membrane vesicles in antibiotic resistance</article-title><source>Annals of the New York Academy of Sciences</source><volume>1519</volume><fpage>63</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1111/nyas.14932</pub-id><pub-id pub-id-type="pmid">36415037</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacNair</surname><given-names>CR</given-names></name><name><surname>Rutherford</surname><given-names>ST</given-names></name><name><surname>Tan</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Alternative therapeutic strategies to treat antibiotic-resistant pathogens</article-title><source>Nature Reviews. Microbiology</source><volume>22</volume><fpage>262</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1038/s41579-023-00993-0</pub-id><pub-id pub-id-type="pmid">38082064</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magana</surname><given-names>M</given-names></name><name><surname>Pushpanathan</surname><given-names>M</given-names></name><name><surname>Santos</surname><given-names>AL</given-names></name><name><surname>Leanse</surname><given-names>L</given-names></name><name><surname>Fernandez</surname><given-names>M</given-names></name><name><surname>Ioannidis</surname><given-names>A</given-names></name><name><surname>Giulianotti</surname><given-names>MA</given-names></name><name><surname>Apidianakis</surname><given-names>Y</given-names></name><name><surname>Bradfute</surname><given-names>S</given-names></name><name><surname>Ferguson</surname><given-names>AL</given-names></name><name><surname>Cherkasov</surname><given-names>A</given-names></name><name><surname>Seleem</surname><given-names>MN</given-names></name><name><surname>Pinilla</surname><given-names>C</given-names></name><name><surname>de la Fuente-Nunez</surname><given-names>C</given-names></name><name><surname>Lazaridis</surname><given-names>T</given-names></name><name><surname>Dai</surname><given-names>T</given-names></name><name><surname>Houghten</surname><given-names>RA</given-names></name><name><surname>Hancock</surname><given-names>REW</given-names></name><name><surname>Tegos</surname><given-names>GP</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The value of antimicrobial peptides in the age of resistance</article-title><source>The Lancet. Infectious Diseases</source><volume>20</volume><fpage>e216</fpage><lpage>e230</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30327-3</pub-id><pub-id pub-id-type="pmid">32653070</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahamoud</surname><given-names>A</given-names></name><name><surname>Chevalier</surname><given-names>J</given-names></name><name><surname>Alibert-Franco</surname><given-names>S</given-names></name><name><surname>Kern</surname><given-names>WV</given-names></name><name><surname>Pagès</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy</article-title><source>The Journal of Antimicrobial Chemotherapy</source><volume>59</volume><fpage>1223</fpage><lpage>1229</lpage><pub-id pub-id-type="doi">10.1093/jac/dkl493</pub-id><pub-id pub-id-type="pmid">17229832</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Majewski</surname><given-names>P</given-names></name><name><surname>Gutowska</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>DGE</given-names></name><name><surname>Hauschild</surname><given-names>T</given-names></name><name><surname>Majewska</surname><given-names>P</given-names></name><name><surname>Hryszko</surname><given-names>T</given-names></name><name><surname>Gizycka</surname><given-names>D</given-names></name><name><surname>Kedra</surname><given-names>B</given-names></name><name><surname>Kochanowicz</surname><given-names>J</given-names></name><name><surname>Glowiński</surname><given-names>J</given-names></name><name><surname>Drewnowska</surname><given-names>J</given-names></name><name><surname>Swiecicka</surname><given-names>I</given-names></name><name><surname>Sacha</surname><given-names>PT</given-names></name><name><surname>Wieczorek</surname><given-names>P</given-names></name><name><surname>Iwaniuk</surname><given-names>D</given-names></name><name><surname>Sulewska</surname><given-names>A</given-names></name><name><surname>Charkiewicz</surname><given-names>R</given-names></name><name><surname>Makarewicz</surname><given-names>K</given-names></name><name><surname>Zebrowska</surname><given-names>A</given-names></name><name><surname>Czaban</surname><given-names>S</given-names></name><name><surname>Radziwon</surname><given-names>P</given-names></name><name><surname>Niklinski</surname><given-names>J</given-names></name><name><surname>Tryniszewska</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Plasmid Mediated <italic>mcr-1.1</italic> colistin-resistance in clinical extraintestinal <italic>Escherichia coli</italic> strains isolated in Poland</article-title><source>Frontiers in Microbiology</source><volume>12</volume><elocation-id>547020</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2021.547020</pub-id><pub-id pub-id-type="pmid">34956105</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuzaki</surname><given-names>K</given-names></name><name><surname>Fukui</surname><given-names>M</given-names></name><name><surname>Fujii</surname><given-names>N</given-names></name><name><surname>Miyajima</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Interactions of an antimicrobial peptide, tachyplesin I, with lipid membranes</article-title><source>Biochimica et Biophysica Acta - Biomembranes</source><volume>1070</volume><fpage>259</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1016/0005-2736(91)90173-6</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuzaki</surname><given-names>K</given-names></name><name><surname>Yoneyama</surname><given-names>S</given-names></name><name><surname>Fujii</surname><given-names>N</given-names></name><name><surname>Miyajima</surname><given-names>K</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Kirino</surname><given-names>Y</given-names></name><name><surname>Anzai</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Membrane permeabilization mechanisms of a cyclic antimicrobial peptide, tachyplesin I, and its linear analog</article-title><source>Biochemistry</source><volume>36</volume><fpage>9799</fpage><lpage>9806</lpage><pub-id pub-id-type="doi">10.1021/bi970588v</pub-id><pub-id pub-id-type="pmid">9245412</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mattiuzzo</surname><given-names>M</given-names></name><name><surname>De Gobba</surname><given-names>C</given-names></name><name><surname>Runti</surname><given-names>G</given-names></name><name><surname>Mardirossian</surname><given-names>M</given-names></name><name><surname>Bandiera</surname><given-names>A</given-names></name><name><surname>Gennaro</surname><given-names>R</given-names></name><name><surname>Scocchi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Proteolytic activity of <italic>Escherichia coli</italic> oligopeptidase B against proline-rich antimicrobial peptides</article-title><source>Journal of Microbiology and Biotechnology</source><volume>24</volume><fpage>160</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.4014/jmb.1310.10015</pub-id><pub-id pub-id-type="pmid">24225368</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McBroom</surname><given-names>AJ</given-names></name><name><surname>Kuehn</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Release of outer membrane vesicles by Gram-negative bacteria is a novel envelope stress response</article-title><source>Molecular Microbiology</source><volume>63</volume><fpage>545</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2958.2006.05522.x</pub-id><pub-id pub-id-type="pmid">17163978</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medvedeva</surname><given-names>ES</given-names></name><name><surname>Baranova</surname><given-names>NB</given-names></name><name><surname>Mouzykantov</surname><given-names>AA</given-names></name><name><surname>Grigorieva</surname><given-names>TY</given-names></name><name><surname>Davydova</surname><given-names>MN</given-names></name><name><surname>Trushin</surname><given-names>MV</given-names></name><name><surname>Chernova</surname><given-names>OA</given-names></name><name><surname>Chernov</surname><given-names>VM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Adaptation of mycoplasmas to antimicrobial agents: Acholeplasma laidlawii extracellular vesicles mediate the export of ciprofloxacin and a mutant gene related to the antibiotic target</article-title><source>TheScientificWorldJournal</source><volume>2014</volume><elocation-id>150615</elocation-id><pub-id pub-id-type="doi">10.1155/2014/150615</pub-id><pub-id pub-id-type="pmid">24605048</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meylan</surname><given-names>S</given-names></name><name><surname>Porter</surname><given-names>CBM</given-names></name><name><surname>Yang</surname><given-names>JH</given-names></name><name><surname>Belenky</surname><given-names>P</given-names></name><name><surname>Gutierrez</surname><given-names>A</given-names></name><name><surname>Lobritz</surname><given-names>MA</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Moskowitz</surname><given-names>SM</given-names></name><name><surname>Collins</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Carbon sources tune antibiotic susceptibility in <italic>Pseudomonas aeruginosa</italic> via tricarboxylic acid cycle control</article-title><source>Cell Chemical Biology</source><volume>24</volume><fpage>195</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2016.12.015</pub-id><pub-id pub-id-type="pmid">28111098</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>AM</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Silhavy</surname><given-names>TJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Novel RpoS-dependent mechanisms strengthen the envelope permeability barrier during stationary phase</article-title><source>Journal of Bacteriology</source><volume>199</volume><elocation-id>e00708-16</elocation-id><pub-id pub-id-type="doi">10.1128/JB.00708-16</pub-id><pub-id pub-id-type="pmid">27821607</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mookherjee</surname><given-names>N</given-names></name><name><surname>Anderson</surname><given-names>MA</given-names></name><name><surname>Haagsman</surname><given-names>HP</given-names></name><name><surname>Davidson</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Antimicrobial host defence peptides: functions and clinical potential</article-title><source>Nature Reviews. Drug Discovery</source><volume>19</volume><fpage>311</fpage><lpage>332</lpage><pub-id pub-id-type="doi">10.1038/s41573-019-0058-8</pub-id><pub-id pub-id-type="pmid">32107480</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morita</surname><given-names>Y</given-names></name><name><surname>Nakashima</surname><given-names>K-I</given-names></name><name><surname>Nishino</surname><given-names>K</given-names></name><name><surname>Kotani</surname><given-names>K</given-names></name><name><surname>Tomida</surname><given-names>J</given-names></name><name><surname>Inoue</surname><given-names>M</given-names></name><name><surname>Kawamura</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Berberine is a novel type efflux inhibitor which attenuates the MexXY-mediated aminoglycoside resistance in <italic>Pseudomonas aeruginosa</italic></article-title><source>Frontiers in Microbiology</source><volume>7</volume><elocation-id>1223</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2016.01223</pub-id><pub-id pub-id-type="pmid">27547203</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>BO</given-names></name><name><surname>Dawson</surname><given-names>RA</given-names></name><name><surname>Alsharaf</surname><given-names>LM</given-names></name><name><surname>Anne Winter</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Protective effects of <italic>Helicobacter pylori</italic> membrane vesicles against stress and antimicrobial agents</article-title><source>Microbiology</source><volume>166</volume><fpage>751</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1099/mic.0.000934</pub-id><pub-id pub-id-type="pmid">32463354</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>CJL</given-names></name><name><surname>Ikuta</surname><given-names>KS</given-names></name><name><surname>Sharara</surname><given-names>F</given-names></name><name><surname>Swetschinski</surname><given-names>L</given-names></name><name><surname>Robles Aguilar</surname><given-names>G</given-names></name><name><surname>Gray</surname><given-names>A</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Bisignano</surname><given-names>C</given-names></name><name><surname>Rao</surname><given-names>P</given-names></name><name><surname>Wool</surname><given-names>E</given-names></name><name><surname>Johnson</surname><given-names>SC</given-names></name><name><surname>Browne</surname><given-names>AJ</given-names></name><name><surname>Chipeta</surname><given-names>MG</given-names></name><name><surname>Fell</surname><given-names>F</given-names></name><name><surname>Hackett</surname><given-names>S</given-names></name><name><surname>Haines-Woodhouse</surname><given-names>G</given-names></name><name><surname>Kashef Hamadani</surname><given-names>BH</given-names></name><name><surname>Kumaran</surname><given-names>EAP</given-names></name><name><surname>McManigal</surname><given-names>B</given-names></name><name><surname>Achalapong</surname><given-names>S</given-names></name><name><surname>Agarwal</surname><given-names>R</given-names></name><name><surname>Akech</surname><given-names>S</given-names></name><name><surname>Albertson</surname><given-names>S</given-names></name><name><surname>Amuasi</surname><given-names>J</given-names></name><name><surname>Andrews</surname><given-names>J</given-names></name><name><surname>Aravkin</surname><given-names>A</given-names></name><name><surname>Ashley</surname><given-names>E</given-names></name><name><surname>Babin</surname><given-names>FX</given-names></name><name><surname>Bailey</surname><given-names>F</given-names></name><name><surname>Baker</surname><given-names>S</given-names></name><name><surname>Basnyat</surname><given-names>B</given-names></name><name><surname>Bekker</surname><given-names>A</given-names></name><name><surname>Bender</surname><given-names>R</given-names></name><name><surname>Berkley</surname><given-names>JA</given-names></name><name><surname>Bethou</surname><given-names>A</given-names></name><name><surname>Bielicki</surname><given-names>J</given-names></name><name><surname>Boonkasidecha</surname><given-names>S</given-names></name><name><surname>Bukosia</surname><given-names>J</given-names></name><name><surname>Carvalheiro</surname><given-names>C</given-names></name><name><surname>Castañeda-Orjuela</surname><given-names>C</given-names></name><name><surname>Chansamouth</surname><given-names>V</given-names></name><name><surname>Chaurasia</surname><given-names>S</given-names></name><name><surname>Chiurchiù</surname><given-names>S</given-names></name><name><surname>Chowdhury</surname><given-names>F</given-names></name><name><surname>Clotaire Donatien</surname><given-names>R</given-names></name><name><surname>Cook</surname><given-names>AJ</given-names></name><name><surname>Cooper</surname><given-names>B</given-names></name><name><surname>Cressey</surname><given-names>TR</given-names></name><name><surname>Criollo-Mora</surname><given-names>E</given-names></name><name><surname>Cunningham</surname><given-names>M</given-names></name><name><surname>Darboe</surname><given-names>S</given-names></name><name><surname>Day</surname><given-names>NPJ</given-names></name><name><surname>De Luca</surname><given-names>M</given-names></name><name><surname>Dokova</surname><given-names>K</given-names></name><name><surname>Dramowski</surname><given-names>A</given-names></name><name><surname>Dunachie</surname><given-names>SJ</given-names></name><name><surname>Duong Bich</surname><given-names>T</given-names></name><name><surname>Eckmanns</surname><given-names>T</given-names></name><name><surname>Eibach</surname><given-names>D</given-names></name><name><surname>Emami</surname><given-names>A</given-names></name><name><surname>Feasey</surname><given-names>N</given-names></name><name><surname>Fisher-Pearson</surname><given-names>N</given-names></name><name><surname>Forrest</surname><given-names>K</given-names></name><name><surname>Garcia</surname><given-names>C</given-names></name><name><surname>Garrett</surname><given-names>D</given-names></name><name><surname>Gastmeier</surname><given-names>P</given-names></name><name><surname>Giref</surname><given-names>AZ</given-names></name><name><surname>Greer</surname><given-names>RC</given-names></name><name><surname>Gupta</surname><given-names>V</given-names></name><name><surname>Haller</surname><given-names>S</given-names></name><name><surname>Haselbeck</surname><given-names>A</given-names></name><name><surname>Hay</surname><given-names>SI</given-names></name><name><surname>Holm</surname><given-names>M</given-names></name><name><surname>Hopkins</surname><given-names>S</given-names></name><name><surname>Hsia</surname><given-names>Y</given-names></name><name><surname>Iregbu</surname><given-names>KC</given-names></name><name><surname>Jacobs</surname><given-names>J</given-names></name><name><surname>Jarovsky</surname><given-names>D</given-names></name><name><surname>Javanmardi</surname><given-names>F</given-names></name><name><surname>Jenney</surname><given-names>AWJ</given-names></name><name><surname>Khorana</surname><given-names>M</given-names></name><name><surname>Khusuwan</surname><given-names>S</given-names></name><name><surname>Kissoon</surname><given-names>N</given-names></name><name><surname>Kobeissi</surname><given-names>E</given-names></name><name><surname>Kostyanev</surname><given-names>T</given-names></name><name><surname>Krapp</surname><given-names>F</given-names></name><name><surname>Krumkamp</surname><given-names>R</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Kyu</surname><given-names>HH</given-names></name><name><surname>Lim</surname><given-names>C</given-names></name><name><surname>Lim</surname><given-names>K</given-names></name><name><surname>Limmathurotsakul</surname><given-names>D</given-names></name><name><surname>Loftus</surname><given-names>MJ</given-names></name><name><surname>Lunn</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Manoharan</surname><given-names>A</given-names></name><name><surname>Marks</surname><given-names>F</given-names></name><name><surname>May</surname><given-names>J</given-names></name><name><surname>Mayxay</surname><given-names>M</given-names></name><name><surname>Mturi</surname><given-names>N</given-names></name><name><surname>Munera-Huertas</surname><given-names>T</given-names></name><name><surname>Musicha</surname><given-names>P</given-names></name><name><surname>Musila</surname><given-names>LA</given-names></name><name><surname>Mussi-Pinhata</surname><given-names>MM</given-names></name><name><surname>Naidu</surname><given-names>RN</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Nanavati</surname><given-names>R</given-names></name><name><surname>Nangia</surname><given-names>S</given-names></name><name><surname>Newton</surname><given-names>P</given-names></name><name><surname>Ngoun</surname><given-names>C</given-names></name><name><surname>Novotney</surname><given-names>A</given-names></name><name><surname>Nwakanma</surname><given-names>D</given-names></name><name><surname>Obiero</surname><given-names>CW</given-names></name><name><surname>Ochoa</surname><given-names>TJ</given-names></name><name><surname>Olivas-Martinez</surname><given-names>A</given-names></name><name><surname>Olliaro</surname><given-names>P</given-names></name><name><surname>Ooko</surname><given-names>E</given-names></name><name><surname>Ortiz-Brizuela</surname><given-names>E</given-names></name><name><surname>Ounchanum</surname><given-names>P</given-names></name><name><surname>Pak</surname><given-names>GD</given-names></name><name><surname>Paredes</surname><given-names>JL</given-names></name><name><surname>Peleg</surname><given-names>AY</given-names></name><name><surname>Perrone</surname><given-names>C</given-names></name><name><surname>Phe</surname><given-names>T</given-names></name><name><surname>Phommasone</surname><given-names>K</given-names></name><name><surname>Plakkal</surname><given-names>N</given-names></name><name><surname>Ponce-de-Leon</surname><given-names>A</given-names></name><name><surname>Raad</surname><given-names>M</given-names></name><name><surname>Ramdin</surname><given-names>T</given-names></name><name><surname>Rattanavong</surname><given-names>S</given-names></name><name><surname>Riddell</surname><given-names>A</given-names></name><name><surname>Roberts</surname><given-names>T</given-names></name><name><surname>Robotham</surname><given-names>JV</given-names></name><name><surname>Roca</surname><given-names>A</given-names></name><name><surname>Rosenthal</surname><given-names>VD</given-names></name><name><surname>Rudd</surname><given-names>KE</given-names></name><name><surname>Russell</surname><given-names>N</given-names></name><name><surname>Sader</surname><given-names>HS</given-names></name><name><surname>Saengchan</surname><given-names>W</given-names></name><name><surname>Schnall</surname><given-names>J</given-names></name><name><surname>Scott</surname><given-names>JAG</given-names></name><name><surname>Seekaew</surname><given-names>S</given-names></name><name><surname>Sharland</surname><given-names>M</given-names></name><name><surname>Shivamallappa</surname><given-names>M</given-names></name><name><surname>Sifuentes-Osornio</surname><given-names>J</given-names></name><name><surname>Simpson</surname><given-names>AJ</given-names></name><name><surname>Steenkeste</surname><given-names>N</given-names></name><name><surname>Stewardson</surname><given-names>AJ</given-names></name><name><surname>Stoeva</surname><given-names>T</given-names></name><name><surname>Tasak</surname><given-names>N</given-names></name><name><surname>Thaiprakong</surname><given-names>A</given-names></name><name><surname>Thwaites</surname><given-names>G</given-names></name><name><surname>Tigoi</surname><given-names>C</given-names></name><name><surname>Turner</surname><given-names>C</given-names></name><name><surname>Turner</surname><given-names>P</given-names></name><name><surname>van Doorn</surname><given-names>HR</given-names></name><name><surname>Velaphi</surname><given-names>S</given-names></name><name><surname>Vongpradith</surname><given-names>A</given-names></name><name><surname>Vongsouvath</surname><given-names>M</given-names></name><name><surname>Vu</surname><given-names>H</given-names></name><name><surname>Walsh</surname><given-names>T</given-names></name><name><surname>Walson</surname><given-names>JL</given-names></name><name><surname>Waner</surname><given-names>S</given-names></name><name><surname>Wangrangsimakul</surname><given-names>T</given-names></name><name><surname>Wannapinij</surname><given-names>P</given-names></name><name><surname>Wozniak</surname><given-names>T</given-names></name><name><surname>Young Sharma</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>KC</given-names></name><name><surname>Zheng</surname><given-names>P</given-names></name><name><surname>Sartorius</surname><given-names>B</given-names></name><name><surname>Lopez</surname><given-names>AD</given-names></name><name><surname>Stergachis</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>C</given-names></name><name><surname>Dolecek</surname><given-names>C</given-names></name><name><surname>Naghavi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis</article-title><source>The Lancet</source><volume>399</volume><fpage>629</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)02724-0</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naghavi</surname><given-names>M</given-names></name><name><surname>Vollset</surname><given-names>SE</given-names></name><name><surname>Ikuta</surname><given-names>KS</given-names></name><name><surname>Swetschinski</surname><given-names>LR</given-names></name><name><surname>Gray</surname><given-names>AP</given-names></name><name><surname>Wool</surname><given-names>EE</given-names></name><name><surname>Robles Aguilar</surname><given-names>G</given-names></name><name><surname>Mestrovic</surname><given-names>T</given-names></name><name><surname>Smith</surname><given-names>G</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Hsu</surname><given-names>RL</given-names></name><name><surname>Chalek</surname><given-names>J</given-names></name><name><surname>Araki</surname><given-names>DT</given-names></name><name><surname>Chung</surname><given-names>E</given-names></name><name><surname>Raggi</surname><given-names>C</given-names></name><name><surname>Gershberg Hayoon</surname><given-names>A</given-names></name><name><surname>Davis Weaver</surname><given-names>N</given-names></name><name><surname>Lindstedt</surname><given-names>PA</given-names></name><name><surname>Smith</surname><given-names>AE</given-names></name><name><surname>Altay</surname><given-names>U</given-names></name><name><surname>Bhattacharjee</surname><given-names>NV</given-names></name><name><surname>Giannakis</surname><given-names>K</given-names></name><name><surname>Fell</surname><given-names>F</given-names></name><name><surname>McManigal</surname><given-names>B</given-names></name><name><surname>Ekapirat</surname><given-names>N</given-names></name><name><surname>Mendes</surname><given-names>JA</given-names></name><name><surname>Runghien</surname><given-names>T</given-names></name><name><surname>Srimokla</surname><given-names>O</given-names></name><name><surname>Abdelkader</surname><given-names>A</given-names></name><name><surname>Abd-Elsalam</surname><given-names>S</given-names></name><name><surname>Aboagye</surname><given-names>RG</given-names></name><name><surname>Abolhassani</surname><given-names>H</given-names></name><name><surname>Abualruz</surname><given-names>H</given-names></name><name><surname>Abubakar</surname><given-names>U</given-names></name><name><surname>Abukhadijah</surname><given-names>HJ</given-names></name><name><surname>Aburuz</surname><given-names>S</given-names></name><name><surname>Abu-Zaid</surname><given-names>A</given-names></name><name><surname>Achalapong</surname><given-names>S</given-names></name><name><surname>Addo</surname><given-names>IY</given-names></name><name><surname>Adekanmbi</surname><given-names>V</given-names></name><name><surname>Adeyeoluwa</surname><given-names>TE</given-names></name><name><surname>Adnani</surname><given-names>QES</given-names></name><name><surname>Adzigbli</surname><given-names>LA</given-names></name><name><surname>Afzal</surname><given-names>MS</given-names></name><name><surname>Afzal</surname><given-names>S</given-names></name><name><surname>Agodi</surname><given-names>A</given-names></name><name><surname>Ahlstrom</surname><given-names>AJ</given-names></name><name><surname>Ahmad</surname><given-names>A</given-names></name><name><surname>Ahmad</surname><given-names>S</given-names></name><name><surname>Ahmad</surname><given-names>T</given-names></name><name><surname>Ahmadi</surname><given-names>A</given-names></name><name><surname>Ahmed</surname><given-names>A</given-names></name><name><surname>Ahmed</surname><given-names>H</given-names></name><name><surname>Ahmed</surname><given-names>I</given-names></name><name><surname>Ahmed</surname><given-names>M</given-names></name><name><surname>Ahmed</surname><given-names>S</given-names></name><name><surname>Ahmed</surname><given-names>SA</given-names></name><name><surname>Akkaif</surname><given-names>MA</given-names></name><name><surname>Al Awaidy</surname><given-names>S</given-names></name><name><surname>Al Thaher</surname><given-names>Y</given-names></name><name><surname>Alalalmeh</surname><given-names>SO</given-names></name><name><surname>AlBataineh</surname><given-names>MT</given-names></name><name><surname>Aldhaleei</surname><given-names>WA</given-names></name><name><surname>Al-Gheethi</surname><given-names>AAS</given-names></name><name><surname>Alhaji</surname><given-names>NB</given-names></name><name><surname>Ali</surname><given-names>A</given-names></name><name><surname>Ali</surname><given-names>L</given-names></name><name><surname>Ali</surname><given-names>SS</given-names></name><name><surname>Ali</surname><given-names>W</given-names></name><name><surname>Allel</surname><given-names>K</given-names></name><name><surname>Al-Marwani</surname><given-names>S</given-names></name><name><surname>Alrawashdeh</surname><given-names>A</given-names></name><name><surname>Altaf</surname><given-names>A</given-names></name><name><surname>Al-Tammemi</surname><given-names>AB</given-names></name><name><surname>Al-Tawfiq</surname><given-names>JA</given-names></name><name><surname>Alzoubi</surname><given-names>KH</given-names></name><name><surname>Al-Zyoud</surname><given-names>WA</given-names></name><name><surname>Amos</surname><given-names>B</given-names></name><name><surname>Amuasi</surname><given-names>JH</given-names></name><name><surname>Ancuceanu</surname><given-names>R</given-names></name><name><surname>Andrews</surname><given-names>JR</given-names></name><name><surname>Anil</surname><given-names>A</given-names></name><name><surname>Anuoluwa</surname><given-names>IA</given-names></name><name><surname>Anvari</surname><given-names>S</given-names></name><name><surname>Anyasodor</surname><given-names>AE</given-names></name><name><surname>Apostol</surname><given-names>GLC</given-names></name><name><surname>Arabloo</surname><given-names>J</given-names></name><name><surname>Arafat</surname><given-names>M</given-names></name><name><surname>Aravkin</surname><given-names>AY</given-names></name><name><surname>Areda</surname><given-names>D</given-names></name><name><surname>Aremu</surname><given-names>A</given-names></name><name><surname>Artamonov</surname><given-names>AA</given-names></name><name><surname>Ashley</surname><given-names>EA</given-names></name><name><surname>Asika</surname><given-names>MO</given-names></name><name><surname>Athari</surname><given-names>SS</given-names></name><name><surname>Atout</surname><given-names>MMW</given-names></name><name><surname>Awoke</surname><given-names>T</given-names></name><name><surname>Azadnajafabad</surname><given-names>S</given-names></name><name><surname>Azam</surname><given-names>JM</given-names></name><name><surname>Aziz</surname><given-names>S</given-names></name><name><surname>Azzam</surname><given-names>AY</given-names></name><name><surname>Babaei</surname><given-names>M</given-names></name><name><surname>Babin</surname><given-names>F-X</given-names></name><name><surname>Badar</surname><given-names>M</given-names></name><name><surname>Baig</surname><given-names>AA</given-names></name><name><surname>Bajcetic</surname><given-names>M</given-names></name><name><surname>Baker</surname><given-names>S</given-names></name><name><surname>Bardhan</surname><given-names>M</given-names></name><name><surname>Barqawi</surname><given-names>HJ</given-names></name><name><surname>Basharat</surname><given-names>Z</given-names></name><name><surname>Basiru</surname><given-names>A</given-names></name><name><surname>Bastard</surname><given-names>M</given-names></name><name><surname>Basu</surname><given-names>S</given-names></name><name><surname>Bayleyegn</surname><given-names>NS</given-names></name><name><surname>Belete</surname><given-names>MA</given-names></name><name><surname>Bello</surname><given-names>OO</given-names></name><name><surname>Beloukas</surname><given-names>A</given-names></name><name><surname>Berkley</surname><given-names>JA</given-names></name><name><surname>Bhagavathula</surname><given-names>AS</given-names></name><name><surname>Bhaskar</surname><given-names>S</given-names></name><name><surname>Bhuyan</surname><given-names>SS</given-names></name><name><surname>Bielicki</surname><given-names>JA</given-names></name><name><surname>Briko</surname><given-names>NI</given-names></name><name><surname>Brown</surname><given-names>CS</given-names></name><name><surname>Browne</surname><given-names>AJ</given-names></name><name><surname>Buonsenso</surname><given-names>D</given-names></name><name><surname>Bustanji</surname><given-names>Y</given-names></name><name><surname>Carvalheiro</surname><given-names>CG</given-names></name><name><surname>Castañeda-Orjuela</surname><given-names>CA</given-names></name><name><surname>Cenderadewi</surname><given-names>M</given-names></name><name><surname>Chadwick</surname><given-names>J</given-names></name><name><surname>Chakraborty</surname><given-names>S</given-names></name><name><surname>Chandika</surname><given-names>RM</given-names></name><name><surname>Chandy</surname><given-names>S</given-names></name><name><surname>Chansamouth</surname><given-names>V</given-names></name><name><surname>Chattu</surname><given-names>VK</given-names></name><name><surname>Chaudhary</surname><given-names>AA</given-names></name><name><surname>Ching</surname><given-names>PR</given-names></name><name><surname>Chopra</surname><given-names>H</given-names></name><name><surname>Chowdhury</surname><given-names>FR</given-names></name><name><surname>Chu</surname><given-names>D-T</given-names></name><name><surname>Chutiyami</surname><given-names>M</given-names></name><name><surname>Cruz-Martins</surname><given-names>N</given-names></name><name><surname>da Silva</surname><given-names>AG</given-names></name><name><surname>Dadras</surname><given-names>O</given-names></name><name><surname>Dai</surname><given-names>X</given-names></name><name><surname>Darcho</surname><given-names>SD</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>De la Hoz</surname><given-names>FP</given-names></name><name><surname>Dekker</surname><given-names>DM</given-names></name><name><surname>Dhama</surname><given-names>K</given-names></name><name><surname>Diaz</surname><given-names>D</given-names></name><name><surname>Dickson</surname><given-names>BFR</given-names></name><name><surname>Djorie</surname><given-names>SG</given-names></name><name><surname>Dodangeh</surname><given-names>M</given-names></name><name><surname>Dohare</surname><given-names>S</given-names></name><name><surname>Dokova</surname><given-names>KG</given-names></name><name><surname>Doshi</surname><given-names>OP</given-names></name><name><surname>Dowou</surname><given-names>RK</given-names></name><name><surname>Dsouza</surname><given-names>HL</given-names></name><name><surname>Dunachie</surname><given-names>SJ</given-names></name><name><surname>Dziedzic</surname><given-names>AM</given-names></name><name><surname>Eckmanns</surname><given-names>T</given-names></name><name><surname>Ed-Dra</surname><given-names>A</given-names></name><name><surname>Eftekharimehrabad</surname><given-names>A</given-names></name><name><surname>Ekundayo</surname><given-names>TC</given-names></name><name><surname>El Sayed</surname><given-names>I</given-names></name><name><surname>Elhadi</surname><given-names>M</given-names></name><name><surname>El-Huneidi</surname><given-names>W</given-names></name><name><surname>Elias</surname><given-names>C</given-names></name><name><surname>Ellis</surname><given-names>SJ</given-names></name><name><surname>Elsheikh</surname><given-names>R</given-names></name><name><surname>Elsohaby</surname><given-names>I</given-names></name><name><surname>Eltaha</surname><given-names>C</given-names></name><name><surname>Eshrati</surname><given-names>B</given-names></name><name><surname>Eslami</surname><given-names>M</given-names></name><name><surname>Eyre</surname><given-names>DW</given-names></name><name><surname>Fadaka</surname><given-names>AO</given-names></name><name><surname>Fagbamigbe</surname><given-names>AF</given-names></name><name><surname>Fahim</surname><given-names>A</given-names></name><name><surname>Fakhri-Demeshghieh</surname><given-names>A</given-names></name><name><surname>Fasina</surname><given-names>FO</given-names></name><name><surname>Fasina</surname><given-names>MM</given-names></name><name><surname>Fatehizadeh</surname><given-names>A</given-names></name><name><surname>Feasey</surname><given-names>NA</given-names></name><name><surname>Feizkhah</surname><given-names>A</given-names></name><name><surname>Fekadu</surname><given-names>G</given-names></name><name><surname>Fischer</surname><given-names>F</given-names></name><name><surname>Fitriana</surname><given-names>I</given-names></name><name><surname>Forrest</surname><given-names>KM</given-names></name><name><surname>Fortuna Rodrigues</surname><given-names>C</given-names></name><name><surname>Fuller</surname><given-names>JE</given-names></name><name><surname>Gadanya</surname><given-names>MA</given-names></name><name><surname>Gajdács</surname><given-names>M</given-names></name><name><surname>Gandhi</surname><given-names>AP</given-names></name><name><surname>Garcia-Gallo</surname><given-names>EE</given-names></name><name><surname>Garrett</surname><given-names>DO</given-names></name><name><surname>Gautam</surname><given-names>RK</given-names></name><name><surname>Gebregergis</surname><given-names>MW</given-names></name><name><surname>Gebrehiwot</surname><given-names>M</given-names></name><name><surname>Gebremeskel</surname><given-names>TG</given-names></name><name><surname>Geffers</surname><given-names>C</given-names></name><name><surname>Georgalis</surname><given-names>L</given-names></name><name><surname>Ghazy</surname><given-names>RM</given-names></name><name><surname>Golechha</surname><given-names>M</given-names></name><name><surname>Golinelli</surname><given-names>D</given-names></name><name><surname>Gordon</surname><given-names>M</given-names></name><name><surname>Gulati</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>RD</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>VK</given-names></name><name><surname>Habteyohannes</surname><given-names>AD</given-names></name><name><surname>Haller</surname><given-names>S</given-names></name><name><surname>Harapan</surname><given-names>H</given-names></name><name><surname>Harrison</surname><given-names>ML</given-names></name><name><surname>Hasaballah</surname><given-names>AI</given-names></name><name><surname>Hasan</surname><given-names>I</given-names></name><name><surname>Hasan</surname><given-names>RS</given-names></name><name><surname>Hasani</surname><given-names>H</given-names></name><name><surname>Haselbeck</surname><given-names>AH</given-names></name><name><surname>Hasnain</surname><given-names>MS</given-names></name><name><surname>Hassan</surname><given-names>II</given-names></name><name><surname>Hassan</surname><given-names>S</given-names></name><name><surname>Hassan Zadeh Tabatabaei</surname><given-names>MS</given-names></name><name><surname>Hayat</surname><given-names>K</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Hegazi</surname><given-names>OE</given-names></name><name><surname>Heidari</surname><given-names>M</given-names></name><name><surname>Hezam</surname><given-names>K</given-names></name><name><surname>Holla</surname><given-names>R</given-names></name><name><surname>Holm</surname><given-names>M</given-names></name><name><surname>Hopkins</surname><given-names>H</given-names></name><name><surname>Hossain</surname><given-names>MM</given-names></name><name><surname>Hosseinzadeh</surname><given-names>M</given-names></name><name><surname>Hostiuc</surname><given-names>S</given-names></name><name><surname>Hussein</surname><given-names>NR</given-names></name><name><surname>Huy</surname><given-names>LD</given-names></name><name><surname>Ibáñez-Prada</surname><given-names>ED</given-names></name><name><surname>Ikiroma</surname><given-names>A</given-names></name><name><surname>Ilic</surname><given-names>IM</given-names></name><name><surname>Islam</surname><given-names>SMS</given-names></name><name><surname>Ismail</surname><given-names>F</given-names></name><name><surname>Ismail</surname><given-names>NE</given-names></name><name><surname>Iwu</surname><given-names>CD</given-names></name><name><surname>Iwu-Jaja</surname><given-names>CJ</given-names></name><name><surname>Jafarzadeh</surname><given-names>A</given-names></name><name><surname>Jaiteh</surname><given-names>F</given-names></name><name><surname>Jalilzadeh Yengejeh</surname><given-names>R</given-names></name><name><surname>Jamora</surname><given-names>RDG</given-names></name><name><surname>Javidnia</surname><given-names>J</given-names></name><name><surname>Jawaid</surname><given-names>T</given-names></name><name><surname>Jenney</surname><given-names>AWJ</given-names></name><name><surname>Jeon</surname><given-names>HJ</given-names></name><name><surname>Jokar</surname><given-names>M</given-names></name><name><surname>Jomehzadeh</surname><given-names>N</given-names></name><name><surname>Joo</surname><given-names>T</given-names></name><name><surname>Joseph</surname><given-names>N</given-names></name><name><surname>Kamal</surname><given-names>Z</given-names></name><name><surname>Kanmodi</surname><given-names>KK</given-names></name><name><surname>Kantar</surname><given-names>RS</given-names></name><name><surname>Kapisi</surname><given-names>JA</given-names></name><name><surname>Karaye</surname><given-names>IM</given-names></name><name><surname>Khader</surname><given-names>YS</given-names></name><name><surname>Khajuria</surname><given-names>H</given-names></name><name><surname>Khalid</surname><given-names>N</given-names></name><name><surname>Khamesipour</surname><given-names>F</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Khan</surname><given-names>MJ</given-names></name><name><surname>Khan</surname><given-names>MT</given-names></name><name><surname>Khanal</surname><given-names>V</given-names></name><name><surname>Khidri</surname><given-names>FF</given-names></name><name><surname>Khubchandani</surname><given-names>J</given-names></name><name><surname>Khusuwan</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Kisa</surname><given-names>A</given-names></name><name><surname>Korshunov</surname><given-names>VA</given-names></name><name><surname>Krapp</surname><given-names>F</given-names></name><name><surname>Krumkamp</surname><given-names>R</given-names></name><name><surname>Kuddus</surname><given-names>M</given-names></name><name><surname>Kulimbet</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Kumaran</surname><given-names>EAP</given-names></name><name><surname>Kuttikkattu</surname><given-names>A</given-names></name><name><surname>Kyu</surname><given-names>HH</given-names></name><name><surname>Landires</surname><given-names>I</given-names></name><name><surname>Lawal</surname><given-names>BK</given-names></name><name><surname>Le</surname><given-names>TTT</given-names></name><name><surname>Lederer</surname><given-names>IM</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>SW</given-names></name><name><surname>Lepape</surname><given-names>A</given-names></name><name><surname>Lerango</surname><given-names>TL</given-names></name><name><surname>Ligade</surname><given-names>VS</given-names></name><name><surname>Lim</surname><given-names>C</given-names></name><name><surname>Lim</surname><given-names>SS</given-names></name><name><surname>Limenh</surname><given-names>LW</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Loftus</surname><given-names>MJ</given-names></name><name><surname>M Amin</surname><given-names>HI</given-names></name><name><surname>Maass</surname><given-names>KL</given-names></name><name><surname>Maharaj</surname><given-names>SB</given-names></name><name><surname>Mahmoud</surname><given-names>MA</given-names></name><name><surname>Maikanti-Charalampous</surname><given-names>P</given-names></name><name><surname>Makram</surname><given-names>OM</given-names></name><name><surname>Malhotra</surname><given-names>K</given-names></name><name><surname>Malik</surname><given-names>AA</given-names></name><name><surname>Mandilara</surname><given-names>GD</given-names></name><name><surname>Marks</surname><given-names>F</given-names></name><name><surname>Martinez-Guerra</surname><given-names>BA</given-names></name><name><surname>Martorell</surname><given-names>M</given-names></name><name><surname>Masoumi-Asl</surname><given-names>H</given-names></name><name><surname>Mathioudakis</surname><given-names>AG</given-names></name><name><surname>May</surname><given-names>J</given-names></name><name><surname>McHugh</surname><given-names>TA</given-names></name><name><surname>Meiring</surname><given-names>J</given-names></name><name><surname>Meles</surname><given-names>HN</given-names></name><name><surname>Melese</surname><given-names>A</given-names></name><name><surname>Melese</surname><given-names>EB</given-names></name><name><surname>Minervini</surname><given-names>G</given-names></name><name><surname>Mohamed</surname><given-names>NS</given-names></name><name><surname>Mohammed</surname><given-names>S</given-names></name><name><surname>Mohan</surname><given-names>S</given-names></name><name><surname>Mokdad</surname><given-names>AH</given-names></name><name><surname>Monasta</surname><given-names>L</given-names></name><name><surname>Moodi Ghalibaf</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>CE</given-names></name><name><surname>Moradi</surname><given-names>Y</given-names></name><name><surname>Mossialos</surname><given-names>E</given-names></name><name><surname>Mougin</surname><given-names>V</given-names></name><name><surname>Mukoro</surname><given-names>GD</given-names></name><name><surname>Mulita</surname><given-names>F</given-names></name><name><surname>Muller-Pebody</surname><given-names>B</given-names></name><name><surname>Murillo-Zamora</surname><given-names>E</given-names></name><name><surname>Musa</surname><given-names>S</given-names></name><name><surname>Musicha</surname><given-names>P</given-names></name><name><surname>Musila</surname><given-names>LA</given-names></name><name><surname>Muthupandian</surname><given-names>S</given-names></name><name><surname>Nagarajan</surname><given-names>AJ</given-names></name><name><surname>Naghavi</surname><given-names>P</given-names></name><name><surname>Nainu</surname><given-names>F</given-names></name><name><surname>Nair</surname><given-names>TS</given-names></name><name><surname>Najmuldeen</surname><given-names>HHR</given-names></name><name><surname>Natto</surname><given-names>ZS</given-names></name><name><surname>Nauman</surname><given-names>J</given-names></name><name><surname>Nayak</surname><given-names>BP</given-names></name><name><surname>Nchanji</surname><given-names>GT</given-names></name><name><surname>Ndishimye</surname><given-names>P</given-names></name><name><surname>Negoi</surname><given-names>I</given-names></name><name><surname>Negoi</surname><given-names>RI</given-names></name><name><surname>Nejadghaderi</surname><given-names>SA</given-names></name><name><surname>Nguyen</surname><given-names>QP</given-names></name><name><surname>Noman</surname><given-names>EA</given-names></name><name><surname>Nwakanma</surname><given-names>DC</given-names></name><name><surname>O’Brien</surname><given-names>S</given-names></name><name><surname>Ochoa</surname><given-names>TJ</given-names></name><name><surname>Odetokun</surname><given-names>IA</given-names></name><name><surname>Ogundijo</surname><given-names>OA</given-names></name><name><surname>Ojo-Akosile</surname><given-names>TR</given-names></name><name><surname>Okeke</surname><given-names>SR</given-names></name><name><surname>Okonji</surname><given-names>OC</given-names></name><name><surname>Olagunju</surname><given-names>AT</given-names></name><name><surname>Olivas-Martinez</surname><given-names>A</given-names></name><name><surname>Olorukooba</surname><given-names>AA</given-names></name><name><surname>Olwoch</surname><given-names>P</given-names></name><name><surname>Onyedibe</surname><given-names>KI</given-names></name><name><surname>Ortiz-Brizuela</surname><given-names>E</given-names></name><name><surname>Osuolale</surname><given-names>O</given-names></name><name><surname>Ounchanum</surname><given-names>P</given-names></name><name><surname>Oyeyemi</surname><given-names>OT</given-names></name><name><surname>P A</surname><given-names>MP</given-names></name><name><surname>Paredes</surname><given-names>JL</given-names></name><name><surname>Parikh</surname><given-names>RR</given-names></name><name><surname>Patel</surname><given-names>J</given-names></name><name><surname>Patil</surname><given-names>S</given-names></name><name><surname>Pawar</surname><given-names>S</given-names></name><name><surname>Peleg</surname><given-names>AY</given-names></name><name><surname>Peprah</surname><given-names>P</given-names></name><name><surname>Perdigão</surname><given-names>J</given-names></name><name><surname>Perrone</surname><given-names>C</given-names></name><name><surname>Petcu</surname><given-names>I-R</given-names></name><name><surname>Phommasone</surname><given-names>K</given-names></name><name><surname>Piracha</surname><given-names>ZZ</given-names></name><name><surname>Poddighe</surname><given-names>D</given-names></name><name><surname>Pollard</surname><given-names>AJ</given-names></name><name><surname>Poluru</surname><given-names>R</given-names></name><name><surname>Ponce-De-Leon</surname><given-names>A</given-names></name><name><surname>Puvvula</surname><given-names>J</given-names></name><name><surname>Qamar</surname><given-names>FN</given-names></name><name><surname>Qasim</surname><given-names>NH</given-names></name><name><surname>Rafai</surname><given-names>CD</given-names></name><name><surname>Raghav</surname><given-names>P</given-names></name><name><surname>Rahbarnia</surname><given-names>L</given-names></name><name><surname>Rahim</surname><given-names>F</given-names></name><name><surname>Rahimi-Movaghar</surname><given-names>V</given-names></name><name><surname>Rahman</surname><given-names>M</given-names></name><name><surname>Rahman</surname><given-names>MA</given-names></name><name><surname>Ramadan</surname><given-names>H</given-names></name><name><surname>Ramasamy</surname><given-names>SK</given-names></name><name><surname>Ramesh</surname><given-names>PS</given-names></name><name><surname>Ramteke</surname><given-names>PW</given-names></name><name><surname>Rana</surname><given-names>RK</given-names></name><name><surname>Rani</surname><given-names>U</given-names></name><name><surname>Rashidi</surname><given-names>M-M</given-names></name><name><surname>Rathish</surname><given-names>D</given-names></name><name><surname>Rattanavong</surname><given-names>S</given-names></name><name><surname>Rawaf</surname><given-names>S</given-names></name><name><surname>Redwan</surname><given-names>EMM</given-names></name><name><surname>Reyes</surname><given-names>LF</given-names></name><name><surname>Roberts</surname><given-names>T</given-names></name><name><surname>Robotham</surname><given-names>JV</given-names></name><name><surname>Rosenthal</surname><given-names>VD</given-names></name><name><surname>Ross</surname><given-names>AG</given-names></name><name><surname>Roy</surname><given-names>N</given-names></name><name><surname>Rudd</surname><given-names>KE</given-names></name><name><surname>Sabet</surname><given-names>CJ</given-names></name><name><surname>Saddik</surname><given-names>BA</given-names></name><name><surname>Saeb</surname><given-names>MR</given-names></name><name><surname>Saeed</surname><given-names>U</given-names></name><name><surname>Saeedi Moghaddam</surname><given-names>S</given-names></name><name><surname>Saengchan</surname><given-names>W</given-names></name><name><surname>Safaei</surname><given-names>M</given-names></name><name><surname>Saghazadeh</surname><given-names>A</given-names></name><name><surname>Saheb Sharif-Askari</surname><given-names>N</given-names></name><name><surname>Sahebkar</surname><given-names>A</given-names></name><name><surname>Sahoo</surname><given-names>SS</given-names></name><name><surname>Sahu</surname><given-names>M</given-names></name><name><surname>Saki</surname><given-names>M</given-names></name><name><surname>Salam</surname><given-names>N</given-names></name><name><surname>Saleem</surname><given-names>Z</given-names></name><name><surname>Saleh</surname><given-names>MA</given-names></name><name><surname>Samodra</surname><given-names>YL</given-names></name><name><surname>Samy</surname><given-names>AM</given-names></name><name><surname>Saravanan</surname><given-names>A</given-names></name><name><surname>Satpathy</surname><given-names>M</given-names></name><name><surname>Schumacher</surname><given-names>AE</given-names></name><name><surname>Sedighi</surname><given-names>M</given-names></name><name><surname>Seekaew</surname><given-names>S</given-names></name><name><surname>Shafie</surname><given-names>M</given-names></name><name><surname>Shah</surname><given-names>PA</given-names></name><name><surname>Shahid</surname><given-names>S</given-names></name><name><surname>Shahwan</surname><given-names>MJ</given-names></name><name><surname>Shakoor</surname><given-names>S</given-names></name><name><surname>Shalev</surname><given-names>N</given-names></name><name><surname>Shamim</surname><given-names>MA</given-names></name><name><surname>Shamshirgaran</surname><given-names>MA</given-names></name><name><surname>Shamsi</surname><given-names>A</given-names></name><name><surname>Sharifan</surname><given-names>A</given-names></name><name><surname>Shastry</surname><given-names>RP</given-names></name><name><surname>Shetty</surname><given-names>M</given-names></name><name><surname>Shittu</surname><given-names>A</given-names></name><name><surname>Shrestha</surname><given-names>S</given-names></name><name><surname>Siddig</surname><given-names>EE</given-names></name><name><surname>Sideroglou</surname><given-names>T</given-names></name><name><surname>Sifuentes-Osornio</surname><given-names>J</given-names></name><name><surname>Silva</surname><given-names>LMLR</given-names></name><name><surname>Simões</surname><given-names>EAF</given-names></name><name><surname>Simpson</surname><given-names>AJH</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Sinto</surname><given-names>R</given-names></name><name><surname>Soliman</surname><given-names>SSM</given-names></name><name><surname>Soraneh</surname><given-names>S</given-names></name><name><surname>Stoesser</surname><given-names>N</given-names></name><name><surname>Stoeva</surname><given-names>TZ</given-names></name><name><surname>Swain</surname><given-names>CK</given-names></name><name><surname>Szarpak</surname><given-names>L</given-names></name><name><surname>T Y</surname><given-names>SS</given-names></name><name><surname>Tabatabai</surname><given-names>S</given-names></name><name><surname>Tabche</surname><given-names>C</given-names></name><name><surname>Taha</surname><given-names>ZM-A</given-names></name><name><surname>Tan</surname><given-names>K-K</given-names></name><name><surname>Tasak</surname><given-names>N</given-names></name><name><surname>Tat</surname><given-names>NY</given-names></name><name><surname>Thaiprakong</surname><given-names>A</given-names></name><name><surname>Thangaraju</surname><given-names>P</given-names></name><name><surname>Tigoi</surname><given-names>CC</given-names></name><name><surname>Tiwari</surname><given-names>K</given-names></name><name><surname>Tovani-Palone</surname><given-names>MR</given-names></name><name><surname>Tran</surname><given-names>TH</given-names></name><name><surname>Tumurkhuu</surname><given-names>M</given-names></name><name><surname>Turner</surname><given-names>P</given-names></name><name><surname>Udoakang</surname><given-names>AJ</given-names></name><name><surname>Udoh</surname><given-names>A</given-names></name><name><surname>Ullah</surname><given-names>N</given-names></name><name><surname>Ullah</surname><given-names>S</given-names></name><name><surname>Vaithinathan</surname><given-names>AG</given-names></name><name><surname>Valenti</surname><given-names>M</given-names></name><name><surname>Vos</surname><given-names>T</given-names></name><name><surname>Vu</surname><given-names>HTL</given-names></name><name><surname>Waheed</surname><given-names>Y</given-names></name><name><surname>Walker</surname><given-names>AS</given-names></name><name><surname>Walson</surname><given-names>JL</given-names></name><name><surname>Wangrangsimakul</surname><given-names>T</given-names></name><name><surname>Weerakoon</surname><given-names>KG</given-names></name><name><surname>Wertheim</surname><given-names>HFL</given-names></name><name><surname>Williams</surname><given-names>PCM</given-names></name><name><surname>Wolde</surname><given-names>AA</given-names></name><name><surname>Wozniak</surname><given-names>TM</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Yadav</surname><given-names>MKK</given-names></name><name><surname>Yaghoubi</surname><given-names>S</given-names></name><name><surname>Yahaya</surname><given-names>ZS</given-names></name><name><surname>Yarahmadi</surname><given-names>A</given-names></name><name><surname>Yezli</surname><given-names>S</given-names></name><name><surname>Yismaw</surname><given-names>YE</given-names></name><name><surname>Yon</surname><given-names>DK</given-names></name><name><surname>Yuan</surname><given-names>C-W</given-names></name><name><surname>Yusuf</surname><given-names>H</given-names></name><name><surname>Zakham</surname><given-names>F</given-names></name><name><surname>Zamagni</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Z-J</given-names></name><name><surname>Zielińska</surname><given-names>M</given-names></name><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Zyoud</surname><given-names>SHH</given-names></name><name><surname>Zyoud</surname><given-names>SH</given-names></name><name><surname>Hay</surname><given-names>SI</given-names></name><name><surname>Stergachis</surname><given-names>A</given-names></name><name><surname>Sartorius</surname><given-names>B</given-names></name><name><surname>Cooper</surname><given-names>BS</given-names></name><name><surname>Dolecek</surname><given-names>C</given-names></name><name><surname>Murray</surname><given-names>CJL</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050</article-title><source>The Lancet</source><volume>404</volume><fpage>1199</fpage><lpage>1226</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(24)01867-1</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Furunaka</surname><given-names>H</given-names></name><name><surname>Miyata</surname><given-names>T</given-names></name><name><surname>Tokunaga</surname><given-names>F</given-names></name><name><surname>Muta</surname><given-names>T</given-names></name><name><surname>Iwanaga</surname><given-names>S</given-names></name><name><surname>Niwa</surname><given-names>M</given-names></name><name><surname>Takao</surname><given-names>T</given-names></name><name><surname>Shimonishi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Tachyplesin, a class of antimicrobial peptide from the hemocytes of the horseshoe crab (Tachypleus tridentatus). Isolation and chemical structure</article-title><source>The Journal of Biological Chemistry</source><volume>263</volume><fpage>16709</fpage><lpage>16713</lpage><pub-id pub-id-type="pmid">3141410</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nang</surname><given-names>SC</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Velkov</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The rise and spread of <italic>mcr</italic> plasmid-mediated polymyxin resistance</article-title><source>Critical Reviews in Microbiology</source><volume>45</volume><fpage>131</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1080/1040841X.2018.1492902</pub-id><pub-id pub-id-type="pmid">31122100</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nevermann</surname><given-names>J</given-names></name><name><surname>Silva</surname><given-names>A</given-names></name><name><surname>Otero</surname><given-names>C</given-names></name><name><surname>Oyarzún</surname><given-names>DP</given-names></name><name><surname>Barrera</surname><given-names>B</given-names></name><name><surname>Gil</surname><given-names>F</given-names></name><name><surname>Calderón</surname><given-names>IL</given-names></name><name><surname>Fuentes</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Identification of genes involved in biogenesis of Outer Membrane Vesicles (OMVs) in <italic>Salmonella enterica</italic> serovar typhi</article-title><source>Frontiers in Microbiology</source><volume>10</volume><elocation-id>104</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2019.00104</pub-id><pub-id pub-id-type="pmid">30778340</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ondov</surname><given-names>BD</given-names></name><name><surname>Treangen</surname><given-names>TJ</given-names></name><name><surname>Melsted</surname><given-names>P</given-names></name><name><surname>Mallonee</surname><given-names>AB</given-names></name><name><surname>Bergman</surname><given-names>NH</given-names></name><name><surname>Koren</surname><given-names>S</given-names></name><name><surname>Phillippy</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mash: fast genome and metagenome distance estimation using MinHash</article-title><source>Genome Biology</source><volume>17</volume><elocation-id>132</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-016-0997-x</pub-id><pub-id pub-id-type="pmid">27323842</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Opperman</surname><given-names>TJ</given-names></name><name><surname>Nguyen</surname><given-names>ST</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Recent advances toward a molecular mechanism of efflux pump inhibition</article-title><source>Frontiers in Microbiology</source><volume>6</volume><elocation-id>421</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2015.00421</pub-id><pub-id pub-id-type="pmid">25999939</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pagliara</surname><given-names>S</given-names></name><name><surname>Chimerel</surname><given-names>C</given-names></name><name><surname>Langford</surname><given-names>R</given-names></name><name><surname>Aarts</surname><given-names>DGAL</given-names></name><name><surname>Keyser</surname><given-names>UF</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Parallel sub-micrometre channels with different dimensions for laser scattering detection</article-title><source>Lab on a Chip</source><volume>11</volume><fpage>3365</fpage><lpage>3368</lpage><pub-id pub-id-type="doi">10.1039/c1lc20399a</pub-id><pub-id pub-id-type="pmid">21804971</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paradis</surname><given-names>E</given-names></name><name><surname>Claude</surname><given-names>J</given-names></name><name><surname>Strimmer</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>APE: analyses of phylogenetics and evolution in R language</article-title><source>Bioinformatics</source><volume>20</volume><fpage>289</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btg412</pub-id><pub-id pub-id-type="pmid">14734327</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Podlesek</surname><given-names>Z</given-names></name><name><surname>Žgur Bertok</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The DNA damage inducible SOS response is a key player in the generation of bacterial persister cells and population wide tolerance</article-title><source>Frontiers in Microbiology</source><volume>11</volume><elocation-id>1785</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2020.01785</pub-id><pub-id pub-id-type="pmid">32849403</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pu</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Ke</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Baker</surname><given-names>MAB</given-names></name><name><surname>Ge</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>XS</given-names></name><name><surname>Bai</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Enhanced efflux activity facilitates drug tolerance in dormant bacterial cells</article-title><source>Molecular Cell</source><volume>62</volume><fpage>284</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2016.03.035</pub-id><pub-id pub-id-type="pmid">27105118</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rácz</surname><given-names>B</given-names></name><name><surname>Spengler</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Repurposing antidepressants and phenothiazine antipsychotics as efflux pump inhibitors in cancer and infectious diseases</article-title><source>Antibiotics</source><volume>12</volume><elocation-id>137</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics12010137</pub-id><pub-id pub-id-type="pmid">36671340</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radchenko</surname><given-names>M</given-names></name><name><surname>Symersky</surname><given-names>J</given-names></name><name><surname>Nie</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structural basis for the blockade of MATE multidrug efflux pumps</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>7995</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms8995</pub-id><pub-id pub-id-type="pmid">26246409</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rima</surname><given-names>M</given-names></name><name><surname>Rima</surname><given-names>M</given-names></name><name><surname>Fajloun</surname><given-names>Z</given-names></name><name><surname>Sabatier</surname><given-names>J-M</given-names></name><name><surname>Bechinger</surname><given-names>B</given-names></name><name><surname>Naas</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Antimicrobial peptides: a potent alternative to antibiotics</article-title><source>Antibiotics</source><volume>10</volume><elocation-id>1095</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics10091095</pub-id><pub-id pub-id-type="pmid">34572678</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>MD</given-names></name><name><surname>McCarthy</surname><given-names>DJ</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>edgeR: a Bioconductor package for differential expression analysis of digital gene expression data</article-title><source>Bioinformatics</source><volume>26</volume><fpage>139</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp616</pub-id><pub-id pub-id-type="pmid">19910308</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>L</given-names></name><name><surname>Machado</surname><given-names>D</given-names></name><name><surname>Couto</surname><given-names>I</given-names></name><name><surname>Amaral</surname><given-names>L</given-names></name><name><surname>Viveiros</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Contribution of efflux activity to isoniazid resistance in the <italic>Mycobacterium tuberculosis</italic> complex</article-title><source>Infection, Genetics and Evolution</source><volume>12</volume><fpage>695</fpage><lpage>700</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2011.08.009</pub-id><pub-id pub-id-type="pmid">21871582</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rybenkov</surname><given-names>VV</given-names></name><name><surname>Zgurskaya</surname><given-names>HI</given-names></name><name><surname>Ganguly</surname><given-names>C</given-names></name><name><surname>Leus</surname><given-names>IV</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Moniruzzaman</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The whole is bigger than the sum of its parts: drug transport in the context of two membranes with active efflux</article-title><source>Chemical Reviews</source><volume>121</volume><fpage>5597</fpage><lpage>5631</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.0c01137</pub-id><pub-id pub-id-type="pmid">33596653</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salek</surname><given-names>RM</given-names></name><name><surname>Neumann</surname><given-names>S</given-names></name><name><surname>Schober</surname><given-names>D</given-names></name><name><surname>Hummel</surname><given-names>J</given-names></name><name><surname>Billiau</surname><given-names>K</given-names></name><name><surname>Kopka</surname><given-names>J</given-names></name><name><surname>Correa</surname><given-names>E</given-names></name><name><surname>Reijmers</surname><given-names>T</given-names></name><name><surname>Rosato</surname><given-names>A</given-names></name><name><surname>Tenori</surname><given-names>L</given-names></name><name><surname>Turano</surname><given-names>P</given-names></name><name><surname>Marin</surname><given-names>S</given-names></name><name><surname>Deborde</surname><given-names>C</given-names></name><name><surname>Jacob</surname><given-names>D</given-names></name><name><surname>Rolin</surname><given-names>D</given-names></name><name><surname>Dartigues</surname><given-names>B</given-names></name><name><surname>Conesa</surname><given-names>P</given-names></name><name><surname>Haug</surname><given-names>K</given-names></name><name><surname>Rocca-Serra</surname><given-names>P</given-names></name><name><surname>O’Hagan</surname><given-names>S</given-names></name><name><surname>Hao</surname><given-names>J</given-names></name><name><surname>van Vliet</surname><given-names>M</given-names></name><name><surname>Sysi-Aho</surname><given-names>M</given-names></name><name><surname>Ludwig</surname><given-names>C</given-names></name><name><surname>Bouwman</surname><given-names>J</given-names></name><name><surname>Cascante</surname><given-names>M</given-names></name><name><surname>Ebbels</surname><given-names>T</given-names></name><name><surname>Griffin</surname><given-names>JL</given-names></name><name><surname>Moing</surname><given-names>A</given-names></name><name><surname>Nikolski</surname><given-names>M</given-names></name><name><surname>Oresic</surname><given-names>M</given-names></name><name><surname>Sansone</surname><given-names>S-A</given-names></name><name><surname>Viant</surname><given-names>MR</given-names></name><name><surname>Goodacre</surname><given-names>R</given-names></name><name><surname>Günther</surname><given-names>UL</given-names></name><name><surname>Hankemeier</surname><given-names>T</given-names></name><name><surname>Luchinat</surname><given-names>C</given-names></name><name><surname>Walther</surname><given-names>D</given-names></name><name><surname>Steinbeck</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>COordination of Standards in MetabOlomicS (COSMOS): facilitating integrated metabolomics data access</article-title><source>Metabolomics</source><volume>11</volume><fpage>1587</fpage><lpage>1597</lpage><pub-id pub-id-type="doi">10.1007/s11306-015-0810-y</pub-id><pub-id pub-id-type="pmid">26491418</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos-Zavaleta</surname><given-names>A</given-names></name><name><surname>Salgado</surname><given-names>H</given-names></name><name><surname>Gama-Castro</surname><given-names>S</given-names></name><name><surname>Sánchez-Pérez</surname><given-names>M</given-names></name><name><surname>Gómez-Romero</surname><given-names>L</given-names></name><name><surname>Ledezma-Tejeida</surname><given-names>D</given-names></name><name><surname>García-Sotelo</surname><given-names>JS</given-names></name><name><surname>Alquicira-Hernández</surname><given-names>K</given-names></name><name><surname>Muñiz-Rascado</surname><given-names>LJ</given-names></name><name><surname>Peña-Loredo</surname><given-names>P</given-names></name><name><surname>Ishida-Gutiérrez</surname><given-names>C</given-names></name><name><surname>Velázquez-Ramírez</surname><given-names>DA</given-names></name><name><surname>Del Moral-Chávez</surname><given-names>V</given-names></name><name><surname>Bonavides-Martínez</surname><given-names>C</given-names></name><name><surname>Méndez-Cruz</surname><given-names>C-F</given-names></name><name><surname>Galagan</surname><given-names>J</given-names></name><name><surname>Collado-Vides</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>RegulonDB v 10.5: tackling challenges to unify classic and high throughput knowledge of gene regulation in <italic>E. coli</italic> K-12</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D212</fpage><lpage>D220</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1077</pub-id><pub-id pub-id-type="pmid">30395280</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scrucca</surname><given-names>L</given-names></name><name><surname>Fop</surname><given-names>M</given-names></name><name><surname>Murphy</surname><given-names>TB</given-names></name><name><surname>Raftery</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>mclust 5: clustering, classification and density estimation using gaussian finite mixture models</article-title><source>The R Journal</source><volume>8</volume><fpage>289</fpage><lpage>317</lpage><pub-id pub-id-type="pmid">27818791</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seemann</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Prokka: rapid prokaryotic genome annotation</article-title><source>Bioinformatics</source><volume>30</volume><fpage>2068</fpage><lpage>2069</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu153</pub-id><pub-id pub-id-type="pmid">24642063</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Seemann</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><data-title>ABRicate: mass screening of contigs for antibiotic resistance genes</data-title><version designator="v1">v1</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/tseemann/abricate">https://github.com/tseemann/abricate</ext-link></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaheen</surname><given-names>A</given-names></name><name><surname>Afridi</surname><given-names>WA</given-names></name><name><surname>Mahboob</surname><given-names>S</given-names></name><name><surname>Sana</surname><given-names>M</given-names></name><name><surname>Zeeshan</surname><given-names>N</given-names></name><name><surname>Ismat</surname><given-names>F</given-names></name><name><surname>Mirza</surname><given-names>O</given-names></name><name><surname>Iqbal</surname><given-names>M</given-names></name><name><surname>Rahman</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Reserpine is the new addition into the repertoire of AcrB efflux pump inhibitors</article-title><source>Molecular Biology</source><volume>53</volume><fpage>596</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1134/S0026893319040113</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Gupta</surname><given-names>VK</given-names></name><name><surname>Pathania</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Efflux pump inhibitors for bacterial pathogens: From bench to bedside</article-title><source>The Indian Journal of Medical Research</source><volume>149</volume><fpage>129</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.4103/ijmr.IJMR_2079_17</pub-id><pub-id pub-id-type="pmid">31219077</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>LL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A gestalt approach to gram-negative entry</article-title><source>Bioorganic &amp; Medicinal Chemistry</source><volume>24</volume><fpage>6379</fpage><lpage>6389</lpage><pub-id pub-id-type="doi">10.1016/j.bmc.2016.06.044</pub-id><pub-id pub-id-type="pmid">27381365</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Kaczmar</surname><given-names>A</given-names></name><name><surname>Bamford</surname><given-names>RA</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Frustaci</surname><given-names>S</given-names></name><name><surname>Kovacs-Simon</surname><given-names>A</given-names></name><name><surname>O’Neill</surname><given-names>P</given-names></name><name><surname>Moore</surname><given-names>K</given-names></name><name><surname>Paszkiewicz</surname><given-names>K</given-names></name><name><surname>Titball</surname><given-names>RW</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The culture environment influences both gene regulation and phenotypic heterogeneity in <italic>Escherichia coli</italic></article-title><source>Frontiers in Microbiology</source><volume>9</volume><elocation-id>1739</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2018.01739</pub-id><pub-id pub-id-type="pmid">30158905</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Metz</surname><given-names>J</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>MMHelper: An automated framework for the analysis of microscopy images acquired with the mother machine</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>10123</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-46567-0</pub-id><pub-id pub-id-type="pmid">31300741</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>F</given-names></name><name><surname>Kuehl</surname><given-names>JV</given-names></name><name><surname>Chandran</surname><given-names>A</given-names></name><name><surname>Arkin</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A simple, cost-effective, and automation-friendly direct PCR approach for bacterial community analysis</article-title><source>mSystems</source><volume>6</volume><elocation-id>e0022421</elocation-id><pub-id pub-id-type="doi">10.1128/msystems.00224-21</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spohn</surname><given-names>R</given-names></name><name><surname>Daruka</surname><given-names>L</given-names></name><name><surname>Lázár</surname><given-names>V</given-names></name><name><surname>Martins</surname><given-names>A</given-names></name><name><surname>Vidovics</surname><given-names>F</given-names></name><name><surname>Grézal</surname><given-names>G</given-names></name><name><surname>Méhi</surname><given-names>O</given-names></name><name><surname>Kintses</surname><given-names>B</given-names></name><name><surname>Számel</surname><given-names>M</given-names></name><name><surname>Jangir</surname><given-names>PK</given-names></name><name><surname>Csörgő</surname><given-names>B</given-names></name><name><surname>Györkei</surname><given-names>Á</given-names></name><name><surname>Bódi</surname><given-names>Z</given-names></name><name><surname>Faragó</surname><given-names>A</given-names></name><name><surname>Bodai</surname><given-names>L</given-names></name><name><surname>Földesi</surname><given-names>I</given-names></name><name><surname>Kata</surname><given-names>D</given-names></name><name><surname>Maróti</surname><given-names>G</given-names></name><name><surname>Pap</surname><given-names>B</given-names></name><name><surname>Wirth</surname><given-names>R</given-names></name><name><surname>Papp</surname><given-names>B</given-names></name><name><surname>Pál</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Integrated evolutionary analysis reveals antimicrobial peptides with limited resistance</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>4538</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-12364-6</pub-id><pub-id pub-id-type="pmid">31586049</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stie</surname><given-names>MB</given-names></name><name><surname>Corezzi</surname><given-names>M</given-names></name><name><surname>Juncos Bombin</surname><given-names>AD</given-names></name><name><surname>Ajalloueian</surname><given-names>F</given-names></name><name><surname>Attrill</surname><given-names>E</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name><name><surname>Jacobsen</surname><given-names>J</given-names></name><name><surname>Chronakis</surname><given-names>IS</given-names></name><name><surname>Nielsen</surname><given-names>HM</given-names></name><name><surname>Foderà</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Waterborne electrospinning of α-lactalbumin generates tunable and biocompatible nanofibers for drug delivery</article-title><source>ACS Applied Nano Materials</source><volume>3</volume><fpage>1910</fpage><lpage>1921</lpage><pub-id pub-id-type="doi">10.1021/acsanm.9b02557</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>MRL</given-names></name><name><surname>Łapińska</surname><given-names>U</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name><name><surname>Masi</surname><given-names>M</given-names></name><name><surname>Blanchfield</surname><given-names>JT</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name><name><surname>Blaskovich</surname><given-names>MAT</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Fluorescent macrolide probes – synthesis and use in evaluation of bacterial resistance</article-title><source>RSC Chemical Biology</source><volume>1</volume><fpage>395</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1039/D0CB00118J</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamer</surname><given-names>YT</given-names></name><name><surname>Toprak</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>On the race to starvation: how do bacteria survive high doses of antibiotics?</article-title><source>Molecular Cell</source><volume>68</volume><fpage>1019</fpage><lpage>1021</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2017.12.004</pub-id><pub-id pub-id-type="pmid">29272702</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamer</surname><given-names>YT</given-names></name><name><surname>Gaszek</surname><given-names>I</given-names></name><name><surname>Rodrigues</surname><given-names>M</given-names></name><name><surname>Coskun</surname><given-names>FS</given-names></name><name><surname>Farid</surname><given-names>M</given-names></name><name><surname>Koh</surname><given-names>AY</given-names></name><name><surname>Russ</surname><given-names>W</given-names></name><name><surname>Toprak</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The antibiotic efflux protein TolC Is a highly evolvable target under colicin E1 or TLS phage selection</article-title><source>Molecular Biology and Evolution</source><volume>38</volume><fpage>4493</fpage><lpage>4504</lpage><pub-id pub-id-type="doi">10.1093/molbev/msab190</pub-id></element-citation></ref><ref id="bib136"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>Y</given-names></name><name><surname>Choi</surname><given-names>PJ</given-names></name><name><surname>Li</surname><given-names>G-W</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Babu</surname><given-names>M</given-names></name><name><surname>Hearn</surname><given-names>J</given-names></name><name><surname>Emili</surname><given-names>A</given-names></name><name><surname>Xie</surname><given-names>XS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Quantifying <italic>E. coli</italic> proteome and transcriptome with single-molecule sensitivity in single cells</article-title><source>Science</source><volume>329</volume><fpage>533</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1126/science.1188308</pub-id><pub-id pub-id-type="pmid">20671182</pub-id></element-citation></ref><ref id="bib137"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomason</surname><given-names>LC</given-names></name><name><surname>Costantino</surname><given-names>N</given-names></name><name><surname>Court</surname><given-names>DLE</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title><italic>E. coli</italic> genome manipulation by P1 transduction</article-title><source>Current Protocols in Molecular Biology</source><volume>1</volume><elocation-id>mb0117s79</elocation-id><pub-id pub-id-type="doi">10.1002/0471142727.mb0117s79</pub-id><pub-id pub-id-type="pmid">18265391</pub-id></element-citation></ref><ref id="bib138"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>NA</given-names></name><name><surname>Sharma-Kuinkel</surname><given-names>BK</given-names></name><name><surname>Maskarinec</surname><given-names>SA</given-names></name><name><surname>Eichenberger</surname><given-names>EM</given-names></name><name><surname>Shah</surname><given-names>PP</given-names></name><name><surname>Carugati</surname><given-names>M</given-names></name><name><surname>Holland</surname><given-names>TL</given-names></name><name><surname>Fowler</surname><given-names>VG</given-names><suffix>Jr</suffix></name></person-group><year iso-8601-date="2019">2019</year><article-title>Methicillin-resistant <italic>Staphylococcus aureus</italic>: an overview of basic and clinical research</article-title><source>Nature Reviews. Microbiology</source><volume>17</volume><fpage>203</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/s41579-018-0147-4</pub-id><pub-id pub-id-type="pmid">30737488</pub-id></element-citation></ref><ref id="bib139"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urbaniec</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Hingley-Wilson</surname><given-names>S</given-names></name><name><surname>McFadden</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Phenotypic heterogeneity in persisters: a novel “hunker” theory of persistence</article-title><source>FEMS Microbiology Reviews</source><volume>46</volume><elocation-id>fuab042</elocation-id><pub-id pub-id-type="doi">10.1093/femsre/fuab042</pub-id><pub-id pub-id-type="pmid">34355746</pub-id></element-citation></ref><ref id="bib140"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van den Bergh</surname><given-names>B</given-names></name><name><surname>Fauvart</surname><given-names>M</given-names></name><name><surname>Michiels</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Formation, physiology, ecology, evolution and clinical importance of bacterial persisters</article-title><source>FEMS Microbiology Reviews</source><volume>41</volume><fpage>219</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1093/femsre/fux001</pub-id><pub-id pub-id-type="pmid">28333307</pub-id></element-citation></ref><ref id="bib141"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Bunt</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Prevalence, risk factors and genetic characterisation of extended-spectrum beta-lactamase and carbapenemase-producing Enterobacteriaceae (ESBL-E and CPE): a community-based cross-sectional study, the Netherlands</article-title><source>Euro Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin</source><volume>24</volume><elocation-id>1800594</elocation-id><pub-id pub-id-type="doi">10.2807/1560-7917.ES.2019.24.41.1800594</pub-id></element-citation></ref><ref id="bib142"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vargiu</surname><given-names>AV</given-names></name><name><surname>Ruggerone</surname><given-names>P</given-names></name><name><surname>Opperman</surname><given-names>TJ</given-names></name><name><surname>Nguyen</surname><given-names>ST</given-names></name><name><surname>Nikaido</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Molecular mechanism of MBX2319 inhibition of <italic>Escherichia coli</italic> AcrB multidrug efflux pump and comparison with other inhibitors</article-title><source>Antimicrobial Agents and Chemotherapy</source><volume>58</volume><fpage>6224</fpage><lpage>6234</lpage><pub-id pub-id-type="doi">10.1128/AAC.03283-14</pub-id><pub-id pub-id-type="pmid">25114133</pub-id></element-citation></ref><ref id="bib143"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velkov</surname><given-names>T</given-names></name><name><surname>Gallardo-Godoy</surname><given-names>A</given-names></name><name><surname>Swarbrick</surname><given-names>JD</given-names></name><name><surname>Blaskovich</surname><given-names>MAT</given-names></name><name><surname>Elliott</surname><given-names>AG</given-names></name><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Thompson</surname><given-names>PE</given-names></name><name><surname>Roberts</surname><given-names>KD</given-names></name><name><surname>Huang</surname><given-names>JX</given-names></name><name><surname>Becker</surname><given-names>B</given-names></name><name><surname>Butler</surname><given-names>MS</given-names></name><name><surname>Lash</surname><given-names>LH</given-names></name><name><surname>Henriques</surname><given-names>ST</given-names></name><name><surname>Nation</surname><given-names>RL</given-names></name><name><surname>Sivanesan</surname><given-names>S</given-names></name><name><surname>Sani</surname><given-names>M-A</given-names></name><name><surname>Separovic</surname><given-names>F</given-names></name><name><surname>Mertens</surname><given-names>H</given-names></name><name><surname>Bulach</surname><given-names>D</given-names></name><name><surname>Seemann</surname><given-names>T</given-names></name><name><surname>Owen</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structure, function, and biosynthetic origin of octapeptin antibiotics active against extensively drug-resistant gram-negative bacteria</article-title><source>Cell Chemical Biology</source><volume>25</volume><fpage>380</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2018.01.005</pub-id><pub-id pub-id-type="pmid">29396290</pub-id></element-citation></ref><ref id="bib144"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Robert</surname><given-names>L</given-names></name><name><surname>Pelletier</surname><given-names>J</given-names></name><name><surname>Dang</surname><given-names>WL</given-names></name><name><surname>Taddei</surname><given-names>F</given-names></name><name><surname>Wright</surname><given-names>A</given-names></name><name><surname>Jun</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Robust growth of <italic>Escherichia coli</italic></article-title><source>Current Biology</source><volume>20</volume><fpage>1099</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2010.04.045</pub-id><pub-id pub-id-type="pmid">20537537</pub-id></element-citation></ref><ref id="bib145"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Jiao</surname><given-names>H</given-names></name><name><surname>Meng</surname><given-names>J</given-names></name><name><surname>Qiao</surname><given-names>M</given-names></name><name><surname>Du</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>M</given-names></name><name><surname>Ming</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Baicalin inhibits biofilm formation and the quorum-sensing system by regulating the msra drug efflux pump in <italic>Staphylococcus saprophyticus</italic></article-title><source>Frontiers in Microbiology</source><volume>10</volume><elocation-id>2800</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2019.02800</pub-id><pub-id pub-id-type="pmid">31921008</pub-id></element-citation></ref><ref id="bib146"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Baicalein resensitizes multidrug-resistant gram-negative pathogens to doxycycline</article-title><source>Microbiology Spectrum</source><volume>11</volume><elocation-id>e0470222</elocation-id><pub-id pub-id-type="doi">10.1128/spectrum.04702-22</pub-id><pub-id pub-id-type="pmid">37070985</pub-id></element-citation></ref><ref id="bib147"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weatherspoon-Griffin</surname><given-names>N</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Kong</surname><given-names>W</given-names></name><name><surname>Hua</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The CpxR/CpxA two-component regulatory system up-regulates the multidrug resistance cascade to facilitate <italic>Escherichia coli</italic> resistance to a model antimicrobial peptide</article-title><source>The Journal of Biological Chemistry</source><volume>289</volume><fpage>32571</fpage><lpage>32582</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.565762</pub-id><pub-id pub-id-type="pmid">25294881</pub-id></element-citation></ref><ref id="bib148"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whittle</surname><given-names>EE</given-names></name><name><surname>Legood</surname><given-names>SW</given-names></name><name><surname>Alav</surname><given-names>I</given-names></name><name><surname>Dulyayangkul</surname><given-names>P</given-names></name><name><surname>Overton</surname><given-names>TW</given-names></name><name><surname>Blair</surname><given-names>JMA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Flow cytometric analysis of efflux by dye accumulation</article-title><source>Frontiers in Microbiology</source><volume>10</volume><elocation-id>2319</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2019.02319</pub-id><pub-id pub-id-type="pmid">31636625</pub-id></element-citation></ref><ref id="bib149"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whittle</surname><given-names>EE</given-names></name><name><surname>McNeil</surname><given-names>HE</given-names></name><name><surname>Trampari</surname><given-names>E</given-names></name><name><surname>Webber</surname><given-names>M</given-names></name><name><surname>Overton</surname><given-names>TW</given-names></name><name><surname>Blair</surname><given-names>JMA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Efflux impacts intracellular accumulation only in actively growing bacterial cells</article-title><source>mBio</source><volume>12</volume><elocation-id>e0260821</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.02608-21</pub-id><pub-id pub-id-type="pmid">34634938</pub-id></element-citation></ref><ref id="bib150"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Windels</surname><given-names>EM</given-names></name><name><surname>Michiels</surname><given-names>JE</given-names></name><name><surname>Fauvart</surname><given-names>M</given-names></name><name><surname>Wenseleers</surname><given-names>T</given-names></name><name><surname>Van den Bergh</surname><given-names>B</given-names></name><name><surname>Michiels</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019a</year><article-title>Bacterial persistence promotes the evolution of antibiotic resistance by increasing survival and mutation rates</article-title><source>The ISME Journal</source><volume>13</volume><fpage>1239</fpage><lpage>1251</lpage><pub-id pub-id-type="doi">10.1038/s41396-019-0344-9</pub-id><pub-id pub-id-type="pmid">30647458</pub-id></element-citation></ref><ref id="bib151"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Windels</surname><given-names>EM</given-names></name><name><surname>Michiels</surname><given-names>JE</given-names></name><name><surname>Van den Bergh</surname><given-names>B</given-names></name><name><surname>Fauvart</surname><given-names>M</given-names></name><name><surname>Michiels</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2019">2019b</year><article-title>Antibiotics: combatting tolerance to stop resistance</article-title><source>mBio</source><volume>10</volume><elocation-id>e02095-19</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.02095-19</pub-id><pub-id pub-id-type="pmid">31506315</pub-id></element-citation></ref><ref id="bib152"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wójcicki</surname><given-names>M</given-names></name><name><surname>Świder</surname><given-names>O</given-names></name><name><surname>Daniluk</surname><given-names>KJ</given-names></name><name><surname>Średnicka</surname><given-names>P</given-names></name><name><surname>Akimowicz</surname><given-names>M</given-names></name><name><surname>Roszko</surname><given-names>MŁ</given-names></name><name><surname>Sokołowska</surname><given-names>B</given-names></name><name><surname>Juszczuk-Kubiak</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Transcriptional regulation of the multiple resistance mechanisms in <italic>Salmonella</italic>-a review</article-title><source>Pathogens</source><volume>10</volume><elocation-id>801</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens10070801</pub-id><pub-id pub-id-type="pmid">34202800</pub-id></element-citation></ref><ref id="bib153"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>E</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>P</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><name><surname>Feng</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Zhan</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Bo</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>clusterProfiler 4.0: A universal enrichment tool for interpreting omics data</article-title><source>Innovation</source><volume>2</volume><elocation-id>100141</elocation-id><pub-id pub-id-type="doi">10.1016/j.xinn.2021.100141</pub-id><pub-id pub-id-type="pmid">34557778</pub-id></element-citation></ref><ref id="bib154"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Zhan</surname><given-names>L</given-names></name><name><surname>Dai</surname><given-names>Z</given-names></name><name><surname>Lam</surname><given-names>TT</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title><italic>Ggtree</italic>: A serialized data object for visualization of a phylogenetic tree and annotation data</article-title><source>iMeta</source><volume>1</volume><elocation-id>e56</elocation-id><pub-id pub-id-type="doi">10.1002/imt2.56</pub-id><pub-id pub-id-type="pmid">38867905</pub-id></element-citation></ref><ref id="bib155"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>A</given-names></name><name><surname>Guan</surname><given-names>Z</given-names></name><name><surname>Raetz</surname><given-names>CRH</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>An undecaprenyl phosphate-aminoarabinose flippase required for polymyxin resistance in <italic>Escherichia coli</italic></article-title><source>The Journal of Biological Chemistry</source><volume>282</volume><fpage>36077</fpage><lpage>36089</lpage><pub-id pub-id-type="doi">10.1074/jbc.M706172200</pub-id><pub-id pub-id-type="pmid">17928292</pub-id></element-citation></ref><ref id="bib156"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ying</surname><given-names>L</given-names></name><name><surname>Xizhen</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Role of berberine as a potential efflux pump inhibitor against MdfA from <italic>Escherichia coli</italic>: in vitro and in silico studies</article-title><source>Microbiology Spectrum</source><volume>0</volume><fpage>e03324</fpage><lpage>e22</lpage><pub-id pub-id-type="doi">10.1128/spectrum.03324-22</pub-id></element-citation></ref><ref id="bib157"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yonezawa</surname><given-names>A</given-names></name><name><surname>Kuwahara</surname><given-names>J</given-names></name><name><surname>Fujii</surname><given-names>N</given-names></name><name><surname>Sugiura</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Binding of tachyplesin I to DNA revealed by footprinting analysis: significant contribution of secondary structure to DNA binding and implication for biological action</article-title><source>Biochemistry</source><volume>31</volume><fpage>2998</fpage><lpage>3004</lpage><pub-id pub-id-type="doi">10.1021/bi00126a022</pub-id><pub-id pub-id-type="pmid">1372516</pub-id></element-citation></ref><ref id="bib158"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>LG</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>QY</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>clusterProfiler: an R package for comparing biological themes among gene clusters</article-title><source>OMICS</source><volume>16</volume><fpage>284</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id><pub-id pub-id-type="pmid">22455463</pub-id></element-citation></ref><ref id="bib159"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>So</surname><given-names>LY</given-names></name><name><surname>Harvey</surname><given-names>PJ</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Dou</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>YH</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Kaas</surname><given-names>Q</given-names></name><name><surname>Chow</surname><given-names>HY</given-names></name><name><surname>Wong</surname><given-names>KY</given-names></name><name><surname>Craik</surname><given-names>DJ</given-names></name><name><surname>Zhang</surname><given-names>XH</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Enhanced activity against multidrug-resistant bacteria through coapplication of an analogue of tachyplesin I and an inhibitor of the QseC/B signaling pathway</article-title><source>Journal of Medicinal Chemistry</source><volume>63</volume><fpage>3475</fpage><lpage>3484</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.9b01563</pub-id><pub-id pub-id-type="pmid">32003561</pub-id></element-citation></ref><ref id="bib160"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Stone</surname><given-names>MRL</given-names></name><name><surname>Sanjaya</surname><given-names>KC</given-names></name><name><surname>Łapińska</surname><given-names>U</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name><name><surname>Blaskovich</surname><given-names>MAT</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Application of antibiotic-derived fluorescent probes to bacterial studies</article-title><source>Methods in Enzymology</source><volume>665</volume><fpage>1</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/bs.mie.2021.11.010</pub-id><pub-id pub-id-type="pmid">35379430</pub-id></element-citation></ref><ref id="bib161"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Kepiro</surname><given-names>I</given-names></name><name><surname>Ryadnov</surname><given-names>MG</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2023">2023a</year><article-title>Single cell killing kinetics differentiate phenotypic bacterial responses to different antibacterial classes</article-title><source>Microbiology Spectrum</source><volume>11</volume><elocation-id>e0366722</elocation-id><pub-id pub-id-type="doi">10.1128/spectrum.03667-22</pub-id><pub-id pub-id-type="pmid">36651776</pub-id></element-citation></ref><ref id="bib162"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Phetsang</surname><given-names>W</given-names></name><name><surname>Stone</surname><given-names>MRL</given-names></name><name><surname>Kc</surname><given-names>S</given-names></name><name><surname>Butler</surname><given-names>MS</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name><name><surname>Elliott</surname><given-names>AG</given-names></name><name><surname>Łapińska</surname><given-names>U</given-names></name><name><surname>Voliotis</surname><given-names>M</given-names></name><name><surname>Tsaneva-Atanasova</surname><given-names>K</given-names></name><name><surname>Pagliara</surname><given-names>S</given-names></name><name><surname>Blaskovich</surname><given-names>MAT</given-names></name></person-group><year iso-8601-date="2023">2023b</year><article-title>Synthesis of vancomycin fluorescent probes that retain antimicrobial activity, identify Gram-positive bacteria, and detect Gram-negative outer membrane damage</article-title><source>Communications Biology</source><volume>6</volume><elocation-id>409</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-023-04745-x</pub-id><pub-id pub-id-type="pmid">37055536</pub-id></element-citation></ref><ref id="bib163"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ahn</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2023">2023c</year><article-title>Advances in the discovery of efflux pump inhibitors as novel potentiators to control antimicrobial-resistant pathogens</article-title><source>Antibiotics</source><volume>12</volume><elocation-id>1417</elocation-id><pub-id pub-id-type="doi">10.3390/antibiotics12091417</pub-id><pub-id pub-id-type="pmid">37760714</pub-id></element-citation></ref><ref id="bib164"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>EJ</given-names></name><name><surname>Valeri</surname><given-names>JA</given-names></name><name><surname>Andrews</surname><given-names>IW</given-names></name><name><surname>Krishnan</surname><given-names>A</given-names></name><name><surname>Bandyopadhyay</surname><given-names>P</given-names></name><name><surname>Anahtar</surname><given-names>MN</given-names></name><name><surname>Herneisen</surname><given-names>A</given-names></name><name><surname>Schulte</surname><given-names>F</given-names></name><name><surname>Linnehan</surname><given-names>B</given-names></name><name><surname>Wong</surname><given-names>F</given-names></name><name><surname>Stokes</surname><given-names>JM</given-names></name><name><surname>Renner</surname><given-names>LD</given-names></name><name><surname>Lourido</surname><given-names>S</given-names></name><name><surname>Collins</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Discovery of antibiotics that selectively kill metabolically dormant bacteria</article-title><source>Cell Chemical Biology</source><volume>31</volume><fpage>712</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2023.10.026</pub-id><pub-id pub-id-type="pmid">38029756</pub-id></element-citation></ref><ref id="bib165"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Joubran</surname><given-names>C</given-names></name><name><surname>Miller-Vedam</surname><given-names>L</given-names></name><name><surname>Isabella</surname><given-names>V</given-names></name><name><surname>Nayar</surname><given-names>A</given-names></name><name><surname>Tentarelli</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Thinking outside the “bug”: a unique assay to measure intracellular drug penetration in gram-negative bacteria</article-title><source>Analytical Chemistry</source><volume>87</volume><fpage>3579</fpage><lpage>3584</lpage><pub-id pub-id-type="doi">10.1021/ac504880r</pub-id><pub-id pub-id-type="pmid">25753586</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1table1" position="float"><label>Appendix 1—table 1.</label><caption><title>Short list of genes involved in biological processes that are differentially regulated in low compared to high tachyplesin-nitrobenzoxadiazole (NBD) accumulators.</title><p>The complete list of genes involved in these processes is reported in <xref ref-type="supplementary-material" rid="fig3sdata3">Figure 3—source data 3</xref>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="2">Cluster</th><th align="left" valign="bottom" colspan="2">Regulation in Low Tachyplesin-NBD Accumulators</th></tr><tr><th align="left" valign="bottom">Up</th><th align="left" valign="bottom">Down</th></tr></thead><tbody><tr><td align="center" valign="bottom" colspan="3"><bold>Translation</bold></td></tr><tr><td align="char" char="." valign="bottom"><bold>2</bold></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"><italic>infC</italic></td></tr><tr><td align="center" valign="bottom" colspan="3"><bold>Ribosomal Proteins</bold></td></tr><tr><td align="char" char="." valign="bottom"><bold>2</bold></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"><italic>rplABCDEFKLMNOQRTUWX</italic>, <italic>rpmACDJ</italic>, <italic>rpsCDEFHJKMNOS</italic></td></tr><tr><td align="char" char="." valign="bottom"><bold>3</bold></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"><italic>rplPSVY</italic>, <italic>rpmI</italic>, <italic>rpsABIPQR</italic></td></tr><tr><td align="center" valign="bottom" colspan="3"><bold>RNA Polymerase and Transcription</bold></td></tr><tr><td align="char" char="." valign="bottom"><bold>2</bold></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"><italic>rpoBCS</italic></td></tr><tr><td align="center" valign="bottom" colspan="3"><bold>DNA Replication and Repair</bold></td></tr><tr><td align="char" char="." valign="bottom"><bold>2</bold></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"><italic>gyrAB</italic>, <italic>hupB</italic>, <italic>mutY</italic>, <italic>parC</italic>, <italic>topA</italic></td></tr><tr><td align="char" char="." valign="bottom"><bold>3</bold></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"><italic>mutMT, ruvA</italic></td></tr><tr><td align="center" valign="bottom" colspan="3"><bold>Glucose Metabolism</bold></td></tr><tr><td align="char" char="." valign="bottom"><bold>2</bold></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"><italic>pgm</italic></td></tr><tr><td align="center" valign="bottom" colspan="3"><bold>Persistence Related Genes</bold></td></tr><tr><td align="char" char="." valign="bottom"><bold>1</bold></td><td align="left" valign="bottom"><italic>spot</italic>, <italic>dinG</italic></td><td align="left" valign="bottom">-</td></tr><tr><td align="char" char="." valign="bottom"><bold>2</bold></td><td align="left" valign="bottom"><italic>relA</italic>, <italic>uvrD</italic>, <italic>plsB</italic>, <italic>phoU</italic></td><td align="left" valign="bottom"><italic>crp</italic>, <italic>hupB</italic></td></tr><tr><td align="char" char="." valign="bottom"><bold>3</bold></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"><italic>dnaJ</italic>, <italic>dnaK</italic>, <italic>lon</italic>, <italic>soxS</italic></td></tr><tr><td align="char" char="." valign="bottom"><bold>5</bold></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"><italic>pspABCDEG</italic></td></tr><tr><td align="center" valign="bottom" colspan="3"><bold>MFS Efflux Pumps</bold></td></tr><tr><td align="char" char="." valign="bottom"><bold>1</bold></td><td align="left" valign="bottom"><italic>mdfA</italic>, <italic>mdtG</italic></td><td align="left" valign="bottom">-</td></tr><tr><td align="char" char="." valign="bottom"><bold>4</bold></td><td align="left" valign="bottom"><italic>emrK</italic>, <italic>mdtML</italic></td><td align="left" valign="bottom">-</td></tr><tr><td align="center" valign="bottom" colspan="3"><bold>ABC Transporters</bold></td></tr><tr><td align="char" char="." valign="bottom"><bold>1</bold></td><td align="left" valign="bottom"><italic>mdlA</italic>, <italic>sapACDF</italic>, <italic>yadG</italic></td><td align="left" valign="bottom">-</td></tr><tr><td align="char" char="." valign="bottom"><bold>3</bold></td><td align="left" valign="bottom"><italic>dppA</italic>, <italic>oppC</italic>, <italic>yejA</italic></td><td align="left" valign="bottom"><italic>ybhRS</italic>, <italic>yhhJ</italic></td></tr><tr><td align="char" char="." valign="bottom"><bold>4</bold></td><td align="left" valign="bottom"><italic>ddpABCDF</italic>, <italic>dppBCDF</italic>, <italic>hisM, ydcSTUV</italic></td><td align="left" valign="bottom">-</td></tr><tr><td align="center" valign="bottom" colspan="3"><bold>RND Efflux Pumps</bold></td></tr><tr><td align="char" char="." valign="bottom"><bold>1</bold></td><td align="left" valign="bottom"><italic>mdtEF</italic></td><td align="left" valign="bottom">-</td></tr><tr><td align="char" char="." valign="bottom"><bold>2</bold></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"><italic>acrB</italic>, <italic>mdtA</italic></td></tr><tr><td align="center" valign="bottom" colspan="3"><bold>MATE-Type Efflux Pumps</bold></td></tr><tr><td align="char" char="." valign="bottom"><bold>2</bold></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"><italic>mdtK</italic></td></tr><tr><td align="center" valign="bottom" colspan="3"><bold>Outer Membrane Efflux Proteins</bold></td></tr><tr><td align="char" char="." valign="bottom"><bold>1</bold></td><td align="left" valign="bottom"><italic>tolC</italic></td><td align="left" valign="bottom">-</td></tr><tr><td align="center" valign="bottom" colspan="3"><bold>Porins</bold></td></tr><tr><td align="char" char="." valign="bottom"><bold>3</bold></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"><italic>ompCF</italic></td></tr><tr><td align="center" valign="bottom" colspan="3"><bold>LPS Biosynthesis, Assembly, Export, and Modification</bold></td></tr><tr><td align="char" char="." valign="bottom"><bold>1</bold></td><td align="left" valign="bottom"><italic>arnBT</italic>, <italic>lplT</italic>, <italic>lptABCD</italic>, <italic>pgpB</italic>, <italic>pssA</italic>, <italic>waaCF</italic>, <italic>yafK</italic></td><td align="left" valign="bottom">-</td></tr><tr><td align="char" char="." valign="bottom"><bold>2</bold></td><td align="left" valign="bottom"><italic>gmhA</italic>, <italic>lpxA</italic>, <italic>psd</italic></td><td align="left" valign="bottom"><italic>clsB</italic>, <italic>lptEG</italic>, <italic>eptA</italic></td></tr><tr><td align="char" char="." valign="bottom"><bold>3</bold></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"><italic>lpxC</italic>, <italic>pagP</italic>, <italic>pgpAC</italic></td></tr><tr><td align="char" char="." valign="bottom"><bold>4</bold></td><td align="left" valign="bottom"><italic>arnF</italic></td><td align="left" valign="bottom">-</td></tr><tr><td align="center" valign="bottom" colspan="3"><bold>Fatty Acid Biosynthesis</bold></td></tr><tr><td align="char" char="." valign="bottom"><bold>1</bold></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"><italic>fabA</italic></td></tr><tr><td align="char" char="." valign="bottom"><bold>2</bold></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"><italic>fabB</italic></td></tr><tr><td align="center" valign="bottom" colspan="3"><bold>Outer Membrane Vesicles</bold></td></tr><tr><td align="char" char="." valign="bottom"><bold>1</bold></td><td align="left" valign="bottom"><italic>nlpA</italic>, <italic>waaCF</italic></td><td align="left" valign="bottom">-</td></tr><tr><td align="char" char="." valign="bottom"><bold>2</bold></td><td align="left" valign="bottom"><italic>lysS</italic></td><td align="left" valign="bottom"><italic>pal</italic>, <italic>tolAB</italic></td></tr><tr><td align="char" char="." valign="bottom"><bold>3</bold></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"><italic>degP</italic>, <italic>mrcB</italic>, <italic>ompAC</italic></td></tr><tr><td align="center" valign="bottom" colspan="3"><bold>Peptidases</bold></td></tr><tr><td align="char" char="." valign="bottom"><bold>1</bold></td><td align="left" valign="bottom"><italic>lepB</italic>, <italic>pepD</italic>, <italic>yafK</italic></td><td align="left" valign="bottom"><italic>prlC</italic></td></tr><tr><td align="char" char="." valign="bottom"><bold>2</bold></td><td align="left" valign="bottom"><italic>pepQ</italic></td><td align="left" valign="bottom"><italic>map</italic></td></tr><tr><td align="char" char="." valign="bottom"><bold>3</bold></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"><italic>ampH</italic>, <italic>dacC</italic>, <italic>lspA</italic>, <italic>mepM</italic>, <italic>pepBT</italic></td></tr><tr><td align="char" char="." valign="bottom"><bold>4</bold></td><td align="left" valign="bottom"><italic>ddpX</italic>, <italic>pbpG</italic></td><td align="left" valign="bottom">-</td></tr><tr><td align="char" char="." valign="bottom"><bold>5</bold></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td></tr><tr><td align="center" valign="bottom" colspan="3"><bold>Proteases</bold></td></tr><tr><td align="char" char="." valign="bottom"><bold>1</bold></td><td align="left" valign="bottom"><italic>degQ</italic>, <italic>pmbA</italic>, <italic>ptrB</italic></td><td align="left" valign="bottom">-</td></tr><tr><td align="char" char="." valign="bottom"><bold>2</bold></td><td align="left" valign="bottom"><italic>ptrA</italic></td><td align="left" valign="bottom"><italic>clpA</italic>, <italic>hflC</italic></td></tr><tr><td align="char" char="." valign="bottom"><bold>3</bold></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"><italic>degP</italic>, <italic>ftsH</italic>, <italic>loiP</italic>, <italic>lon</italic>, <italic>ompT</italic>, <italic>prc</italic>, <italic>yccA</italic>, <italic>ydgD</italic></td></tr><tr><td align="char" char="." valign="bottom"><bold>5</bold></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"><italic>htpX</italic></td></tr><tr><td align="center" valign="bottom" colspan="3"><bold>Biofilm and Curli Biosynthesis</bold></td></tr><tr><td align="char" char="." valign="bottom"><bold>3</bold></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom"><italic>bssRS</italic>, <italic>tabA</italic></td></tr><tr><td align="char" char="." valign="bottom"><bold>4</bold></td><td align="left" valign="bottom"><italic>csgCDEFG</italic></td><td align="left" valign="bottom">-</td></tr></tbody></table></table-wrap><table-wrap id="app1table2" position="float"><label>Appendix 1—table 2.</label><caption><title>Lipids and metabolites upregulated in low or high tachyplesin-nitrobenzoxadiazole (NBD) accumulators compared to untreated bacteria.</title><p>Lipid or metabolite name, composition, adduct, retention time (RT), theoretical and experimentally measured mass, formula, variable importance in projection (VIP), and concentration in parts per million (∆ppm) measured via quadrupole time-of-flight liquid chromatography/mass spectrometry.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Name</th><th align="left" valign="bottom">Composition</th><th align="left" valign="bottom">Adduct</th><th align="left" valign="bottom">RT</th><th align="left" valign="bottom">Theoretical mass</th><th align="left" valign="bottom">Experimental mass</th><th align="left" valign="bottom">Formula</th><th align="left" valign="bottom">VIP Score</th><th align="left" valign="bottom">∆ppm</th></tr></thead><tbody><tr><td align="left" valign="bottom" colspan="9"><bold>Lipids and metabolites upregulated in low tachyplesin-NBD accumulators</bold></td></tr><tr><td align="left" valign="bottom">LPE 20:4</td><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">[M+H]</td><td align="char" char="." valign="bottom">1.49</td><td align="char" char="." valign="bottom">502.2928</td><td align="char" char="." valign="bottom">502.2925</td><td align="left" valign="bottom">C<sub>25</sub> H<sub>44</sub> NO<sub>7</sub> P</td><td align="char" char="." valign="bottom">1.46</td><td align="char" char="." valign="bottom">–0.59</td></tr><tr><td align="left" valign="bottom">SM 34:1</td><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">[M+H]</td><td align="char" char="." valign="bottom">3.40</td><td align="char" char="." valign="bottom">703.5749</td><td align="char" char="." valign="bottom">703.5751</td><td align="left" valign="bottom">C<sub>39</sub> H<sub>79</sub> N<sub>2</sub> O<sub>6</sub> P</td><td align="char" char="." valign="bottom">1.30</td><td align="char" char="." valign="bottom">0.28</td></tr><tr><td align="left" valign="bottom">PE 32:1</td><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">[M+H]</td><td align="char" char="." valign="bottom">3.20</td><td align="char" char="." valign="bottom">689.4996</td><td align="char" char="." valign="bottom">689.4997</td><td align="left" valign="bottom">C<sub>37</sub> H<sub>72</sub> NO<sub>8</sub> P</td><td align="char" char="." valign="bottom">1.48</td><td align="char" char="." valign="bottom">0.14</td></tr><tr><td align="left" valign="bottom">PE 36:5</td><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">[M+H]</td><td align="char" char="." valign="bottom">3.25</td><td align="char" char="." valign="bottom">738.5069</td><td align="char" char="." valign="bottom">738.5067</td><td align="left" valign="bottom">C<sub>41</sub> H<sub>72</sub> NO<sub>8</sub> P</td><td align="char" char="." valign="bottom">1.60</td><td align="char" char="." valign="bottom">–0.27</td></tr><tr><td align="left" valign="bottom">PE 38:5</td><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">[M+H]</td><td align="char" char="." valign="bottom">3.40</td><td align="char" char="." valign="bottom">766.5382</td><td align="char" char="." valign="bottom">766.5380</td><td align="left" valign="bottom">C<sub>43</sub> H<sub>76</sub> NO<sub>8</sub> P</td><td align="char" char="." valign="bottom">1.56</td><td align="char" char="." valign="bottom">–0.26</td></tr><tr><td align="left" valign="bottom">SM 34:1</td><td align="left" valign="bottom">18:1; 16:0</td><td align="char" char="." valign="bottom">[M-H]</td><td align="char" char="." valign="bottom">3.8</td><td align="char" char="." valign="bottom">701.5603</td><td align="char" char="." valign="bottom">701.5603</td><td align="left" valign="bottom">C<sub>39</sub> H<sub>79</sub> N<sub>2</sub> O<sub>6</sub> P</td><td align="char" char="." valign="bottom">1.97</td><td align="char" char="." valign="bottom">0.28</td></tr><tr><td align="left" valign="bottom">LPC 18:1</td><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">[M-H]</td><td align="char" char="." valign="bottom">1.09</td><td align="char" char="." valign="bottom">520.3408</td><td align="char" char="." valign="bottom">520.3406</td><td align="left" valign="bottom">C<sub>26</sub> H<sub>52</sub> NO<sub>7</sub> P</td><td align="char" char="." valign="bottom">1.23</td><td align="char" char="." valign="bottom">–0.38</td></tr><tr><td align="left" valign="bottom" colspan="9"><bold>Lipids and metabolites upregulated in high tachyplesin-NBD accumulators</bold></td></tr><tr><td align="left" valign="bottom">Cer 32:332<bold>:3</bold></td><td align="left" valign="bottom">14:2; 18:1</td><td align="char" char="." valign="bottom">[M+H]</td><td align="char" char="." valign="bottom">3.32</td><td align="char" char="." valign="bottom">506.4568</td><td align="char" char="." valign="bottom">506.4567<bold>45</bold></td><td align="left" valign="bottom">C<sub>32</sub> H<sub>59</sub> NO<sub>3</sub></td><td align="char" char="." valign="bottom">1.37</td><td align="char" char="." valign="bottom">–0.78</td></tr><tr><td align="left" valign="bottom">PC 36:3</td><td align="left" valign="bottom">18:0; 18:3</td><td align="char" char="." valign="bottom">[M+H]</td><td align="char" char="." valign="bottom">3.74</td><td align="char" char="." valign="bottom">788.5851</td><td align="char" char="." valign="bottom">788.5849</td><td align="left" valign="bottom">C<sub>44</sub> H<sub>82</sub> NO<sub>8</sub> P</td><td align="char" char="." valign="bottom">1.42</td><td align="char" char="." valign="bottom">–0.25</td></tr><tr><td align="left" valign="bottom">LPC 22:1</td><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">[M+H]</td><td align="char" char="." valign="bottom">1.19</td><td align="char" char="." valign="bottom">578.418</td><td align="char" char="." valign="bottom">578.4160</td><td align="left" valign="bottom">C<sub>30</sub> H<sub>60</sub> NO<sub>7</sub> P</td><td align="char" char="." valign="bottom">1.46</td><td align="char" char="." valign="bottom">–3.45</td></tr><tr><td align="left" valign="bottom">SM 40:2</td><td align="left" valign="bottom">16:1; 24:1</td><td align="char" char="." valign="bottom">[M+H]</td><td align="char" char="." valign="bottom">3.48</td><td align="char" char="." valign="bottom">785.6531</td><td align="char" char="." valign="bottom">785.6560</td><td align="left" valign="bottom">C<sub>45</sub> H<sub>89</sub> N<sub>2</sub> O<sub>6</sub> P</td><td align="char" char="." valign="bottom">1.52</td><td align="char" char="." valign="bottom">3.69</td></tr><tr><td align="left" valign="bottom">PE 30:0</td><td align="left" valign="bottom">16:0; 14:0</td><td align="char" char="." valign="bottom">[M+H]</td><td align="char" char="." valign="bottom">3.08</td><td align="char" char="." valign="bottom">664.4912</td><td align="char" char="." valign="bottom">664.4910</td><td align="left" valign="bottom">C<sub>35</sub> H<sub>70</sub> NO<sub>8</sub> P</td><td align="char" char="." valign="bottom">1.64</td><td align="char" char="." valign="bottom">–0.30</td></tr><tr><td align="left" valign="bottom">PE 31:0</td><td align="left" valign="bottom">16:0; 15:0</td><td align="char" char="." valign="bottom">[M+H]</td><td align="char" char="." valign="bottom">3.19</td><td align="char" char="." valign="bottom">678.5069</td><td align="char" char="." valign="bottom">678.5067</td><td align="left" valign="bottom">C<sub>36</sub> H<sub>72</sub> NO<sub>8</sub> P</td><td align="char" char="." valign="bottom">1.71</td><td align="char" char="." valign="bottom">–0.29</td></tr><tr><td align="left" valign="bottom">PE 32:2</td><td align="left" valign="bottom">16:1; 16:1</td><td align="char" char="." valign="bottom">[M+H]</td><td align="char" char="." valign="bottom">3.21</td><td align="char" char="." valign="bottom">688.4912</td><td align="char" char="." valign="bottom">688.4910</td><td align="left" valign="bottom">C<sub>37</sub> H<sub>70</sub> NO<sub>8</sub> P</td><td align="char" char="." valign="bottom">1.63</td><td align="char" char="." valign="bottom">–0.29</td></tr><tr><td align="left" valign="bottom">LPC 18:1</td><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">[M-H]</td><td align="char" char="." valign="bottom">1.09</td><td align="char" char="." valign="bottom">520.3408</td><td align="char" char="." valign="bottom">520.3403</td><td align="left" valign="bottom">C<sub>26</sub> H<sub>52</sub> NO<sub>7</sub> P</td><td align="char" char="." valign="bottom">1.91</td><td align="char" char="." valign="bottom">–0.96</td></tr><tr><td align="left" valign="bottom">SM 34:1</td><td align="left" valign="bottom">18:1; 16:0</td><td align="char" char="." valign="bottom">[M-H]</td><td align="char" char="." valign="bottom">3.8</td><td align="char" char="." valign="bottom">701.5603</td><td align="char" char="." valign="bottom">701.5601</td><td align="left" valign="bottom">C<sub>39</sub> H<sub>79</sub> N<sub>2</sub> O<sub>6</sub> P</td><td align="char" char="." valign="bottom">1.97</td><td align="char" char="." valign="bottom">–0.28</td></tr><tr><td align="left" valign="bottom">PC 35:0</td><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">[M-H]</td><td align="char" char="." valign="bottom">2.49</td><td align="char" char="." valign="bottom">774.6018</td><td align="char" char="." valign="bottom">774.6016</td><td align="left" valign="bottom">C<sub>43</sub> H<sub>86</sub> NO<sub>8</sub> P</td><td align="char" char="." valign="bottom">1.26</td><td align="char" char="." valign="bottom">–0.25</td></tr><tr><td align="left" valign="bottom">PG 38:7</td><td align="left" valign="bottom">-</td><td align="char" char="." valign="bottom">[M-H]</td><td align="char" char="." valign="bottom">1.63</td><td align="char" char="." valign="bottom">791.4868</td><td align="char" char="." valign="bottom">791.4861</td><td align="left" valign="bottom">C<sub>44</sub> H<sub>73</sub> O<sub>10</sub> P</td><td align="char" char="." valign="bottom">1.63</td><td align="char" char="." valign="bottom">–0.88</td></tr><tr><td align="left" valign="bottom">PS 37:7</td><td align="left" valign="bottom">20:5; 17:2</td><td align="char" char="." valign="bottom">[M-H]</td><td align="char" char="." valign="bottom">5.69</td><td align="char" char="." valign="bottom">790.4664</td><td align="char" char="." valign="bottom">790.4667</td><td align="left" valign="bottom">C<sub>43</sub> H<sub>70</sub> NO<sub>10</sub> P</td><td align="char" char="." valign="bottom">1.19</td><td align="char" char="." valign="bottom">0.37</td></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.99752.4.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Soldati-Favre</surname><given-names>Dominique</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>University of Geneva</institution><country>Switzerland</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Compelling</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> study by Lee et al. explores the heterogeneous response of non-growing bacteria to the antimicrobial peptide (AMP) tachyplesin. The authors identify a subpopulation of cells that evade lethal damage by limiting the intracellular accumulation of a fluorescently labeled tachyplesin analog. The study provides <bold>compelling</bold> evidence that reduced drug accumulation underlies the decreased susceptibility of this subpopulation to the AMP. The molecular basis of this phenotype is well supported by the data.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.99752.4.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This work contributes several important and interesting observations regarding the heterotolerance of non-growing <italic>Escherichia coli</italic> and <italic>Pseudomonas aeruginosa</italic> to the antimicrobial peptide tachyplesin. The primary mechanism of action of tachyplesin is thought to be disruption of the bacterial cell envelope, leading to leakage of cellular contents after a threshold level of accumulation. Although the MIC for tachyplesin in exponentially growing <italic>E. coli</italic> is just 1 ug/ml, the authors observe that a substantial fraction of a stationary phase population of bacteria survives much higher concentrations, up to 64 ug/ml. By using a fluorescently labelled analogue of tachyplesin, the authors show that the amount of per-cell intracellular accumulation of tachyplesin displays a bimodal distribution, and that the fraction of &quot;low accumulators&quot; correlates with the fraction of survivors. Using a microfluidic device, they show that low accumulators exclude propidium iodide, suggesting that their cell envelopes remain largely intact, while high accumulators of tachyplesin also stain with propidium iodide. They show that this phenomenon holds for several clinical isolates of <italic>E. coli</italic> with different genetic determinants of antibiotic resistance, and for a strain of Pseudomonas aeruginosa. However, the bimodal distribution does not occur in these organisms for several other antimicrobial peptides, or for tachyplesin in Klebsiella pneumoniae or Staphylococcus aureus, indicating some degree of specificity in the interaction between AMP and bacterial cell envelope. They next explore the dynamics of the fluorescent tachyplesin accumulation and interestingly show that a high degree of accumulation is initially seen in all cells, but that the &quot;low accumulator&quot; subpopulation manages to decrease the amount of intracellular fluorescence over time, while the &quot;high accumulator&quot; subpopulation continues to increase its intracellular fluorescence. Focusing on increased efflux as a hypothesised mechanism for the &quot;low accumulator&quot; phenotype, based on transcriptomic analysis of the two subpopulations, the authors screen putative efflux inhibitors to see if they can block the formation of the low accumulator subpopulation. They find that both the protonophore CCCP and the SSRI sertraline can block the formation of this subpopulation and that a combination of sertraline plus tachyplesin kills a greater fraction of the stationary phase cells than either agent alone, similar to the killing observed when growing cells are treated with tachyplesin.</p><p>Strengths:</p><p>This study provides new insight into the heterogeneous behaviours of non-growing bacteria when exposed to an antimicrobial peptide, and into the dynamics of their response. The single-cell analysis by FACS and microscopy is compelling. The results provide a much-needed single-cell perspective on the phenomenon of tolerance to AMPs and a good starting point for further exploration.</p><p>Weaknesses:</p><p>The authors have substantially improved the clarity of the manuscript and have added additional experiments to probe further the location of the AMP relative to low and high accumulators, and the physiological states of these sub-populations. These experiments strengthen the assertion that low accumulators keep the AMP at the cell surface while high accumulators permit intracellular access to the AMP.</p><p>The phenomenon of the emergence of low accumulators, which are phenotypically tolerant to the antimicrobial peptide tachyplesin, is interesting and important even if there is still work to be done to understand the mechanism by which it occurs.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.99752.4.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This study reports on the existence of subpopulations of isogenic <italic>E. coli</italic> and P. aeruginosa cells that are tolerant to the antimicrobial peptide tachyplesin and are characterized by accumulation of low levels of a fluorescent tachyplesin-NBD conjugate. The authors then set out to address the molecular mechanisms, providing interesting insights even though the mechanism remains incompletely defined: The work demonstrates that increased efflux may cause this phenotype, putatively together with other changes in membrane lipid composition. The authors further demonstrate that pharmacological manipulation can prevent the generation of tolerance. The authors are cautious in their interpretation, and the claims made are largely justified by the data.</p><p>Strengths:</p><p>Going beyond the commonly used bulk techniques for studying susceptibility to AMPs, Lee et al. used fluorescent antibiotic conjugates in combination with flow cytometry analysis to study variability in drug accumulation at the single cell level. This powerful approach enabled the authors to expose bimodal drug accumulation patterns that were condition-dependent but conserved across a variety of <italic>E. coli</italic> clinical isolates. Using cell sorting in combination with colony-forming unit assays as well as quantitative fluorescence microscopic analysis in a microfluidics setup, the authors compellingly demonstrate that low accumulators (where fluorescence signal is mostly restricted to the membrane) can survive antibiotic treatment, whereas high accumulators (with high intracellular fluorescence) were killed.</p><p>The relevance of efflux for the ‘low accumulator’ phenotype and its survival is convincingly demonstrated by the following lines of evidence: (i) A time-course experiment on tachyplesin-NBD pre-loaded cells revealed that all cells initially were high accumulators, before a subpopulation of cells subsequently managed to reduce signal intensity, demonstrating that the ‘low accumulator’ phenotype is an induced response and not a pre-existing property. I(i) Double-mutants deficient in the delta acrA delta tolC double-KO, which showed reduced levels of low accumulators. Interestingly, ‘low accumulator’ populations were nearly abrogated in bacteria deficient in the qse quorum sensing system, suggesting its centrality for the tachyplesin response. Even though this system may control acrA, the strength of the phenotype may suggest that it may control additional as-of-yet unidenitified factors relevant in the response to tachyplesin. I(ii) treatment with efflux pump inhibitor sertraline and verapamil (even though some caution needs to be taken since it is not perfectly selective, see weakness) prevents generation of low accumulators. The observation that sertraline enhances tachyplesin-based killing is an important basis for developing combination therapies.</p><p>The study convincingly illustrates how susceptibility to tachyplesin adaptively changes in a heterogeneous way dependent on the growth phases and nutrient availability. This is highly relevant also beyond the presented example of tachyplesin and similar subpopulation-based adaptive changes to the susceptibility towards antimicrobial peptides or other drugs may occur during infections in vivo and they would likely be missed by standardized in vitro susceptibility testing.</p><p>Weaknesses:</p><p>Some mechanistic questions regarding tachyplesin accumulation and survival remain. One general shortcoming of the setup of the transcriptomics experiment is that the tachyplesin-NBD probe itself has antibiotic efficacy and induces phenotypes (and eventually cell death) in the ‘high accumulator’ cells. As the authors state themselves, this makes it challenging to interpret whether any differences seen between the two groups are causative for the observed accumulation pattern of if they are a consequence of differential accumulation and downstream phenotypic effects.</p></body></sub-article><sub-article article-type="referee-report" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.99752.4.sa3</article-id><title-group><article-title>Reviewer #3 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>This important study shows that stationary phase bacteria survive antimicrobial peptide treatment by switching on efflux pumps, generating low accumulating subpopulations that evade killing-a finding with clear implications for the design of peptide based antibiotics and for researchers studying antimicrobial resistance. The evidence is solid and frequently convincing, as diverse single-cell assays, genetics and chemical inhibition coherently link reduced intracellular peptide to survival, even though a few mechanistic details warrant further exploration.</p><p>Strengths:</p><p>The authors investigate how <italic>Escherichia coli</italic> (and, to a lesser extent, <italic>Pseudomonas aeruginosa</italic>) survive exposure to the antimicrobial peptide (AMP) tachyplesin. Because resistance to AMPs is thought to rely heavily on non genetic adaptations rather than on classical mutation-based mechanisms, the study focuses on phenotypic heterogeneity and seeks to pinpoint the cellular processes that protect a subset of cells. Using fluorescently labelled tachyplesin, single cell imaging, flow cytometry, transcriptomics, targeted genetics, and chemical perturbations, the authors report that stationary phase cultures harbor two phenotypic states: high accumulating cells that die and low accumulating cells that survive. They further propose and show that inducible efflux activity is the primary driver of survival and show that either efflux inhibition (sertraline, verapamil) or nutrient supplementation prevents the emergence of low accumulators and boosts killing.</p><p>The experiments unambiguously reveal that the cells respond to stress heterogeneously, with two distinct subpopulations - one with better survival than the other. This primary phenotype is convincingly shown across various <italic>E. coli</italic> strains, including clinical isolates. The authors probed the underlying mechanism from several angles, with important additional experiments in the revised version that strengthens the original conclusions in several ways. Newly added efflux assays with ethidium bromide, together with proteinase treatment experiments and ΔacrAΔtolC and ΔqseB/qseC mutant data, illustrate that the low-accumulating subpopulation can actively export intracellular compounds. The authors took great care to temper their language to acknowledge other potential alternatives that could explain some of the data such as altered influx, vesicle release or proteolysis, metabolic activity of the cells, an indirect effects of sertraline treatment. Additional metabolic dye measurements confirm that low accumulators are less metabolically active, and a new data on nutrient supplementation shows that forcing growth increases peptide uptake and lethality. The authors clarify the crucial point of where antimicrobial peptides actually bind on the cell within the broader survival mechanism and present their conclusions, along with potential caveats, with commendable clarity.</p><p>Weaknesses:</p><p>Despite these advances, the contribution of efflux may require more direct evidence to further dissect whether efflux is necessary, sufficient, or contributory. The facts that the key low-efflux mutant still retains a small fraction of survivors and that the inhibitors used may cause other physiological changes leading to higher efflux are still unaccounted for. The lipidomic and vesicle findings, while intriguing, remain descriptive, and direct tests of their functional relevance would further solidify the mechanistic models.</p><p>Conclusion:</p><p>Even with these limitations, the study provides valuable insight into non genetic resistance mechanisms to AMPs and highlights inducible heterogeneity as a critical obstacle to peptide therapeutics. In a much broader context, this study also underscores the importance of efflux physiology even for those antimicrobials that seemingly would not have intracellular targets.</p></body></sub-article><sub-article article-type="author-comment" id="sa4"><front-stub><article-id pub-id-type="doi">10.7554/eLife.99752.4.sa4</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Ka Kiu</given-names></name><role specific-use="author">Author</role><aff><institution>University of Exeter</institution><addr-line><named-content content-type="city">Exeter</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Łapińska</surname><given-names>Urszula</given-names></name><role specific-use="author">Author</role><aff><institution>University of Exeter</institution><addr-line><named-content content-type="city">Exeter</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Tolle</surname><given-names>Giulia</given-names></name><role specific-use="author">Author</role><aff><institution>University of Cagliari</institution><addr-line><named-content content-type="city">cagliari</named-content></addr-line><country>Italy</country></aff></contrib><contrib contrib-type="author"><name><surname>Micaletto</surname><given-names>Maureen</given-names></name><role specific-use="author">Author</role><aff><institution>University of Exeter</institution><addr-line><named-content content-type="city">Exeter</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Bing</given-names></name><role specific-use="author">Author</role><aff><institution>University of Queensland</institution><addr-line><named-content content-type="city">Brisbane</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Phetsang</surname><given-names>Wanida</given-names></name><role specific-use="author">Author</role><aff><institution>University of Queensland</institution><addr-line><named-content content-type="city">brisbane</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Verderosa</surname><given-names>Anthony D</given-names></name><role specific-use="author">Author</role><aff><institution>University of Queensland</institution><addr-line><named-content content-type="city">brisbane</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Invergo</surname><given-names>Brandon M</given-names></name><role specific-use="author">Author</role><aff><institution>University of Exeter</institution><addr-line><named-content content-type="city">Exeter</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Westley</surname><given-names>Joseph</given-names></name><role specific-use="author">Author</role><aff><institution>University of Exeter</institution><addr-line><named-content content-type="city">Exeter</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Bebes</surname><given-names>Attila</given-names></name><role specific-use="author">Author</role><aff><institution>University of Exeter</institution><addr-line><named-content content-type="city">Exeter</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Yuecel</surname><given-names>Raif</given-names></name><role specific-use="author">Author</role><aff><institution>University of Exeter</institution><addr-line><named-content content-type="city">exeter</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>ONeill</surname><given-names>Paul A</given-names></name><role specific-use="author">Author</role><aff><institution>University of Exeter</institution><addr-line><named-content content-type="city">exeter</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Farbos</surname><given-names>Audrey</given-names></name><role specific-use="author">Author</role><aff><institution>University of Exeter</institution><addr-line><named-content content-type="city">exeter</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Jeffries</surname><given-names>Aaron R</given-names></name><role specific-use="author">Author</role><aff><institution>University of Exeter</institution><addr-line><named-content content-type="city">exeter</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>van Houte</surname><given-names>Stineke</given-names></name><role specific-use="author">Author</role><aff><institution>University of Exeter</institution><addr-line><named-content content-type="city">exeter</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Caboni</surname><given-names>Pierluigi</given-names></name><role specific-use="author">Author</role><aff><institution>University of Cagliari</institution><addr-line><named-content content-type="city">cagliari</named-content></addr-line><country>Italy</country></aff></contrib><contrib contrib-type="author"><name><surname>Blaskovich</surname><given-names>Mark</given-names></name><role specific-use="author">Author</role><aff><institution>University of Queensland</institution><addr-line><named-content content-type="city">Brisbane</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="author"><name><surname>Housden</surname><given-names>Benjamin E</given-names></name><role specific-use="author">Author</role><aff><institution>University of Exeter</institution><addr-line><named-content content-type="city">Exeter</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Tsaneva-Atanasova</surname><given-names>Krasimira</given-names></name><role specific-use="author">Author</role><aff><institution>Exeter University</institution><addr-line><named-content content-type="city">Exeter</named-content></addr-line><country>United Kingdom</country></aff></contrib><contrib contrib-type="author"><name><surname>Pagliara</surname><given-names>Stefano</given-names></name><role specific-use="author">Author</role><aff><institution>Living Systems Institute, University of Exeter</institution><addr-line><named-content content-type="city">Exeter</named-content></addr-line><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the previous reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer 1:</bold></p></disp-quote><p>We would like to thank Reviewer 1 for recognising the importance of our findings on the heterogeneity in bacterial responses to tachyplesin.</p><disp-quote content-type="editor-comment"><p>(1) A double deletion of acrA and tolC (two out of the three components of the major constitutive RND efflux pump) reduces the appearance of the low accumulator phenotype, but interestingly, the single deletions have no effect, and a well-characterised inhibitor of RND efflux pumps also has no effect. The authors identify a two-component system, qseCB, that appears necessary for the appearance of low accumulators, but this system has pleiotropic effects on many cellular systems, with only tenuous connections to efflux. The selected pharmacological agents that could prevent the appearance of low accumulators do not offer clear insight into the mechanism by which low accumulators arise, because they have diverse modes of action.</p></disp-quote><p>We have added that “QseBC, was previously inferred to mediate resistance to a tachyplesin analogue by upregulating efflux genes based on transcriptomic analysis and hyper susceptibility of <italic>ΔqseBΔqseC</italic> mutants[113]”. However, we have also acknowledged that “it is conceivable that the deletion of QseBC has pleiotropic effects on other cellular mechanisms involved in tachyplesin accumulation” and that “it is also conceivable that sertraline prevented the formation of the low accumulator phenotype via efflux-independent mechanisms”.</p><p>These amendments are reported on lines 525-527, 532-534 and 539-541 of our revised manuscript.</p><disp-quote content-type="editor-comment"><p>(2) The transcriptomics data collected for low and high accumulator sub-populations are interesting, but in my opinion, the conclusions that can be drawn from these data remain overstated. It is not possible to make any claims about the total amount of &quot;protein synthesis, energy production, and gene expression&quot; on the basis of RNA-Seq data. The reads from each sample are normalised, so there is no information about the total amount of transcript. Many elements of total cellular activity are post-transcriptionally regulated, so it is impossible to assess from transcriptomics alone. Finally, the transcriptomic data are analysed in aggregated clusters of genes that are enriched for biological processes, for example: &quot;Cluster 2 included processes involved in protein synthesis, energy production, and gene expression that were downregulated to a greater extent in low accumulators than high accumulators&quot;. However, this obscures the fact that these clusters include genes that are generally inhibitory of the process named, as well as genes that facilitate the process.</p></disp-quote><p>We have now acknowledged that “that our data do not take into account post-transcriptional modifications that represent a second control point to survive external stressors”.</p><p>These amendments are reported on lines 534-535 of our revised manuscript.</p><p>The raw transcript counts can be found in Figure 3 – Source Data, we had added these data in our previous manuscript as requested by this reviewer.</p><p>We would also like to clarify that we have analysed our transcriptomic data via both clustering (i.e. Figure 3) and direct comparison of genes of interest (Table S1) and transcription factors (i.e. genes that are generally inhibitory of the process named, as well as genes that facilitate the process, Figure S12).</p><p>Finally, we would like to point out that in our revised manuscript (both this and its previous version), we are stating “Cluster 2 included processes involved in protein synthesis, energy production, and gene expression that were downregulated to a greater extent in low accumulators than high accumulators”. We do not think this is an overstatement, and we do not use these data to make conclusions on the total amount of &quot;protein synthesis, energy production, and gene expression&quot;.</p><disp-quote content-type="editor-comment"><p>(3) The authors have added an experiment to attempt to assess overall metabolic activity in the low accumulator and high accumulator populations, which is a welcome addition. They apply the redox dye resazurin and observe lower resorufin (reduced form) fluorescence in the low accumulator population, which they take to indicate a lower respiration rate. This seems possible, however, an important caveat is that they have shown the low accumulator population to retain substantially lower amounts of multiple different fluorescent molecules (tachyplesin-NBD, propidium iodide, ethidium bromide) intracellularly compared to the high accumulator population. It seems possible that the low accumulator population is also capable of removing resazurin or resorufin from the intracellular space, regardless of metabolic rate. Indeed, it has previously been shown that efflux by RND efflux pumps influences resazurin reduction to resorufin in both P. aeruginosa and <italic>E. coli</italic>. By measuring only the retained redox dye using flow cytometry, the results may be confounded by the demonstrated ability of the low accumulator population to remove various fluorescent dyes. More work is needed to strongly support broad conclusions about the physiological states of the low and high accumulator populations. The phenomenon of the emergence of low accumulators, which are phenotypically tolerant to the antimicrobial peptide tachyplesin, is interesting and important even if there is still work to be done to understand the mechanism by which it occurs.</p></disp-quote><p>We have now clarified that these assays were performed in the presence of 50 μM CCCP and that “CCCP was included to minimise differences in efflux activity and preserve resorufin retention between low and high accumulators, though some variability in efflux may still persist”. We have now added this information on lines 401-406. This information was only present in the caption of Figure S16 of our previous version of this manuscript.</p><p>We agree with the reviewers that more work needs to be done to fully understand this new phenomenon, and we had already acknowledged in our previous version of this manuscript that other mechanisms could play a role in this new phenomenon, see lines 489-517 of the current manuscript.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer 2:</bold></p></disp-quote><p>We would like to thank the reviewer for recognising that all their previous comments have now been satisfactorily addressed.</p><disp-quote content-type="editor-comment"><p>(1) Some mechanistic questions regarding tachyplesin-accumulation and survival remain. One general shortcoming of the setup of the transcriptomics experiment is that the tachyplesin-NBD probe itself has antibiotic efficacy and induces phenotypes (and eventually cell death) in the ‘high accumulator’ cells. As the authors state themselves, this makes it challenging to interpret whether any differences seen between the two groups are causative for the observed accumulation pattern of if they are a consequence of differential accumulation and downstream phenotypic effects.</p></disp-quote><p>We agree with the reviewer and we had explicitly acknowledged this possibility on lines 281-285 (of the previous and current version of this manuscript).</p><disp-quote content-type="editor-comment"><p>(2) The statement ‘Moreover, we found that the fluorescence of low accumulators decreased over time when bacteria were treated with 20 μg mL’ is, in my opinion, not supported by the data shown in Figure S4C. That figure shows that the abundance of ‘low accumulator’ cells decreases over time. Following the rationale that protease K treatment may cleave surface associated/ extracellular tachyplesin-NDB, this should lead to a shift of ‘low accumulator’ population to the left, indicating reduced fluorescence intensity per cell. This is not so case, but the population just disappears. However, after 120 min of treatment more cells appear in the ‘high accumulator’ state. This result is somewhat puzzling.</p></disp-quote><p>We agree with the reviewer that our previous discussion of this data could have been misleading. We have now reworded this part of the text as follows: “We found that the fluorescence of high accumulators did not decrease over time when tachyplesin-NBD was removed from the extracellular environment and bacteria were treated with 20 μg mL<sup>-1</sup> (0.7 μM) proteinase K, a widely-occurring serine protease that can cleave the peptide bonds of AMPs [43–45] (Figure S4B and C). These data suggest that tachyplesin-NBD primarily accumulates intracellularly in high accumulators”.</p><p>It is conceivable that extended exposure to proteinase K (i.e. we see a decrease in the abundance of low accumulators after 90 min treatment with proteinase K) increased the permeability to tachyplesin-NBD of low accumulators, allowing tachyplesin-NBD to move from either the extracellular space or the membrane to the cell interior. However, we do not have data to prove this point.</p><p>Therefore, we have now removed our claim that the data obtained using proteinase K suggest that tachyplesin-NBD accumulates primarily in the membranes of low accumulators. We believe that our two separate microscopy analyses provide more direct, stronger and less ambiguous evidence that tachyplesin-NBD accumulates primarily in the membranes of low accumulators.</p><disp-quote content-type="editor-comment"><p>(3) The authors used the metabolic dye resazurin to measure the metabolic activity of low vs. high accumulators. I am not entirely convinced that the lower fluorescence resorufin fluorescence in tachyplesin-NBD accumulators really indicates lower metabolic activity, since a cell's fluorescence levels would also be affected by the cellular uptake and efflux. It appears plausible that the lower resorufin-fluorescence may result from reduced accumulation/increased efflux in the ‘low-tachyplesin NBD´ population.</p></disp-quote><p>We have now clarified that these assays were performed in the presence of 50 μM CCCP and that “CCCP was included to minimise differences in efflux activity and preserve resorufin retention between low and high accumulators, though some variability in efflux may still persist.” We have now added this information on lines 401-406. This information was only present in the caption of Figure S16 of our previous version of this manuscript.</p><disp-quote content-type="editor-comment"><p>(4) P8 line 343. The text should refer to Figure. 13B, instead of 14B</p></disp-quote><p>We have now changed the text accordingly on line 337.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer 3:</bold></p></disp-quote><p>We would like to thank the reviewer for recognising that we have done a very impressive job in taking care of their comments.</p><disp-quote content-type="editor-comment"><p>(1) Despite these advances, the contribution of efflux may require more direct evidence to further dissect whether efflux is necessary, sufficient, or contributory. The facts that the key low efflux mutant still retains a small fraction of survivors and that the inhibitors used may cause other physiological changes leading to higher efflux are still unaccounted for. The lipidomic and vesicle findings, while intriguing, remain descriptive, and direct tests of their functional relevance would further solidify the mechanistic models.</p></disp-quote><p>We agree with the reviewers that more work needs to be done to fully understand this new phenomenon, and we had already acknowledged in our previous version of this manuscript that other mechanisms could play a role in this new phenomenon, see lines 489-517 of the current manuscript.</p></body></sub-article></article>